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Global, regional, and national comparative risk assessment of 
79 behavioural, environmental and occupational, and metabolic 
risks or clusters of risks, 1990–2015: a systematic analysis for the 
Global Burden of Disease Study 2015
GBD 2015 Risk Factors Collaborators*
Summary
Background The Global Burden of Diseases, Injuries, and Risk Factors Study 2015 provides an up-to-date synthesis of 
the evidence for risk factor exposure and the attributable burden of disease. By providing national and subnational 
assessments spanning the past 25 years, this study can inform debates on the importance of addressing risks in context. 
Methods We used the comparative risk assessment framework developed for previous iterations of the Global Burden of 
Disease Study to estimate attributable deaths, disability-adjusted life-years (DALYs), and trends in exposure by age group, 
sex, year, and geography for 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks 
from 1990 to 2015. This study included 388 risk-outcome pairs that met World Cancer Research Fund-deﬁ ned criteria for 
convincing or probable evidence. We extracted relative risk and exposure estimates from randomised controlled trials, 
cohorts, pooled cohorts, household surveys, census data, satellite data, and other sources. We used statistical models to 
pool data, adjust for bias, and incorporate covariates. We developed a metric that allows comparisons of exposure across 
risk factors—the summary exposure value. Using the counterfactual scenario of theoretical minimum risk level, we 
estimated the portion of deaths and DALYs that could be attributed to a given risk. We decomposed trends in attributable 
burden into contributions from population growth, population age structure, risk exposure, and risk-deleted cause-
speciﬁ c DALY rates. We characterised risk exposure in relation to a Socio-demographic Index (SDI). 
Findings Between 1990 and 2015, global exposure to unsafe sanitation, household air pollution, childhood underweight, 
childhood stunting, and smoking each decreased by more than 25%. Global exposure for several occupational risks, 
high body-mass index (BMI), and drug use increased by more than 25% over the same period. All risks jointly evaluated 
in 2015 accounted for 57·8% (95% CI 56·6–58·8) of global deaths and 41·2% (39·8–42·8) of DALYs. In 2015, the ten 
largest contributors to global DALYs among Level 3 risks were high systolic blood pressure (211·8 million [192·7 million 
to 231·1 million] global DALYs), smoking (148·6 million [134·2 million to 163·1 million]), high fasting plasma glucose 
(143·1 million [125·1 million to 163·5 million]), high BMI (120·1 million [83·8 million to 158·4 million]), childhood 
undernutrition (113·3 million [103·9 million to 123·4 million]), ambient particulate matter (103·1 million [90·8 million 
to 115·1 million]), high total cholesterol (88·7 million [74·6 million to 105·7 million]), household air pollution 
(85·6 million [66·7 million to 106·1 million]), alcohol use (85·0 million [77·2 million to 93·0 million]), and diets high 
in sodium (83·0 million [49·3 million to 127·5 million]). From 1990 to 2015, attributable DALYs declined for 
micronutrient deﬁ ciencies, childhood undernutrition, unsafe sanitation and water, and household air pollution; 
reductions in risk-deleted DALY rates rather than reductions in exposure drove these declines. Rising exposure 
contributed to notable increases in attributable DALYs from high BMI, high fasting plasma glucose, occupational 
carcinogens, and drug use. Environmental risks and childhood undernutrition declined steadily with SDI; low physical 
activity, high BMI, and high fasting plasma glucose increased with SDI. In 119 countries, metabolic risks, such as high 
BMI and fasting plasma glucose, contributed the most attributable DALYs in 2015. Regionally, smoking still ranked 
among the leading ﬁ ve risk factors for attributable DALYs in 109 countries; childhood underweight and unsafe sex 
remained primary drivers of early death and disability in much of sub-Saharan Africa.
Interpretation Declines in some key environmental risks have contributed to declines in critical infectious diseases. 
Some risks appear to be invariant to SDI. Increasing risks, including high BMI, high fasting plasma glucose, drug use, 
and some occupational exposures, contribute to rising burden from some conditions, but also provide opportunities 
for intervention. Some highly preventable risks, such as smoking, remain major causes of attributable DALYs, even as 
exposure is declining. Public policy makers need to pay attention to the risks that are increasingly major contributors 
to global burden.  
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Introduction
Analysis of the causes of poor health—speciﬁ cally, the 
connections between risk factors and development of 
poor health—can provide insights into opportunities 
and priorities for prevention, research, policy, and 
development. One of the mainstays of modern epidem-
iology is quantiﬁ cation of elevated risks for particular 
diseases or injuries from exposure to a given risk factor 
for groups of individuals. Quantiﬁ cation of elevated risk 
for exposed groups of individuals from an array of risk-
outcome pairs is important to inform decision making on 
individual health; however, public policy debates require 
the comprehensive metric of population-level risk, which 
is a function of elevated risk in the exposed population 
and the fraction of the population exposed to a given risk. 
Eﬀ orts to measure population risk have combined data for 
excess risk with the number of individuals exposed to 
provide comparative quantiﬁ cation of diﬀ erent health 
risks for populations that have been inﬂ uential in 
establishment of policy priorities.1,2
The comparative risk assessment (CRA) approach 
developed for the Global Burden of Diseases, Injuries, and 
Risk Factors (GBD) Study3,4 provides an overarching 
conceptual framework for population risk assessment 
across risks and over time. The scale of the GBD Study 
required extensive work to develop exposure metrics, 
assess relationships, and compile health data from 
diﬀ erent parts of the world with diﬀ ering levels of metadata 
and uncertainty, and the unique contribution of this work 
has been broadly recognised.5–7 A robust debate on speciﬁ c 
risks and results emerged after publication of the Global 
Burden of Diseases, Injuries, and Risk Factors Study 2013 
(GBD 2013).8 Inclusion and exclusion of particular risks 
and outcomes;3,4,9 the optimum targets for indicators such 
as high systolic blood pressure,10,11 cholesterol,11,12 diets high 
in sodium,13 and air pollution;4,14 and the certainty of some 
dietary components of risk8,15 were challenged, in addition 
to some details of methods. Underlying many of these 
discussions were heterogeneities in the strength of causal 
evidence for diﬀ erent risk-outcome pairs.8
The Global Burden of Diseases, Injuries, and Risk 
Factors Study 2015 (GBD 2015) CRA, in addition to 
updating data and methods, adds new transparency about 
the evidence supporting causal connections for each of the 
388 risk-outcome pairs included in the analysis, allows the 
quantiﬁ cation and reporting of levels and trends in 
exposure, decomposes changes in attributable burden into 
population growth, ageing, risk exposure, and risk-deleted 
disability-adjusted life-year (DALY) rates, and examines 
how risks change with development. As with all iterations 
of the GBD Study, GBD 2015 results presented here 
supersede all previously published GBD CRA estimates.
Methods
Overview
The CRA conceptual framework was developed by 
Murray and Lopez,16 who established a causal web of 
hierarchically organised risks or causes that contribute to 
Research in context
Evidence before this study
The most recent assessment of attributable deaths and 
disability-adjusted life-years (DALYs) at the global, regional, and 
national level was the Global Burden of Diseases, Injuries, and 
Risk Factors Study 2013, which covered 79 risk factors or 
combinations of risks from 1990 to 2013 in 188 countries. 
Added value of this study
This study (the Global Burden of Diseases, Injuries, and Risk 
Factors Study 2015) incorporates recently published studies, 
newly acquired data for exposure to relative risks, and new 
risk-outcome pairs meeting study inclusion criteria. To enhance 
transparency of the supporting evidence, we provided an 
assessment of the strength of evidence supporting causality for 
all 388 risk-outcome pairs. For the ﬁ rst time, we separately 
assessed trends in risk exposure by computing a summary 
exposure value, which allows comparisons over time and across 
place for dichotomous, polytomous, and continuous risks. 
Quantiﬁ cation of exposure trends allowed decomposition of 
trends in attributable DALYs into the portion contributed by 
changes in population growth, population structure, exposure, 
and risk-deleted DALY rates. We found that reductions in 
exposure have been key drivers of change for only a small set of 
environmental risks, including sanitation, household air 
pollution, and behavioural risks (eg, undernutrition and 
smoking). For many risks, trends in attributable DALYs have 
been driven by the interplay between population growth, 
ageing, and declines in risk-deleted DALY rates. For some 
risks, including body-mass index, fasting plasma glucose, 
occupational exposure to carcinogens, and drug use, exposure is 
increasing and driving up attributable burden. Although an 
average risk transition has occurred as countries move through 
the development continuum, many risks initially increase and 
then decline at the highest development levels. We document 
leading risks for each country and territory included in the study. 
Implications of all the available evidence
Risk assessments allow identiﬁ cation of several groups of risk 
factors that deserve policy attention. Risks such as smoking, 
unsafe sanitation, and childhood undernutrition still cause 
many attributable DALYs, but recent trends show that exposure 
can be reduced. This assessment of risk also shows many large 
global risks for which changes in exposure are slow, such as 
high systolic blood pressure, ambient air pollution, diets high in 
sodium, high cholesterol, and alcohol intake, highlighting huge 
opportunities for intervention. Two large risks—high BMI and 
high fasting plasma glucose—have particularly large and 
concerning increases in exposure. 
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health outcomes (methods appendix p 161), which allows 
quantiﬁ cation of risks or causes at any level in the 
framework. In GBD 2015, as in previous iterations of 
the GBD Study, we evaluated a set of behavioural, 
environmental and occupational, and metabolic risks, 
where risk-outcome pairs were included based on 
evidence rules (methods appendix p 161). These risks 
were organised into four hierarchical levels, described in 
table 1. To date, we have not quantiﬁ ed the contribution 
of other classes of risk factors (methods appendix p 161); 
however, using an analysis of the relationship between 
risk exposures and development, measured with use of 
the Socio-demographic Index (SDI), we provide some 
insights into the potential magnitude of distal social, 
cultural, and economic factors.
Two types of risk assessments are possible within the 
CRA framework: attributable burden and avoidable 
burden. Attributable burden is the reduction in current 
disease burden that would have been possible if past 
population exposure had shifted to an alternative or 
counterfactual distribution of risk exposure. Avoidable 
burden is the potential reduction in future disease 
burden that could be achieved by changing the current 
distribution of exposure to a counterfactual distribution 
of exposure. Murray and Lopez16 identiﬁ ed four types 
of counterfactual exposure distributions: theoretical, 
plausible, feasible, and cost-eﬀ ective minimum risk. In 
GBD studies to date and in this study, we focus on 
attributable burden using the theoretical minimum risk 
level (TMREL), which is the level of risk exposure that 
minimises risk at the population level, or the level of risk 
that captures the maximum attributable burden.
Overall, this analysis follows the CRA methods used in 
GBD 2013.4 The methods described in this study provide 
a high-level overview of the analytical logic, with a focus 
on areas of notable change from the methods used in 
GBD 2013, with details provided in the methods 
appendix. This study complies with the Guidelines for 
Accurate and Transparent Health Estimates Reporting 
statement (methods appendix pp 177–79).17
Geographic units of analysis and years for estimation
In the GBD framework, geographies have been arranged 
as a set of hierarchical categories: seven super-regions, 
21 regions nested within the seven super-regions, and 
195 countries and territories nested in the 21 regions. 
Additionally, GBD collaborator interest and availability of 
data resulted in an expansion of countries for which we 
disaggregate our estimates at the subnational level. At the 
ﬁ rst level of subnational division, 256 geographic units 
are included in GBD 2015. For this study, we present 
results for the 195 national and territory-level geographies. 
We produced a complete set of age-speciﬁ c, sex-speciﬁ c, 
cause-speciﬁ c, and location-speciﬁ c estimates of risk 
factor exposure and attributable burden for 1990, 1995, 
2000, 2005, 2010, and 2015 for included risk factors. 
Results presented in this study emphasise results for 
1990, 2005, and 2015; online data visualisations provide 
access to results for all GBD metrics from 1990 to 2015.
Attributable burden formula
Four key components are included in estimation of the 
burden attributable to a given risk factor: the metric of 
burden being assessed (number of deaths, years of life lost 
[YLLs], years lived with disability [YLDs], or DALYs [the sum 
of YLLs and YLDs]), the exposure levels for a risk factor, the 
relative risk of a given outcome due to exposure, and the 
counterfactual level of risk factor exposure. Estimates of 
attributable DALYs for a risk-outcome pair are equal to 
DALYs for the outcome multiplied by the population 
attributable fraction (PAF) for the risk-outcome pair for a 
given age, sex, location, and year. A similar logic applies for 
estimation of attributable deaths, YLLs, or YLDs. Risks are 
categorised on the basis of how exposure was measured: 
dichotomous, polytomous, and continuous. The PAF 
represents the proportion of risk that would be reduced in a 
given year if the exposure to a risk factor in the past were 
reduced to a counterfactual level of exposure (methods 
appendix p 27).
Causal evidence for risk-outcome pairs
In this study, as in GBD 2013, we have included risk-
outcome pairs that we have assessed as meeting the World 
Cancer Research Fund grades of convincing or probable 
evidence (methods appendix pp 12–13 contains deﬁ nitions 
of these grades).9 Table 2 provides a summary of the 
evidence supporting a causal relationship between a risk 
and an outcome for each pair included in GBD 2015. For 
each risk-outcome pair, we used recent systematic reviews 
to identify independent prospective studies (randomised 
controlled trials, non-randomised interventions, and 
cohorts) that evaluated the putative relationship. For risk-
outcome pairs for which no recent systematic review was 
available, we either updated reviews developed for GBD 
2013 or did a new systematic search of literature (methods 
appendix pp 44–159). Table 2 summarises the evidence 
using multiple dimensions, which supports our 
assessment that each included risk-outcome pair meets 
the criteria of convincing or probable evidence (methods 
appendix [pp 12–13] contains a justiﬁ cation of the criteria 
presented to support causality). In this summary of 
evidence, we have focused on randomised controlled trials 
and prospective observational studies, along with 
supporting evidence, like dose-response relationships and 
biologically plausible mechanisms. Other evidence 
supporting causal connections, such as case-control 
studies, are not summarised in table 2.
Estimation process
Information about the data sources, estimation methods, 
computational tools, and statistical analysis used in 
derivation of our estimates are provided in the methods 
appendix. The analytical steps for estimation of burden 
attributable to single or clusters of risk-outcome pairs are 
See Online for appendix
For the online data 
visualisations see http://vizhub.
healthdata.org/gbd-compare
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Exposure deﬁ nition Theoretical minimum risk exposure level Data representativeness index
<2005 2005–15 Total
All risk factors ·· ·· 100·0% 100·0% 100·0%
Environmental and occupational risks ·· ·· 100·0% 100·0% 100·0%
Unsafe water, sanitation, and 
handwashing
·· ·· 73·2% 60·6% 78·8%
Unsafe water source Proportion of households with access to diﬀ erent water 
sources (unimproved, improved except piped, piped water 
supply) and reported use of household water treatment 
methods (boiling or ﬁ ltering; chlorinating or solar ﬁ ltering; 
no treatment) 
All households have access to water from a piped 
water supply that is also boiled or ﬁ ltered before 
drinking
83·5% 70·1% 88·4%
Unsafe sanitation Proportion of households with access to diﬀ erent 
sanitation facilities (unimproved, improved except sewer, 
sewer connection)
All households have access to toilets with sewer 
connection
83·5% 69·5% 88·4%
No handwashing with soap Proportion of individuals who wash their hands with soap 
and water after potential faecal contact
All individuals wash hands with soap and water 
after potential faecal contact
7·6% 24·2% 27·3%
Air pollution ·· ·· 100·0% 100·0% 100·0%
Ambient particulate matter 
pollution
Annual average daily exposure to outdoor air 
concentrations of PM with an aerodynamic diameter 
smaller than 2·5 μm, measured in μg/m³ 
Uniform distribution between 2·4 μg/m³ and 
5·9 μg/m³
100·0% 100·0% 100·0%
Household air pollution from solid 
fuels
Annual average daily exposure to household concentrations 
of PM with an aerodynamic diameter smaller than 2·5 μm, 
measured in μg/m³ from solid fuel use (coal, wood, 
charcoal, dung, and agricultural residues)
No households are exposed to excess indoor 
concentration of particles from solid fuel use 
(assuming concentration of particulate matters, 
aerodynamic diameter smaller than 2·5 μm, 
measured in μg/m³ in no fuel use is consistent with 
a theoretical minimum risk level of 2·4–5·9)
69·7% 60·6% 75·8%
Ambient ozone pollution Seasonal (3 month) hourly maximum ozone 
concentrations, measured in ppb
Uniform distribution between 33·3 μg/m³ and 
41·9 μg/m³, according to minimum/5th percentile 
concentrations
100·0% 100·0% 100·0%
Other environmental risks ·· ·· 44·9% 40·9% 47·0%
Residential radon Average daily exposure to indoor air radon levels measured 
in becquerels (radon disintegrations per s) per cubic metre 
(Bq/m³)
10 Bq/m³, corresponding to the outdoor 
concentration of radon
36·4% 36·4% 36·4%
Lead exposure Blood lead levels in μg/dL of blood, bone lead levels in μg/g 
of bone
2 μg/dL, corresponding to lead levels in 
preindustrial humans as natural sources of lead 
prevent the feasibility of zero exposure
33·3% 19·2% 36·9%
Occupational risks ·· ·· 94·4% 93·4% 94·4%
Occupational carcinogens 94·4% 93·4% 94·4%
Occupational exposure to asbestos Proportion of the population with cumulative exposure to 
asbestos 
No occupational exposure to asbestos 94·4% 93·4% 94·4%
Occupational exposure to arsenic Proportion of the population ever exposed to arsenic at 
work/through their occupation
No occupational exposure to arsenic 94·4% 93·4% 94·4%
Occupational exposure to benzene Proportion of the population ever exposed to benzene at 
work/through their occupation
No occupational exposure to benzene 94·4% 93·4% 94·4%
Occupational exposure to 
beryllium
Proportion of the population ever exposed to beryllium at 
work/through their occupation
No occupational exposure to beryllium 94·4% 93·4% 94·4%
Occupational exposure to 
cadmium
Proportion of the population ever exposed to cadmium at 
work/through their occupation
No occupational exposure to cadmium 94·4% 93·4% 94·4%
Occupational exposure to 
chromium
Proportion of the population ever exposed to chromium at 
work/through their occupation
No occupational exposure to chromium 94·4% 93·4% 94·4%
Occupational exposure to diesel 
engine exhaust
Proportion of the population ever exposed to diesel engine 
exhaust at work/through their occupation
No occupational exposure to diesel engine exhaust 94·4% 93·4% 94·4%
Occupational exposure to second-
hand smoke
Proportion of the population ever exposed to second-hand 
smoke at work/through their occupation
No occupational exposure to second-hand smoke 94·4% 93·4% 94·4%
Occupational exposure to 
formaldehyde
Proportion of the population ever exposed to 
formaldehyde at work/through their occupation
No occupational exposure to formaldehyde 94·4% 93·4% 94·4%
Occupational exposure to nickel Proportion of the population ever exposed to nickel at 
work/through their occupation
No occupational exposure to nickel 94·4% 93·4% 94·4%
Occupational exposure to 
polycyclic aromatic hydrocarbons
Proportion of the population ever exposed to polycyclic 
aromatic hydrocarbons at work/through their occupation
No occupational exposure to polycyclic aromatic 
hydrocarbons
94·4% 93·4% 94·4%
(Table 1 continues on next page)
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Exposure deﬁ nition Theoretical minimum risk exposure level Data representativeness index
<2005 2005–15 Total
(Continued from previous page)
Occupational exposure to silica Proportion of the population ever exposed to silica at work/
through their occupation
No occupational exposure to silica 94·4% 93·4% 94·4%
Occupational exposure to 
sulphuric acid
Proportion of the population ever exposed to sulphuric acid 
at work/through their occupation
No occupational exposure to sulphuric acid 94·4% 93·4% 94·4%
Occupational exposure to 
trichloroethylene
Proportion of the population ever exposed to 
trichloroethylene at work/through their occupation
No occupational exposure to trichloroethylene 94·4% 93·4% 94·4%
Occupational asthmagens Proportion of the population currently exposed to 
asthmagens at work/through their occupation
Background asthmagen exposures 94·4% 93·4% 94·4%
Occupational particulate matter, 
gases, and fumes
Proportion of the population ever exposed to particulates, 
gases, or fumes at work/through their occupation
No occupational exposure to particulates, gases, or 
fumes
94·4% 93·4% 94·4%
Occupational noise Proportion of the population ever exposed to noise greater 
than 85 decibels at work/through their occupation
Background noise exposure 94·4% 93·4% 94·4%
Occupational injuries Proportion of the population at risk of injuries related to 
work/through their occupation
The rate of injury deaths per 100 000 person-years 
is zero
24·2% 32·3% 35·4%
Occupational ergonomic factors Proportion of the population who are exposed to 
ergonomic risk factors for low back pain at work/through 
their occupation
All individuals have the ergonomic factors of clerical 
and related workers
94·4% 93·4% 94·4%
Behavioural risks ·· ·· 100·0% 100·0% 100·0%
Child and maternal malnutrition ·· ·· 93·9% 91·4% 93·9%
Suboptimal breastfeeding 70·7% 57·6% 77·8%
Non-exclusive breastfeeding Proportion of children younger than 6 months who receive 
predominant, partial, or no breastfeeding
All children are exclusively breastfed for ﬁ rst 
6 months of life
70·7% 57·6% 77·8%
Discontinued breastfeeding Proportion of children aged 6–23 months who do not 
receive any breastmilk
All children continue to receive breastmilk until 
2 years of age
68·1% 65·3% 79·2%
Childhood undernutrition 77·8% 61·6% 79·3%
Childhood underweight Proportion of children less than –3 SDs, –3 to –2 SDs, and –2 
to –1 SDs of the WHO 2006 standard weight-for-age curve
All children are above –1 SD of the WHO 2006 
standard weight-for-age curve
77·3% 61·6% 78·8%
Childhood wasting Proportion of children less than –3 SDs, –3 to –2 SDs, and –2 
to –1 SDs of the WHO 2006 standard weight-for-length 
curve
All children are above –1 SD of the WHO 2006 
standard weight-for-height curve 
75·8% 61·1% 79·3%
Childhood stunting Proportion of children less than –3 SDs, –3 to –2 SDs, and –2 
to –1 SDs of the WHO 2006 standard height-for-age curve
All children are above –1 SD of the WHO 2006 
standard height-for-height curve
92·3% 79·6% 93·7%
Iron deﬁ ciency Peripheral blood haemoglobin concentration in g/L Country speciﬁ c 66·8% 30·7% 68·3%
Vitamin A deﬁ ciency Proportion of children aged 28 days to 5 years with serum 
retinol concentration <0·7 μmol/L
No childhood vitamin A deﬁ ciency 38·9% 5·1% 40·9%
Zinc deﬁ ciency Proportion of the population with inadequate zinc intake 
versus loss
No inadequate zinc intake 84·3% 84·3% 84·3%
Tobacco smoke ·· ·· 87·9% 94·4% 97·0%
Smoking Proportion of the population with cumulative exposure to 
tobacco smoking; proportion of the population who 
currently smoke
100% of population are lifelong non-smokers 84·8% 92·4% 95·5%
Second-hand smoke Average daily exposure to indoor air PM from second-hand 
smoke with an aerodynamic diameter smaller than 2·5 μg, 
measured in μg/m³
No second-hand smoke exposure 58·6% 79·8% 86·4%
Alcohol and drug use ·· ·· 100·0% 100·0% 100·0%
Alcohol use Average daily alcohol consumption of pure alcohol 
(measured in g/day) in current drinkers who had consumed 
alcohol during the past 12 months; binge drinking: 
proportion of the population reporting binge consumption 
of at least 60 g for males and 48 g for females of pure 
alcohol on a single occasion
No alcohol consumption 100·0% 100·0% 100·0%
Drug use Proportion of the population dependent on opioids, 
cannabis, cocaine, or amphetamines; proportion of the 
population who have ever injected drugs
No use 26·3% 49·0% 50·0%
(Table 1 continues on next page)
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Exposure deﬁ nition Theoretical minimum risk exposure level Data representativeness index
<2005 2005–15 Total
(Continued from previous page)
Dietary risks ·· ·· 90·4% 92·4% 92·9%
Diet low in fruits Average daily consumption of fruits (fresh, frozen, cooked, 
canned, or dried, excluding fruit juices and salted or pickled 
fruits)
Consumption of fruit between 200 g and 300 g per 
day
88·9% 88·9% 88·9%
Diet low in vegetables Average daily consumption of vegetables (fresh, frozen, 
cooked, canned or dried vegetables including legumes but 
excluding salted or pickled vegetables, juices, nuts and 
seeds, and starchy vegetables such as potatoes or corn)
Consumption of vegetables between 340 g and 
500 g per day
88·9% 88·9% 88·9%
Diet low in whole grains Average daily consumption of whole grains (bran, germ, 
and endosperm in their natural proportion) from breakfast 
cereals, bread, rice, pasta, biscuits, muﬃ  ns, tortillas, 
pancakes, and other sources
Consumption of whole grains between 100 g and 
150 g per day
10·6% 9·1% 16·2%
Diet low in nuts and seeds Average daily consumption of nut and seed foods Consumption of nuts and seeds between 16 g and 
25 g per day
88·9% 88·9% 88·9%
Diet low in milk Average daily consumption of milk, including non-fat, low-
fat, and full-fat milk, excluding soy milk and other plant 
derivatives
Consumption of milk between 350 g and 520 g per 
day
88·9% 88·9% 88·9%
Diet high in red meat Average daily consumption of red meat (beef, pork, lamb, 
and goat but excluding poultry, ﬁ sh, eggs, and all processed 
meats)
Consumption of red meat between 18 g and 27 g 
per day
88·9% 88·9% 88·9%
Diet high in processed meat Average daily consumption of meat preserved by smoking, 
curing, salting, or addition of chemical preservatives
Consumption of processed meat between 0 g and 
4 g per day
22·2% 11·6% 27·3%
Diet high in sugar-sweetened 
beverages
Average daily consumption of beverages with ≥50 kcal per 
226·8 g serving, including carbonated beverages, sodas, 
energy drinks, and fruit drinks, but excluding 100% fruit 
and vegetable juices
Consumption of sugar-sweetened beverages 
between 0 g and 5 g per day 
22·2% 12·6% 26·8%
Diet low in ﬁ bre Average daily intake of ﬁ bre from all sources, including 
fruits, vegetables, grains, legumes, and pulses
Consumption of ﬁ bre between 19 g and 28 g per 
day
88·9% 88·9% 88·9%
Diet low in calcium Average daily intake of calcium from all sources, including 
milk, yogurt, and cheese
Consumption of calcium between 1·00 g and 1·50 g 
per day
88·9% 88·9% 88·9%
Diet low in seafood omega-3 fatty 
acids 
Average daily intake of eicosapentaenoic acid and 
docosahexaenoic acid
Consumption of seafood omega-3 fatty acids 
between 200 mg and 300 mg per day
88·9% 88·9% 88·9%
Diet low in polyunsaturated fatty 
acids
Average daily intake of omega-6 fatty acids from all 
sources, mainly liquid vegetable oils, including soybean oil, 
corn oil, and saﬄ  ower oil
Consumption of polyunsaturated fatty acids 
between 9% and 13% of total daily energy
88·9% 88·9% 88·9%
Diet high in trans fatty acids Average daily intake of trans fat from all sources, mainly 
partially hydrogenated vegetable oils and ruminant 
products
Consumption of trans fatty acids between 0% and 
1% of total daily energy
39·9% 39·4% 39·9%
Diet high in sodium 24 h urinary sodium measured in g per day 24 h urinary sodium between 1 g and 5 g per day 28·8% 13·1% 32·3%
Sexual abuse and violence ·· ·· 43·9% 59·1% 66·2%
Childhood sexual abuse Proportion of the population who have ever experienced 
one or more acts of childhood sexual abuse, deﬁ ned as the 
experience with an older person of unwanted non-contact, 
contact abuse, or intercourse, when aged 15 years or 
younger
No childhood sexual abuse 27·8% 19·7% 34·3%
Intimate partner violence Proportion of the population who have ever experienced 
one or more acts of physical or sexual violence by a present 
or former intimate partner since age 15 years
No intimate partner violence 41·9% 56·6% 63·6%
Unsafe sex Proportion of the population with exposure to sexual 
encounters that convey the risk of disease
No exposure to a disease agent through sex 17·7% 48·0% 48·0%
Low physical activity Average weekly physical activity at work, at home, 
transport related, and recreational measured by MET 
min per week 
Highly active, ≥8000 MET min per week 45·5% 50·5% 66·7%
Metabolic risks ·· ·· 83·8% 88·4% 93·9%
High fasting plasma glucose Serum fasting plasma glucose measured in mmol/L 4·8–5·4 46·0% 60·1% 71·2%
High total cholesterol Serum total cholesterol, measured in mmol/L 2·78–3·38 49·5% 48·5% 69·2%
High systolic blood pressure Systolic blood pressure, measured in mm Hg 110–115 55·1% 66·2% 79·3%
(Table 1 continues on next page)
Articles
www.thelancet.com   Vol 388   October 8, 2016 1665
summarised in the methods appendix (p 162). Table 1 
provides deﬁ nitions of exposure for each risk factor, the 
TMREL used, and metrics of data availability. For each 
risk, we estimated eﬀ ect size as a function of age and sex 
and exposure level, mean exposure, the distribution of 
exposure across individuals, and the TMREL. The 
approach taken is largely similar to GBD 2013 for 
each quantity for each risk. Some methodological 
improvements have been implemented and new data 
sources incorporated. The methods appendix (pp 44–159) 
provides details of each step by risk. Citation information 
for the data sources used for relative risks are provided in 
searchable form through a web tool. We estimate the 
joint eﬀ ects of combinations of risk factors using the 
same methods as GBD 2013, namely using published 
studies to estimate the fraction of a risk that was mediated 
through the other risk (methods appendix pp 28–35). 
Relative risks by age and sex for each risk factor and 
outcome pair are provided in the methods appendix 
(pp 215–44).
All point estimates are reported with 95% uncertainty 
intervals (UIs). UIs include uncertainty from each 
relevant component, consisting of exposure, relative 
risks, TMREL, and burden rates. Where percentage 
change is reported (with 95% UIs), we computed it on 
the basis of the point estimates being compared. In this 
study, we provide further methodological detail on new 
extensions to the CRA analysis.
Summary exposure value calculation
In previous GBD studies, we did not report comparable 
exposure metrics for the risk factors included because of 
the complexity of quantiﬁ cation of polytomous and 
continuous risks.18 Because of substantial interest in the 
trends in exposure, we developed a summary measure of 
exposure for each risk. This measure, called the summary 
exposure value (SEV), is the relative risk-weighted 
prevalence of exposure. Formally, it is deﬁ ned as:
where Pri is prevalence of category i exposure, RRi is 
relative risk of the category i, and RRmax is the maximum 
relative risk observed (between categories). This quantity 
is estimated for each age, sex, location, year, and outcome. 
For each risk factor, a single SEV is estimated by 
averaging of the outcome of speciﬁ c SEV values for each 
age, sex, location, and year across outcomes. In the case 
of dichotomous exposure, SEV is equal to prevalence. 
For continuous risks:
where P(x) is the density of exposure at level x of 
exposure, RR(x) is relative risk of the level x, and RRmax is 
the highest relative risk that is supported by data and 
reﬂ ects a level where more than 1% of the global 
population are exposed to that level or a higher risk.
SEV takes the value zero when no excess risk for a 
population exists and the value one when the population 
is at the highest level of risk; we report SEV on a scale 
from 0% to 100% to emphasise that it is risk-weighted 
prevalence. We computed as the level for exposure with 
the highest relative risk supported by cohort or trial data 
and for which at least 1% or more of the global 
population is exposed. For comparison purposes, we 
have also computed age-standardised SEVs for every 
risk factor from the most detailed level using the GBD 
population standard.
Decomposition of changes in deaths and DALYs into the 
contribution of population growth, ageing, risk 
exposure, and risk-deleted DALY rates
We did two related decomposition analyses of changes in 
DALYs from 1990 to 2015: decomposing changes in 
cause-speciﬁ c DALYs due to changes in population 
growth, population age structure, exposure to all risks for 
a disease, and risk-deleted death and DALY rates; and 
decomposing changes in risk-attributable all-cause 
DALYs due to changes in population growth, population 
age structure, risk exposure to the single risk factor, and 
Exposure deﬁ nition Theoretical minimum risk exposure level Data representativeness index
<2005 2005–15 Total
(Continued from previous page)
High body-mass index Body-mass index, measured in kg/m² 20–25 78·3% 83·3% 90·9%
Low bone mineral density Standardised mean bone mineral density values measured 
at the femoral neck in g/cm²
99th percentile of NHANES 2005–10 by age and sex 23·7% 11·1% 25·8%
Low glomerular ﬁ ltration rate Proportion of the population with a glomerular ﬁ ltration 
rate <60 mL/min per 1·73 m², and excluding end-stage 
renal disease
>60 mL/min per 1·73 m² 9·1% 17·2% 20·2%
The percentage of available data is calculated out of a total of 519 subnational Level 2 geographies. PM=particulate matter. ppb=parts per billion. MET=metabolic equivalent. NHANES=National Health and 
Nutrition Examination Survey.
Table 1: Global Burden of Disease 2015 risk factor hierarchy, exposure deﬁ nitions, theoretical minimum risk exposure level, and data representativeness index for 1985–2015, pre-2005, 
and 2005–15 
For the web tool see http://ghdx.
healthdata.org/
SEV =
Σi=1 PriRRi    1
n
RRmax    1    
SEV =
∫x=l RR(x)P(x)dx    1
u
RRmax    1    
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Outcome RCTs 
(n)
RCTs with 
signiﬁ cant 
eﬀ ect in 
the 
opposite 
direction 
(%)
RCTs 
with null 
ﬁ ndings 
(%)
Prospective 
observational 
studies (n)*
Prospective 
observational 
studies with 
signiﬁ cant 
association in 
the opposite 
direction (%)
Lower 
limit of 
RR >1·5
Dose-
response 
relationship
Biological 
plausibility†
Analogy‡
Unsafe water, sanitation, and handwashing
Unsafe water source: chlorination or 
solar (point-of-use treatment)
Diarrhoeal diseases 24 0 42% 6 0 Yes ·· Yes No
Unsafe water source: ﬁ lter Diarrhoeal diseases 11 0 45% 2 0 Yes ·· Yes No
Unsafe water source: improved water Diarrhoeal diseases 0 ·· ·· 5 0 Yes ·· Yes No
Unsafe water source: improved water Typhoid fever 0 ·· ·· 0 ·· Yes ·· Yes Yes
Unsafe water source: improved water Paratyphoid fever 0 ·· ·· 0 ·· Yes ·· Yes Yes
Unsafe water source: piped Diarrhoeal diseases 1 0 0 9 11% Yes ·· Yes No
Unsafe water source: piped Typhoid fever 0 ·· ·· 0 ·· Yes ·· Yes Yes
Unsafe water source: piped Paratyphoid fever 0 ·· ·· 0 ·· Yes ·· Yes Yes
Unsafe sanitation: improved sanitation Diarrhoeal diseases 0 ·· ·· 9 0 Yes ·· Yes No
Unsafe sanitation: improved sanitation Typhoid fever 0 ·· ·· 0 ·· Yes ·· Yes Yes
Unsafe sanitation: improved sanitation Paratyphoid fever 0 ·· ·· 0 ·· Yes ·· Yes Yes
Unsafe sanitation: piped Diarrhoeal diseases 0 ·· ·· 1 0 Yes ·· Yes No
Unsafe sanitation: piped Typhoid fever 0 ·· ·· 0 ·· Yes ·· Yes Yes
Unsafe sanitation: piped Paratyphoid fever 0 ·· ·· 0 ·· Yes ·· Yes Yes
No handwashing with soap Diarrhoeal diseases 19 0 42% 0 ·· No ·· Yes No
No handwashing with soap Typhoid fever 0 ·· ·· 0 ·· No ·· Yes Yes
No handwashing with soap Paratyphoid fever 0 ·· ·· 0 ·· No ·· Yes Yes
No handwashing with soap Lower respiratory infections 1 0 0 6 0 No ·· Yes No
Air pollution
Ambient particulate matter pollution Lower respiratory infections 0 ·· ·· 13 0 No Yes Yes No
Ambient particulate matter pollution Ischaemic stroke 0 ·· ·· 25 0 No Yes Yes Yes
Ambient particulate matter pollution Haemorrhagic stroke 0 ·· ·· 25 0 No Yes Yes Yes
Ambient particulate matter pollution Ischaemic heart disease 0 ·· ·· 16 0 No Yes Yes Yes
Ambient particulate matter pollution Chronic obstructive 
pulmonary disease
0 ·· ·· 11 0 No Yes Yes Yes
Ambient particulate matter pollution Tracheal, bronchial, and lung 
cancer
0 ·· ·· 27 0 No Yes Yes Yes
Household air pollution from solid fuels Lower respiratory infections 0 ·· ·· 0 ·· No Yes Yes No
Household air pollution from solid fuels Cataract 0 ·· ·· 0 ·· No Yes Yes No
Household air pollution from solid fuels Ischaemic stroke 0 ·· ·· 25 0 No Yes Yes Yes
Household air pollution from solid fuels Haemorrhagic stroke 0 ·· ·· 25 0 No Yes Yes Yes
Household air pollution from solid fuels Ischaemic heart disease 0 ·· ·· 16 0 No Yes Yes Yes
Household air pollution from solid fuels Chronic obstructive 
pulmonary disease
0 ·· ·· 0 ·· No Yes Yes Yes
Household air pollution from solid fuels Tracheal, bronchial, and lung 
cancer
0 ·· ·· 0 ·· No Yes Yes Yes
Ambient ozone pollution Chronic obstructive 
pulmonary disease
0 ·· ·· 4 0 No Yes Yes No
Other environmental risks
Residential radon Tracheal, bronchial, and lung 
cancer
0 ·· ·· 3 0 No Yes Yes No
Lead exposure Systolic blood pressure 0 ·· ·· 3 0 ·· Yes Yes ··
Lead exposure Idiopathic intellectual 
disability
0 ·· ·· 8 0 No Yes Yes No
Occupational risks
Occupational exposure to asbestos Larynx cancer 0 ·· ·· 27 ·· No ·· Yes Yes
Occupational exposure to asbestos Tracheal, bronchial, and lung 
cancer
0 ·· ·· 18 0 Yes ·· Yes Yes
(Table 2 continues on next page)
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Outcome RCTs 
(n)
RCTs with 
signiﬁ cant 
eﬀ ect in 
the 
opposite 
direction 
(%)
RCTs 
with null 
ﬁ ndings 
(%)
Prospective 
observational 
studies (n)*
Prospective 
observational 
studies with 
signiﬁ cant 
association in 
the opposite 
direction (%)
Lower 
limit of 
RR >1·5
Dose-
response 
relationship
Biological 
plausibility†
Analogy‡
(Continued from previous page)
Occupational exposure to asbestos Ovarian cancer 0 ·· ·· 15 0 No ·· Yes Yes
Occupational exposure to asbestos Mesothelioma 0 ·· ·· 5 0 Yes ·· Yes Yes
Occupational exposure to arsenic Tracheal, bronchial, and lung 
cancer
0 ·· ·· 3 0 No ·· Yes No
Occupational exposure to benzene Leukaemia 0 ·· ·· 12 0 Yes ·· Yes No
Occupational exposure to beryllium Tracheal, bronchial, and lung 
cancer
0 ·· ·· 4 0 No ·· Yes No
Occupational exposure to cadmium Tracheal, bronchial, and lung 
cancer
0 ·· ·· 7 0 No ·· Yes No
Occupational exposure to chromium Tracheal, bronchial, and lung 
cancer
0 ·· ·· 26 0 No ·· Yes No
Occupational exposure to diesel engine 
exhaust
Tracheal, bronchial, and lung 
cancer
0 ·· ·· 17 0 No ·· Yes No
Occupational exposure to second-hand 
smoke
Tracheal, bronchial, and lung 
cancer
0 ·· ·· 25 0 No ·· Yes No
Occupational exposure to 
formaldehyde
Nasopharyngeal cancer 0 ·· ·· 1 0 No ·· Yes Yes
Occupational exposure to 
formaldehyde
Leukaemia 0 ·· ·· 12 0 No ·· Yes Yes
Occupational exposure to nickel Tracheal, bronchial, and lung 
cancer
0 ·· ·· 1 0 No ·· Yes No
Occupational exposure to polycyclic 
aromatic hydrocarbons
Tracheal, bronchial, and lung 
cancer
0 ·· ·· 39 0 No ·· Yes No
Occupational exposure to silica Tracheal, bronchial, and lung 
cancer
0 ·· ·· 17 0 No ·· Yes No
Occupational exposure to sulphuric acid Larynx cancer 0 ·· ·· 3 0 Yes ·· Yes No
Occupational exposure to 
trichloroethylene
Kidney cancer 0 ·· ·· 20 0 No ·· Yes No
Occupational asthmagens Asthma 0 ·· ·· 3 0 No ·· Yes No
Occupational particulate matter, gases, 
and fumes
Chronic obstructive 
pulmonary disease
0 ·· ·· 1 0 No ·· Yes No
Occupational noise Age-related and other hearing 
loss
0 ·· ·· 4 0 Yes ·· Yes No
Occupational ergonomic factors Low back pain 0 ·· ·· 10 0 No ·· Yes No
Child and maternal malnutrition
Non-exclusive breastfeeding Diarrhoeal diseases 0 ·· ·· 5 0 Yes ·· Yes No
Non-exclusive breastfeeding Lower respiratory infections 0 ·· ·· 6 0 Yes ·· Yes No
Discontinued breastfeeding Diarrhoeal diseases 0 ·· ·· 2 0 No ·· Yes No
Childhood underweight Diarrhoeal diseases 0 ·· ·· 7 ·· Yes ·· Yes No
Childhood underweight Lower respiratory infections 0 ·· ·· 7 ·· Yes ·· Yes No
Childhood underweight Measles 0 ·· ·· 7 ·· Yes ·· Yes No
Childhood wasting Diarrhoeal diseases 0 ·· ·· 7 ·· Yes ·· Yes No
Childhood wasting Lower respiratory infections 0 ·· ·· 7 ·· Yes ·· Yes No
Childhood wasting Measles 0 ·· ·· 7 ·· Yes ·· Yes No
Childhood stunting Diarrhoeal diseases 0 ·· ·· 7 ·· No ·· Yes No
Childhood stunting Lower respiratory infections 0 ·· ·· 7 ·· No ·· Yes No
Childhood stunting Measles 0 ·· ·· 7 ·· No ·· Yes No
Iron deﬁ ciency Maternal haemorrhage 0 ·· ·· 0 ·· No ·· Yes Yes
Iron deﬁ ciency Maternal sepsis and other 
pregnancy-related infections
0 ·· ·· 0 ·· No ·· Yes Yes
(Table 2 continues on next page)
Articles
1668 www.thelancet.com   Vol 388   October 8, 2016
Outcome RCTs 
(n)
RCTs with 
signiﬁ cant 
eﬀ ect in 
the 
opposite 
direction 
(%)
RCTs 
with null 
ﬁ ndings 
(%)
Prospective 
observational 
studies (n)*
Prospective 
observational 
studies with 
signiﬁ cant 
association in 
the opposite 
direction (%)
Lower 
limit of 
RR >1·5
Dose-
response 
relationship
Biological 
plausibility†
Analogy‡
(Continued from previous page)
Vitamin A deﬁ ciency Diarrhoeal diseases 19 0 63% 0 ·· No ·· Yes No
Vitamin A deﬁ ciency Measles 12 0 83% 0 ·· Yes ·· Yes No
Zinc deﬁ ciency Diarrhoeal diseases 14 0 29% 0 ·· No ·· Yes No
Zinc deﬁ ciency Lower respiratory infections 6 0 17% 0 ·· No ·· Yes No
Tobacco smoke
Smoking Tuberculosis 0 ·· ·· 4 0 No ·· Yes Yes
Smoking Lower respiratory infections 0 ·· ·· 0 ·· No ·· Yes Yes
Smoking Lip and oral cavity cancer 0 ·· ·· 3 0 Yes ·· Yes Yes
Smoking Nasopharyngeal cancer 0 ·· ·· 3 0 Yes ·· Yes Yes
Smoking Oesophageal cancer 0 ·· ·· 5 0 Yes ·· Yes Yes
Smoking Larynx cancer 0 ·· ·· 4 0 Yes ·· Yes Yes
Smoking Stomach cancer 0 ·· ·· 9 0 No ·· Yes Yes
Smoking Colon and rectum cancer 0 ·· ·· 19 0 No ·· Yes Yes
Smoking Liver cancer 0 ·· ·· 54 0 Yes ·· Yes Yes
Smoking Pancreatic cancer 0 ·· ·· 13 0 Yes ·· Yes Yes
Smoking Tracheal, bronchial, and lung 
cancer
0 ·· ·· 38 0 Yes ·· Yes Yes
Smoking Cervical cancer 0 ·· ·· 15 0 No ·· Yes Yes
Smoking Kidney cancer 0 ·· ·· 8 0 Yes ·· Yes Yes
Smoking Bladder cancer 0 ·· ·· 17 0 Yes ·· Yes Yes
Smoking Leukaemia 0 ·· ·· 14 0 No ·· Yes Yes
Smoking Ischaemic heart disease 0 ·· ·· 86 ·· No ·· Yes Yes
Smoking Ischemic stroke 0 ·· ·· 60 ·· No ·· Yes Yes
Smoking Haemorrhagic stroke 0 ·· ·· 60 ·· No ·· Yes Yes
Smoking Hypertensive heart disease 0 ·· ·· 5 ·· No ·· Yes Yes
Smoking Atrial ﬁ brillation and ﬂ utter 0 ·· ·· 16 0 No ·· Yes Yes
Smoking Aortic aneurysm 0 ·· ·· 10 0 No ·· Yes Yes
Smoking Peripheral vascular disease 0 ·· ·· 10 0 No ·· Yes Yes
Smoking Other cardiovascular and 
circulatory diseases
0 ·· ·· 1 0 No ·· Yes Yes
Smoking Chronic obstructive 
pulmonary disease
0 ·· ·· 42 0 Yes ·· Yes Yes
Smoking Silicosis 0 ·· ·· 0 ·· No ·· Yes Yes
Smoking Asbestosis 0 ·· ·· 0 ·· No ·· Yes Yes
Smoking Coal workers pneumoconiosis 0 ·· ·· 0 ·· Yes ·· Yes Yes
Smoking Other pneumoconiosis 0 ·· ·· 0 ·· Yes ·· Yes Yes
Smoking Asthma 0 ·· ·· 6 0 No ·· Yes Yes
Smoking Interstitial lung disease and 
pulmonary sarcoidosis
0 ·· ·· 0 ·· Yes ·· Yes Yes
Smoking Other chronic respiratory 
diseases
0 ·· ·· 1 0 Yes ·· Yes Yes
Smoking Peptic ulcer disease 0 ·· ·· 7 0 No ·· Yes No
Smoking Diabetes mellitus 0 ·· ·· 51 0 No ·· Yes No
Smoking Cataract 0 ·· ·· 10 0 No ·· Yes No
Smoking Macular degeneration 0 ·· ·· 5 20% No ·· Yes No
Smoking Rheumatoid arthritis 0 ·· ·· 5 0 No ·· Yes No
Smoking Hip fracture 0 ·· ·· 15 20% No ·· Yes Yes
(Table 2 continues on next page)
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Outcome RCTs 
(n)
RCTs with 
signiﬁ cant 
eﬀ ect in 
the 
opposite 
direction 
(%)
RCTs 
with null 
ﬁ ndings 
(%)
Prospective 
observational 
studies (n)*
Prospective 
observational 
studies with 
signiﬁ cant 
association in 
the opposite 
direction (%)
Lower 
limit of 
RR >1·5
Dose-
response 
relationship
Biological 
plausibility†
Analogy‡
(Continued from previous page)
Smoking Non-hip fracture 0 ·· ·· 14 14% No ·· Yes Yes
Second-hand smoke Otitis media 0 ·· ·· 17 0 No Yes Yes No
Second-hand smoke Tracheal, bronchial, and lung 
cancer
0 ·· ·· 4 0 No Yes Yes Yes
Second-hand smoke Ischaemic heart disease 0 ·· ·· 4 25% No Yes Yes Yes
Second-hand smoke Ischaemic stroke 0 ·· ·· 10 0 Yes Yes Yes Yes
Second-hand smoke Haemorrhagic stroke 0 ·· ·· 10 0 Yes Yes Yes Yes
Alcohol and drug use
Alcohol use Tuberculosis 0 ·· ·· 3 0 No Yes Yes Yes
Alcohol use Lower respiratory infections 0 ·· ·· 2 0 No Yes Yes Yes
Alcohol use Lip and oral cavity cancer 0 ·· ·· 1 0 No Yes Yes Yes
Alcohol use Nasopharyngeal cancer 0 ·· ·· 1 0 No Yes Yes Yes
Alcohol use Other pharyngeal cancer 0 ·· ·· 1 0 No Yes Yes Yes
Alcohol use Oesophageal cancer 0 ·· ·· 1 0 No Yes Yes Yes
Alcohol use Colon and rectum cancer 0 ·· ·· 6 0 No Yes Yes Yes
Alcohol use Liver cancer 0 ·· 3 0 No Yes Yes Yes
Alcohol use Laryngeal cancer 0 ·· ·· 0 ·· No Yes Yes Yes
Alcohol use Breast cancer 0 ·· ·· 12 0 No Yes Yes Yes
Alcohol use Ischaemic heart disease 0 ·· ·· 32 0 No Yes Yes Yes
Alcohol use Ischaemic stroke 0 ·· ·· 20 0 No Yes Yes Yes
Alcohol use Haemorrhagic stroke 0 ·· ·· 16 0 No Yes Yes Yes
Alcohol use Atrial ﬁ brillation and ﬂ utter 0 ·· ·· 10 0 No Yes Yes Yes
Alcohol use Hypertensive heart disease 0 ·· ·· 2 0 No Yes Yes Yes
Alcohol use Pancreatitis 0 ·· ·· 4 0 No Yes Yes No
Alcohol use Epilepsy 0 ·· ·· 0 ·· No Yes Yes No
Alcohol use Diabetes mellitus 0 ·· ·· 9 0 No Yes Yes No
Alcohol use Cirrhosis 0 ·· ·· 14 0 No Yes Yes Yes
Alcohol use Injuries 0 ·· ·· 29 0 No Yes Yes Yes
Alcohol use Self-harm 0 ·· ·· 0 ·· No Yes Yes Yes
Alcohol use Interpersonal violence 0 ·· ·· 11 0 No Yes Yes Yes
Drug use Hepatitis B 0 ·· ·· 6 0 Yes ·· Yes Yes
Drug use Hepatitis C 0 ·· ·· 16 0 Yes ·· Yes Yes
Drug use Self-harm 0 ·· ·· 1 0 No ·· Yes No
Dietary risks
Diet low in fruits Lip and oral cavity cancer 0 ·· ·· 2 0 No Yes Yes Yes
Diet low in fruits Nasopharyngeal cancer 0 ·· ·· 2 0 No Yes Yes Yes
Diet low in fruits Other pharyngeal cancer 0 ·· ·· 2 0 No Yes Yes Yes
Diet low in fruits Larynx cancer 0 ·· ·· 2 0 No Yes Yes Yes
Diet low in fruits Oesophageal cancer 0 ·· ·· 5 0 No Yes Yes Yes
Diet low in fruits Tracheal, bronchial, and lung 
cancer
0 ·· ·· 22 0 No Yes Yes Yes
Diet low in fruits Ischaemic heart disease 0 ·· ·· 9 0 No Yes Yes Yes
Diet low in fruits Ischaemic stroke 0 ·· ·· 9 0 No Yes Yes Yes
Diet low in fruits Haemorrhagic stroke 0 ·· ·· 5 0 No Yes Yes Yes
Diet low in fruits Diabetes mellitus 0 ·· ·· 9 0 No Yes Yes No
Diet low in vegetables Oesophageal cancer 0 ·· ·· 5 0 No Yes Yes No
Diet low in vegetables Ischaemic heart disease 0 ·· ·· 9 0 No Yes Yes Yes
(Table 2 continues on next page)
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Outcome RCTs 
(n)
RCTs with 
signiﬁ cant 
eﬀ ect in 
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RCTs 
with null 
ﬁ ndings 
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Prospective 
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studies (n)*
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studies with 
signiﬁ cant 
association in 
the opposite 
direction (%)
Lower 
limit of 
RR >1·5
Dose-
response 
relationship
Biological 
plausibility†
Analogy‡
(Continued from previous page)
Diet low in vegetables Ischaemic stroke 0 ·· ·· 8 0 No Yes Yes Yes
Diet low in vegetables Haemorrhagic stroke 0 ·· ·· 5 0 No Yes Yes Yes
Diet low in whole grains Ischaemic heart disease 0 ·· ·· 7 0 No Yes Yes Yes
Diet low in whole grains Ischaemic stroke 0 ·· ·· 6 0 No Yes Yes Yes
Diet low in whole grains Haemorrhagic stroke 0 ·· ·· 6 0 No Yes Yes Yes
Diet low in whole grains Diabetes mellitus 0 ·· ·· 10 0 No Yes Yes No
Diet low in nuts and seeds Ischaemic heart disease 1 0 100% 6 0 No Yes Yes No
Diet low in nuts and seeds Diabetes mellitus 1 0 100% 5 0 No Yes Yes No
Diet low in milk Colon and rectum cancer 0 ·· ·· 7 0 No Yes Yes No
Diet high in red meats Colon and rectum cancer 0 ·· ·· 8 0 No Yes Yes No
Diet high in red meats Diabetes mellitus 0 ·· ·· 9 11% No Yes Yes No
Diet high in processed meats Colon and rectum cancer 0 ·· ·· 9 11% No Yes Yes No
Diet high in processed meats Ischaemic heart disease 0 ·· ·· 5 0 No Yes Yes No
Diet high in processed meats Diabetes mellitus 0 ·· ·· 8 0 No Yes Yes No
Diet high in sugar-sweetened beverages Body-mass index 10 0 60% 22 0 ·· Yes Yes ··
Diet low in ﬁ bre Colon and rectum cancer 0 ·· ·· 15 0 No Yes Yes No
Diet low in ﬁ bre Ischaemic heart disease 0 ·· ·· 12 0 No Yes Yes No
Diet low in calcium Colon and rectum cancer 0 ·· ·· 13 0 No Yes Yes No
Diet low in seafood omega-3 fatty acids Ischaemic heart disease 17 0 88% 16 0 No Yes Yes No
Diet low in polyunsaturated fatty acids Ischaemic heart disease 8 0 75% 11 0 No Yes Yes No
Diet high in trans fatty acids Ischaemic heart disease 0 ·· ·· 4 0 No Yes Yes No
Diet high in sodium Systolic blood pressure 45 0 73% ·· ·· ·· Yes Yes ··
Diet high in sodium Stomach cancer 0 ·· ·· 3 0 No Yes Yes No
Sexual abuse and violence
Intimate partner violence HIV/AIDS 0 ·· ·· 2 0 No ·· Yes No
Intimate partner violence Maternal abortion, 
miscarriage, and ectopic 
pregnancy
0 ·· ·· 1 0 Yes ·· Yes No
Intimate partner violence Depressive disorders 0 ·· ·· 6 0 No ·· Yes Yes
Intimate partner violence Self-harm 0 ·· ·· 2 0 Yes ·· Yes Yes
Childhood sexual abuse Alcohol use disorders 0 ·· ·· 4 0 No ·· Yes Yes
Childhood sexual abuse Depressive disorders 0 ·· ·· 5 0 No ·· Yes Yes
Childhood sexual abuse Self-harm 0 ·· ·· 8 0 No ·· Yes Yes
Low physical activity
Low physical activity Colon and rectum cancer 0 ·· ·· 20 15% No Yes Yes Yes
Low physical activity Breast cancer 0 ·· ·· 35 0 No Yes Yes Yes
Low physical activity Ischaemic heart disease 0 ·· ·· 45 9% No Yes Yes Yes
Low physical activity Ischaemic stroke 0 ·· ·· 27 11% No Yes Yes Yes
Low physical activity Diabetes mellitus 0 ·· ·· 57 7% No Yes Yes No
Metabolic risks
High fasting plasma glucose Ischaemic heart disease 8 0 100% 150 ·· Yes Yes Yes Yes
High fasting plasma glucose Ischaemic stroke 9 0 100% 150 ·· Yes Yes Yes Yes
High fasting plasma glucose Haemorrhagic stroke 9 0 100% 150 ·· Yes Yes Yes Yes
High fasting plasma glucose Peripheral vascular disease 14 ·· ·· 4 0 Yes Yes Yes Yes
High fasting plasma glucose Tuberculosis 0 ·· ·· 17 0 Yes Yes Yes No
High fasting plasma glucose Chronic kidney disease 5 ·· ·· 32 ·· Yes Yes Yes No
High total cholesterol Ischaemic heart disease 21 0 57% 88 ·· Yes Yes Yes Yes
(Table 2 continues on next page)
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(Continued from previous page)
High total cholesterol Ischaemic stroke 21 0 57% 88 ·· Yes Yes Yes Yes
High systolic blood pressure Rheumatic heart disease 0 ·· ·· 62 ·· Yes Yes Yes Yes
High systolic blood pressure Ischaemic heart disease 56 0 ·· 88 ·· Yes Yes Yes Yes
High systolic blood pressure Ischaemic stroke 54 0 ·· 150 ·· Yes Yes Yes Yes
High systolic blood pressure Haemorrhagic stroke 54 0 ·· 150 ·· Yes Yes Yes Yes
High systolic blood pressure Cardiomyopathy and 
myocarditis
0 ·· ·· 62 ·· Yes Yes Yes Yes
High systolic blood pressure Atrial ﬁ brillation and ﬂ utter 20 5% 60% 88 ·· Yes Yes Yes Yes
High systolic blood pressure Aortic aneurysm 0 ·· ·· 62 ·· Yes Yes Yes Yes
High systolic blood pressure Peripheral vascular disease 0 ·· ·· 88 ·· Yes Yes Yes Yes
High systolic blood pressure Endocarditis 0 ·· ·· 62 ·· Yes Yes Yes Yes
High systolic blood pressure Other cardiovascular and 
circulatory diseases
0 ·· ·· 88 ·· No Yes Yes Yes
High systolic blood pressure Chronic kidney disease 8 ·· ·· 88 ·· Yes Yes Yes No
High body-mass index Oesophageal cancer 0 ·· ·· 8 0 No Yes Yes Yes
High body-mass index Colon and rectum cancer 0 ·· ·· 38 0 No Yes Yes Yes
High body-mass index Liver cancer 0 ·· ·· 34 0 No Yes Yes Yes
High body-mass index Gallbladder and biliary tract 
cancer
0 ·· ·· 10 0 No Yes Yes Yes
High body-mass index Pancreatic cancer 0 ·· ·· 20 0 No Yes Yes Yes
High body-mass index Breast cancer (after 
menopause)
0 ·· ·· 44 2% No Yes Yes Yes
High body-mass index Breast cancer (before 
menopause)
0 ·· ·· 25 8% No Yes Yes No
High body-mass index Uterine cancer 0 ·· ·· 37 0 No Yes Yes Yes
High body-mass index Ovarian cancer 0 ·· ·· 31 3% No Yes Yes Yes
High body-mass index Kidney cancer 0 ·· ·· 28 0 No Yes Yes Yes
High body-mass index Thyroid cancer 0 ·· ·· 16 0 No Yes Yes Yes
High body-mass index Leukaemia 0 ·· ·· 17 0 No Yes Yes Yes
High body-mass index Ischaemic heart disease 0 ·· ·· 129 ·· No Yes Yes Yes
High body-mass index Ischaemic stroke 0 ·· ·· 102 ·· No Yes Yes Yes
High body-mass index Haemorrhagic stroke 0 ·· ·· 129 ·· No Yes Yes Yes
High body-mass index Hypertensive heart disease 0 ·· ·· 85 ·· No Yes Yes Yes
High body-mass index Diabetes mellitus 0 ·· ·· 85 ·· Yes Yes Yes No
High body-mass index Chronic kidney disease 0 ·· ·· 57 ·· No Yes Yes No
High body-mass index Osteoarthritis 0 ·· ·· 32 0 No Yes Yes Yes
High body-mass index Low back pain 0 ·· ·· 5 0 No Yes Yes Yes
Low bone mineral density Injuries 0 ·· ·· 12 ·· No Yes Yes Yes
Low glomerular ﬁ ltration rate Ischaemic heart disease 0 ·· ·· 10 0 Yes ·· Yes Yes
Low glomerular ﬁ ltration rate Ischaemic stroke 0 ·· ·· 12 0 Yes ·· Yes Yes
Low glomerular ﬁ ltration rate Haemorrhagic stroke 0 ·· ·· 12 0 Yes ·· Yes Yes
Low glomerular ﬁ ltration rate Peripheral vascular disease 0 ·· ·· 1 0 Yes ·· Yes Yes
Low glomerular ﬁ ltration rate Gout 0 ·· ·· 3 0 Yes ·· Yes No
If multiple reports existed from one study, we counted them as one study. We only assessed the dose-response relationship for continuous risks. To evaluate the magnitude of the eﬀ ect size for continuous risks, 
we evaluated the RR comparing the 75th percentile with the 25th percentile of the exposure distribution at the global level. Additional information for this table is found in the methods appendix (pp 245–63). 
RCT=randomised controlled trial. RR=relative risk. *Prospective cohort studies or non-randomised interventions. †Whether or not any biological or mechanistic pathway exists that could potentially explain the 
relationship of the risk-outcome pair. ‡Whether or not the risk is associated with another outcome from the same category and whether or not any evidence exists that it can cause the current outcome through 
the same pathway. 
Table 2: Epidemiological evidence supporting causality for risk-outcome pairs included in the Global Burden of Disease study 2015
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risk-deleted DALY rates. Risk-deleted rates are the rates 
after removal of the eﬀ ect of a risk factor or combination 
of risk factors; in other words, observed DALY rates 
multiplied by one minus the PAF for the risk or set of 
risks. Our decomposition analyses draw from methods 
developed by Das Gupta19 to provide a computationally 
tractable solution to estimate the contribution of multiple 
factors to an outcome (methods appendix pp 36–37). For 
some risks where the PAF is 100%, such as fasting 
plasma glucose and diabetes, the methods have had to be 
further adapted. We were not able to include three 
outcomes in this analysis: cervical cancer, sexually 
transmitted diseases, and HIV/AIDS.
Risk transition with development
We examined how changes in risk exposure were related 
to changes along the development spectrum. Drawing 
from methods used to construct the Human Development 
Index,20 we constructed the SDI, a summary measure of 
overall development based on estimates of lag-dependent 
income per capita, average educational attainment over 
the age of 15 years, and total fertility rate. In the SDI, we 
weighted each component equally and rescaled them 
from zero (for the lowest value observed during 
1980–2015) to one (for the highest value observed) for 
income per capita and average years of schooling, and 
the reverse for the total fertility rate. We computed the 
ﬁ nal SDI score as the geometric mean of each of the 
components. For each risk, we calculated the average 
relationship between risk exposure, as measured by SEV, 
and SDI across all geography years by age and sex using 
spline regression (methods appendix pp 38–39). We then 
used this relationship to characterise how exposures to 
risk vary on the basis of SDI alone.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The authors had full access to all the data in 
the study and had ﬁ nal responsibility to submit for 
publication. 
Results
Global exposure to risks
The SEV is a single, interpretable measure, which 
captures risk-weighted exposure for a population, or risk-
weighted prevalence of an exposure. The scale for SEV 
spans 0% to 100%, such that an SEV of 0% reﬂ ects no 
risk exposure in a population and 100% indicates that an 
entire population has maximum possible risk. A decline 
in SEV indicates reduced exposure to a given risk factor, 
whereas an increase in SEV indicates increased exposure. 
Table 3 provides age-standardised SEVs for 61 risks at the 
global level, by sex, for 1990, 2005, and 2015 (results 
appendix pp 3619–4070 contains results for every 
geography). From 1990 to 2015, SEVs decreased by more 
than 30% for four risks: unsafe sanitation (38·3% 
[95% UI 36·1–40·5]), childhood underweight (34·2% 
[30·9–37·9]), childhood stunting (33·4% [30·3–37·4]), 
and household air pollution (30·2% [26·9–33·2]). The 
global SEV for smoking also decreased by 2015, 
decreasing by 27·5% (23·2–30·9) for men and 28·7% 
(20·2–34·1) for women; notably, smoking exposure 
among men still far exceeded that for women in 2015. 
Signiﬁ cant, although more moderate than for smoking 
reductions in global SEVs for both sexes occurred for 
second-hand smoke (12·2% [9·4–15·1]), unsafe water 
(9·4% [5·3–13·0]), and diet high in red meat (9·0% 
[7·6–10·3]) from 1990 to 2015. Risk exposure for high 
total cholesterol signiﬁ cantly declined for both men and 
women during this time, although this decrease was 
smaller among men (3·2% [2·2–4·4]) than among 
women (5·6% [4·6–6·7]). For a subset of occupational 
risk factors, such as ergonomic factors and asthmagens, 
global SEVs were reduced from 1990 to 2015.
For a subset of risks, minimal changes in exposure 
occurred between 1990 and 2015. This ﬁ nding was 
particularly evident among various dietary risks (eg, diet 
low in fruits) and behaviours related to nutrition 
(eg, non-exclusive and discontinued breastfeeding). 
Discordant trends emerged by sex for some risk factors, 
such as low physical activity, where global SEVs for men 
increased by 2·4% (95% UI 1·8–2·9), whereas the SEV for 
women declined by 1·5% (1·0–2·0). Global SEVs 
signiﬁ cantly increased for 27 risk factors for both sexes 
combined from 1990 to 2015; signiﬁ cant increases occurred 
for 24 risks for men alone and 23 risks for women alone. 
We recorded the most pronounced rises for various 
occupational exposures, such as diesel engine exhaust, 
silica, and benzene. Global SEVs for high body-mass index 
(BMI) increased by 38·7% (29·9–55·6) for men and 34·4% 
(27·7–45·7) for women. For both sexes, other risks with 
large increases included drug use (30·2% [23·3–39·1]), 
ambient ozone pollution (24·6% [15·0–31·9]), and high 
fasting plasma glucose (23·8% [22·4–25·4]).
Global attributable burden for all risk factors combined 
and their overlap
The proportion of deaths, YLLs, YLDs, and DALYs that 
could be jointly attributable to all risk factors combined 
diﬀ ered by cause group and measure of health (table 4). 
Globally, 57·8% (95% UI 56·6–58·8) of deaths, 48·4% 
(47·4–49·3) of YLLs, 26·1% (25·0–27·1) of YLDs, and 
41·2% (39·8–42·8) of DALYs could be attributed to the 
risk factors currently assessed as part of GBD 2015. 
Across health outcomes, attributable DALYs were 
highest for non-communicable diseases (NCDs), 
although the percentage of attributable burden ranged 
from 20·9% (19·7–22·0) for YLDs to 64·8% (63·3–66·2) 
for deaths in 2015. Among NCD cause groups, 
attributable DALYs were as high as 85·3% (84·0–86·6) 
for cardiovascular and circulatory diseases compared 
with low attributable DALYs, even among leading 
causes of disease burden (ie, 16·0% [13·9–18·2] for 
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Men Women
1990 (%) 2005 (%) 2015 (%) Percentage 
change 
1990–2005
Percentage 
change 
2005–15
Percentage 
change 
1990–2015
1990 (%) 2005 (%) 2015 (%) Percentage 
change 
1990–2005
Percentage 
change 
2005–15
Percentage 
change 
1990–2015
Unsafe sanitation 55·0
(53·8 to 
56·5)
42·6
(41·5 to 
43·8)
33·7
(32·2 to 
35·1)
–22·6
(–24·0 to 
–20·9)*
–26·5
(–23·5 to 
–18·5)*
–38·8
(–41·0 to 
–36·6)*
54·2
(52·8 to 
55·7)
42·3
(41·2 to 
43·6)
33·7
(32·2 to 
35·1)
–21·9
(–23·4 to 
–20·2)*
–25·6
(–23·0 to 
–18·0)*
–37·8
(–40·0 to 
–35·6)*
Childhood underweight 13·2
(11·7 to 
14·7)
11·3
(9·9 to 
12·6)
8·7
(7·4 to 
10·0)
–14·5
(–16·9 to 
–12·1)*
–30·0
(–26·5 to 
–20·1)*
–34·2
(–37·8 to 
–30·8)*
13·1
(11·6 to 
14·5)
11·2
(9·8 to 
12·5)
8·6
(7·3 to 
9·9)
–14·7
(–17·1 to 
–12·3)*
–29·9
(–26·5 to 
–20·1)*
–34·3
(–37·9 to 
–31·0)*
Childhood stunting 27·0
(18·6 to 
29·6)
22·5
(15·7 to 
24·8)
18·0
(12·6 to 
20·2)
–16·7
(–19·1 to 
–14·6)*
–25·2
(–23·5 to 
–17·7)*
–33·5
(–37·6 to 
–30·5)*
26·3
(18·1 to 
28·8)
21·9
(15·2 to 
24·2)
17·5
(12·2 to 
19·8)
–16·6
(–19·0 to 
–14·5)*
–24·9
(–23·2 to 
–17·5)*
–33·2
(–37·3 to 
–30·2)*
Household air pollution from solid 
fuels
23·2
(15·7 to 
32·1)
19·9
(13·5 to 
27·6)
16·0
(10·8 to 
22·2)
–14·1
(–16·1 to 
–12·1)*
–24·2
(–22·6 to 
–16·3)*
–30·8
(–33·9 to 
–27·4)*
29·3
(20·2 to 
39·3)
25·4
(17·6 to 
34·1)
20·6
(14·1 to 
27·6)
–13·3
(–15·4 to 
–11·2)*
–23·2
(–21·9 to 
–15·8)*
–29·6
(–32·7 to 
–26·3)*
Smoking 29·0
(27·0 to 
31·6)
24·7
(22·7 to 
27·4)
21·0
(19·4 to 
23·4)
–15·0
(–17·5 to 
–12·3)*
–17·2
(–17·9 to 
–11·5)*
–27·5
(–30·9 to 
–23·2)*
8·7
(7·7 to 
10·6)
7·6
(6·6 to 
9·5)
6·2
(5·5 to 
7·9)
–12·9
(–16·0 to 
–8·2)*
–22·2
(–24·1 to 
–11·8)*
–28·7
(–34·1 to 
–20·2)*
Occupational ergonomic factors 36·5
(35·4 to 
37·9)
30·5
(29·2 to 
32·0)
26·8
(25·3 to 
28·6)
–16·5
(–17·6 to 
–15·3)*
–13·7
(–13·5 to 
–10·6)*
–26·6
(–28·6 to 
–24·3)*
23·9
(23·3 to 
24·7)
22·2
(21·4 to 
23·0)
21·3
(20·4 to 
22·4)
–7·4
(–8·5 to 
–6·3)*
–4·0
(–5·2 to 
–2·5)*
–11·0
(–12·9 to 
–9·0)*
Lead exposure 19·4
(7·6 to 
36·3)
18·6
(7·3 to 
35·2)
15·7
(5·7 to 
31·5)
–4·1
(–6·3 to 
–2·6)*
–18·0
(–22·4 to 
–10·4)*
–18·8
(–26·3 to 
–13·1)*
17·5
(6·3 to 
34·2)
17·1
(6·2 to 
33·7)
14·5
(4·8 to 
30·2)
–2·5
(–4·7 to 
–0·9)*
–17·9
(–22·7 to 
–10·3)*
–17·3
(–25·6 to 
–11·9)*
Occupational asthmagens 30·2
(23·1 to 
38·1)
26·3
(20·4 to 
32·9)
23·6
(18·7 to 
29·2)
–12·9
(–14·7 to 
–10·6)*
–11·5
(–12·0 to 
–8·1)*
–21·8
(–24·7 to 
–18·1)*
17·3
(13·0 to 
22·7)
16·9
(12·8 to 
21·9)
17·1
(13·3 to 
21·7)
–2·6
(–6·0 to 
1·2)
1·4
(–1·1 to 
4·2)
–1·3
(–5·8 to 
4·9)
Childhood sexual abuse 8·8
(4·6 to 
9·4)
7·9
(4·1 to 
8·4)
7·5
(3·9 to 
8·0)
–10·4
(–12·0 to 
–8·9)*
–4·9
(–6·2 to 
–3·2)*
–14·6
(–15·9 to 
–13·3)*
9·8
(5·1 to 
10·4)
8·9
(4·6 to 
9·5)
8·6
(4·5 to 
9·2)
–9·0
(–10·6 to 
–7·5)*
–3·5
(–5·0 to 
–1·8)*
–12·1
(–13·5 to 
–10·6)*
Vitamin A deﬁ ciency 32·4
(30·6 to 
34·6)
32·4
(30·4 to 
34·7)
28·4
(26·7 to 
30·4)
–0·3
(–3·1 to 2·5)
–13·8
(–14·6 to 
–9·5)*
–12·4
(–15·0 to 
–9·8)*
29·5
(27·8 to 
31·7)
29·2
(27·4 to 
31·5)
25·8
(24·2 to 
27·8)
–1·0
(–3·8 to 
1·9)
–13·2
(–14·2 to 
–9·1)*
–12·6
(–15·2 to 
–9·8)*
Second-hand smoke 21·0
(19·4 to 
22·6)
19·2
(17·8 to 
20·8)
18·5
(17·0 to 
20·1)
–8·5
(–10·7 to 
–6·3)*
–3·5
(–5·1 to 
–1·6)*
–11·6
(–14·5 to 
–8·7)*
31·7
(29·8 to 
33·8)
29·1
(27·6 to 
30·7)
27·8
(26·3 to 
29·3)
–8·1
(–10·9 to 
–5·5)*
–4·8
(–5·8 to 
–3·4)*
–12·3
(–15·6 to 
–9·3)*
Childhood wasting 6·2
(5·5 to 
6·8)
6·0
(5·3 to 
6·6)
5·4
(4·8 to 
6·0)
–2·1
(–6·6 to 
2·6)
–11·4
(–15·0 to 
–5·7)*
–12·1
(–16·7 to 
–7·0)*
6·0
(5·3 to 
6·6)
5·9
(5·1 to 
6·4)
5·3
(4·6 to 
5·9)
–2·2
(–6·9 to 
2·5)
–11·3
(–14·9 to 
–5·6)*
–12·1
(–16·7 to 
–6·9)*
Occupational exposure to arsenic 0·3
(0·3 to 
0·3)
0·3
(0·3 to 
0·3)
0·3
(0·3 to 
0·3)
0·3
(–0·5 to 1·0)
–9·9
(–9·6 to 
–8·5)*
–8·8
(–9·6 to 
–7·9)*
0·1
(0·1 to 
0·1)
0·1
(0·1 to 
0·1)
0·1
(0·1 to 
0·1)
2·5
(1·0 to 
4·1)*
–20·5
(–18·1 to 
–15·8)*
–14·9
(–16·6 to 
–13·3)*
Unsafe water source 62·1
(57·8 to 
66·8)
58·6
(53·6 to 
64·1)
56·0
(50·4 to 
62·1)
–5·7
(–8·2 to 
–3·2)*
–4·7
(–6·2 to 
–2·6)*
–10·0
(–13·5 to 
–5·9)*
61·1
(56·8 to 
65·8)
58·0
(53·0 to 
63·5)
55·7
(50·2 to 
61·8)
–5·1
(–7·6 to 
–2·4)*
–4·3
(–5·8 to 
–2·2)*
–8·9
(–12·6 to 
–4·9)*
Diet high in red meat 10·5
(8·9 to 
12·5)
9·8
(8·2 to 
11·7)
9·7
(8·0 to 
11·5)
–6·5
(–7·8 to 
–5·3)*
–2·0
(–3·3 to 
–0·8)*
–8·4
(–9·8 to 
–6·9)*
9·5
(7·9 to 
11·4)
8·8
(7·3 to 
10·6)
8·6
(7·1 to 
10·4)
–7·2
(–8·5 to 
–5·9)*
–2·7
(–3·8 to 
–1·4)*
–9·6
(–11·0 to 
–8·1)*
No handwashing with soap 84·3
(81·3 to 
87·2)
80·7
(76·7 to 
84·6)
77·1
(72·4 to 
81·8)
–4·4
(–5·9 to 
–2·9)*
–4·6
(–5·8 to 
–3·2)*
–8·6
(–11·3 to 
–6·0)*
83·9
(80·8 to 
86·8)
80·3
(76·3 to 
84·3)
76·9
(72·2 to 
81·6)
–4·2
(–5·7 to 
–2·8)*
–4·5
(–5·6 to 
–3·1)*
–8·4
(–11·0 to 
–5·8)*
Occupational exposure to asbestos 2·5
(1·7 to 
4·2)
2·3
(1·6 to 
3·7)
2·4
(1·7 to 
3·7)
–8·4
(–15·3 to 
2·7)
4·9
(–0·4 to 
11·8)
–3·7
(–14·3 to 
10·6)
0·9
(0·7 to 
1·5)
0·7
(0·5 to 
1·2)
0·8
(0·6 to 
1·2)
–21·5
(–30·4 to 
–9·1)*
3·0
(–3·2 to 
10·5)
–19·1
(–27·4 to 
–8·5)*
Zinc deﬁ ciency 16·8
(9·8 to 
20·3)
16·8
(9·8 to 
20·2)
15·6
(9·1 to 
18·8)
–0·0
(–2·6 to 
2·9)
–7·8
(–9·6 to 
–4·7)*
–7·2
(–9·6 to 
–4·4)*
16·8
(9·8 to 
20·2)
16·8
(9·8 to 
20·3)
15·6
(9·1 to 
18·9)
0·3
(–2·3 to 
3·2)
–7·6
(–9·4 to 
–4·4)*
–6·8
(–9·2 to 
–4·0)*
Iron deﬁ ciency ·· ·· ·· ·· ·· ·· 17·6
(12·4 to 
23·7)
17·5
(12·6 to 
23·4)
16·5
(12·1 to 
21·8)
–0·5
(–7·2 to 
4·7)
–6·0
(–14·7 to 
1·1)
–6·1
(–19·1 to 
5·0)
(Table 3 continues on next page)
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Men Women
1990 (%) 2005 (%) 2015 (%) Percentage 
change 
1990–2005
Percentage 
change 
2005–15
Percentage 
change 
1990–2015
1990 (%) 2005 (%) 2015 (%) Percentage 
change 
1990–2005
Percentage 
change 
2005–15
Percentage 
change 
1990–2015
(Continued from previous page)
Low bone mineral density 19·0
(15·8 to 
22·9)
18·3
(15·3 to 
22·0)
17·8
(14·4 to 
21·6)
–3·8
(–8·4 to 
1·6)
–2·8
(–8·3 to 
2·8)
–6·4
(–11·5 to 
–0·9)*
22·1
(18·8 to 
25·8)
21·5
(18·3 to 
24·9)
21·1
(17·5 to 
25·0)
–2·7
(–6·4 to 
1·0)
–1·9
(–6·5 to 
2·9)
–4·6
(–8·8 to 
–0·2)*
Alcohol use 10·9
(10·1 to 
11·6)
10·5
(9·8 to 
11·3)
10·7
(9·5 to 
11·8)
–2·8
(–3·7 to 
–1·8)*
1·7
(–3·0 to 5·1)
–1·1
(–6·0 to 
2·3)
5·9
(5·3 to 
6·4)
5·3
(4·8 to 
5·8)
5·1
(4·5 to 
5·7)
–10·1
(–11·0 to 
–9·3)*
–3·4
(–6·4 to 
–0·9)*
–13·1
(–16·1 to 
–10·7)*
High total cholesterol 30·4
(24·2 to 
37·2)
29·8
(23·7 to 
36·6)
29·4
(23·3 to 
36·2)
–1·8
(–2·7 to 
–1·0)*
–1·5
(–2·1 to 
–0·8)*
–3·2
(–4·4 to 
–2·2)*
33·7
(27·5 to 
40·6)
32·4
(26·2 to 
39·3)
31·8
(25·7 to 
38·6)
–3·9
(–4·8 to 
–3·0)*
–1·8
(–2·5 to 
–1·2)*
–5·6
(–6·7 to 
–4·6)*
Occupational noise 42·5
(32·4 to 
53·5)
40·6
(30·5 to 
52·9)
40·5
(31·0 to 
53·4)
–4·5
(–10·4 to 
1·0)
–0·3
(–3·8 to 3·2)
–4·7
(–10·9 to 
1·2)
25·2
(19·4 to 
32·9)
24·1
(18·4 to 
32·5)
24·4
(18·9 to 
33·4)
–4·5
(–10·5 to 
0·9)
1·2
(–4·1 to 
6·1)
–3·3
(–9·8 to 
3·7)
Diet high in processed meat 9·2
(7·3 to 
11·3)
9·0
(7·1 to 
11·1)
8·9
(7·0 to 
11·0)
–2·6
(–3·9 to 
–1·2)*
–0·6
(–1·9 to 
0·8)
–3·1
(–4·6 to 
–1·7)*
8·4
(6·6 to 
10·5)
8·1
(6·3 to 
10·1)
8·0
(6·3 to 
10·0)
–3·6
(–5·0 to 
–2·3)*
–1·0
(–2·3 to 
0·3)
–4·6
(–6·1 to 
–3·3)*
Diet low in ﬁ bre 15·6
(8·0 to 
24·3)
15·2
(7·8 to 
23·7)
15·0
(7·6 to 
23·5)
–2·5
(–4·1 to 
–1·1)*
–1·2
(–3·5 to 
0·9)
–3·7
(–5·3 to 
–2·5)*
14·4
(7·2 to 
22·7)
14·0
(6·9 to 
22·1)
13·8
(6·8 to 
21·8)
–2·8
(–4·7 to 
–1·3)*
–1·1
(–3·4 to 
1·2)
–3·9
(–5·4 to 
–2·6)*
Non-exclusive breastfeeding 16·5
(8·1 to 
40·4)
15·8
(8·2 to 
37·6)
15·9
(8·4 to 
37·1)
–4·6
(–13·0 to 
11·9)
1·2
(–7·9 to 
18·6)
–3·5
(–14·2 to 
23·2)
16·5
(8·0 to 
40·4)
15·7
(8·1 to 
37·6)
15·9
(8·3 to 
37·1)
–5·0
(–13·0 to 
10·5)
1·0
(–7·4 to 
17·7)
–4·0
(–14·0 to 
21·4)
Occupational exposure to beryllium 0·1
(0·1 to 
0·1)
0·1
(0·1 to 
0·1)
0·1
(0·1 to 
0·1)
7·8
(6·3 to 
9·1)*
–10·3
(–10·3 to 
–8·5)*
–2·3
(–3·8 to 
–0·8)*
0·1
(0·1 to 
0·1)
0·1
(0·1 to 
0·1)
0·0
(0·0 to 
0·1)
12·9
(10·3 to 
15·5)*
–20·2
(–18·4 to 
–15·2)*
–6·1
(–8·8 to 
–3·4)*
Diet low in vegetables 57·7
(39·1 to 
77·0)
57·6
(39·0 to 
77·1)
56·8
(38·5 to 
76·1)
–0·1
(–0·7 to 0·5)
–1·3
(–1·8 to 
–0·8)*
–1·4
(–2·2 to 
–0·7)*
56·2
(37·9 to 
75·5)
55·9
(37·6 to 
75·2)
55·3
(37·2 to 
74·4)
–0·4
(–1·0 to 
0·2)
–1·1
(–1·8 to 
–0·6)*
–1·5
(–2·5 to 
–0·8)*
Occupational particulate matter, 
gases, and fumes
23·4
(17·7 to 
30·5)
22·8
(17·5 to 
29·5)
23·2
(18·0 to 
29·7)
–2·6
(–4·6 to 
–0·6)*
1·6
(0·7 to 2·7)*
–1·1
(–3·8 to 
2·0)
13·3
(10·0 to 
19·2)
13·0
(9·9 to 
18·4)
13·0
(9·9 to 
18·5)
–2·6
(–5·5 to 
–0·0)*
0·2
(–0·7 to 
1·1)
–2·4
(–5·3 to 
0·2)
Diet low in whole grains 71·8
(52·1 to 
89·1)
71·7
(51·9 to 
89·2)
71·3
(51·5 to 
89·1)
–0·1
(–0·5 to 0·2)
–0·5
(–0·9 to 
–0·1)*
–0·7
(–1·2 to 
0·0)
71·7
(52·0 to 
89·0)
71·5
(51·8 to 
89·0)
71·1
(51·3 to 
88·8)
–0·2
(–0·6 to 
0·1)
–0·6
(–1·0 to 
–0·2)*
–0·9
(–1·4 to 
–0·1)*
Low glomerular ﬁ ltration rate 3·5
(3·1 to 
3·8)
3·4
(3·1 to 
3·7)
3·5
(3·1 to 
3·8)
–1·1
(–2·2 to 
–0·0)*
1·6
(0·8 to 
2·5)*
0·5
(–0·5 to 
1·4)
4·9
(4·4 to 
5·3)
4·8
(4·4 to 
5·3)
4·8
(4·4 to 
5·3)
–0·7
(–1·9 to 
0·3)
0·6
(–0·3 to 
1·5)
–0·2
(–1·3 to 
1·0)
Diet low in fruits 58·7
(41·1 to 
75·6)
58·9
(41·3 to 
75·8)
58·6
(40·9 to 
75·4)
0·3
(0·1 to 
0·6)*
–0·6
(–1·1 to 
–0·1)*
–0·3
(–0·7 to 
0·1)
55·3
(38·3 to 
71·7)
55·6
(38·5 to 
72·0)
55·0
(38·0 to 
71·5)
0·6
(0·3 to 
0·9)*
–1·0
(–1·7 to 
–0·5)*
–0·4
(–1·1 to 
0·1)
Diet low in nuts and seeds 96·3
(84·3 to 
99·8)
96·1
(84·0 to 
99·8)
96·0
(83·9 to 
99·7)
–0·2
(–0·5 to 
–0·0)*
–0·1
(–0·2 to 0·1)
–0·3
(–0·6 to 
–0·1)*
96·1
(83·8 to 
99·8)
95·9
(83·5 to 
99·8)
95·8
(83·4 to 
99·7)
–0·2
(–0·5 to 
–0·0)*
–0·1
(–0·2 to 
0·0)
–0·3
(–0·6 to 
–0·1)*
Diet low in seafood omega-3 fatty 
acids
77·3
(57·6 to 
94·0)
77·3
(57·6 to 
94·0)
77·4
(57·8 to 
94·1)
–0·0
(–0·3 to 0·2)
0·2
(0·0 to 
0·5)*
0·2
(–0·1 to 
0·6)
77·3
(57·5 to 
94·0)
77·4
(57·7 to 
94·1)
77·6
(57·9 to 
94·3)
0·1
(–0·1 to 
0·4)
0·3
(0·1 to 
0·6)*
0·5
(0·1 to 
0·9)*
Discontinued breastfeeding 13·5
(13·3 to 
14·0)
12·9
(12·8 to 
13·2)
13·7
(13·5 to 
14·1)
–4·8
(–7·1 to 
–2·5)*
5·6
(3·9 to 
8·0)*
0·8
(–1·8 to 
3·9)
13·5
(13·3 to 
13·9)
12·8
(12·7 to 
13·1)
13·5
(13·4 to 
13·9)
–5·4
(–7·5 to 
–3·2)*
5·4
(3·7 to 
7·8)*
0·0
(–2·5 to 
3·0)
Low physical activity 45·3
(40·9 to 
49·2)
45·9
(41·5 to 
49·8)
46·3
(42·0 to 
50·3)
1·3
(0·7 to 
2·0)*
1·0
(0·7 to 1·4)*
2·4
(1·8 to 
2·9)*
39·9
(35·7 to 
43·9)
39·4
(35·1 to 
43·4)
39·4
(35·0 to 
43·4)
–1·3
(–1·8 to 
–0·8)*
–0·2
(–0·6 to 
0·2)
–1·5
(–2·0 to 
–1·0)*
Diet low in milk 81·0
(63·4 to 
95·4)
81·6
(64·0 to 
95·9)
81·9
(64·2 to 
96·2)
0·8
(0·5 to 1·1)*
0·4
(0·2 to 
0·5)*
1·2
(0·9 to 
1·5)*
80·0
(62·4 to 
94·7)
80·8
(63·1 to 
95·2)
81·2
(63·5 to 
95·7)
1·0
(0·6 to 
1·3)*
0·5
(0·3 to 
0·7)*
1·5
(1·1 to 
1·9)*
Diet low in calcium 63·3
(34·2 to 
94·0)
63·9
(34·6 to 
94·8)
64·3
(35·1 to 
95·2)
0·9
(0·5 to 
1·4)*
0·7
(0·1 to 1·5)*
1·6
(0·8 to 
2·7)*
60·2
(32·2 to 
91·4)
61·0
(32·6 to 
92·6)
61·7
(33·3 to 
93·3)
1·3
(0·7 to 
2·0)*
1·0
(0·3 to 
2·0)*
2·4
(1·4 to 
3·7)*
(Table 3 continues on next page)
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Men Women
1990 (%) 2005 (%) 2015 (%) Percentage 
change 
1990–2005
Percentage 
change 
2005–15
Percentage 
change 
1990–2015
1990 (%) 2005 (%) 2015 (%) Percentage 
change 
1990–2005
Percentage 
change 
2005–15
Percentage 
change 
1990–2015
(Continued from previous page)
Occupational exposure to nickel 0·9
(0·9 to 
1·0)
1·1
(1·1 to 
1·1)
1·0
(1·0 to 
1·0)
13·6
(12·1 to 
14·9)*
–8·5
(–8·7 to 
–7·0)*
4·6
(3·1 to 
6·2)*
0·4
(0·4 to 
0·4)
0·5
(0·5 to 
0·5)
0·4
(0·4 to 
0·4)
14·9
(12·3 to 
17·6)*
–19·4
(–17·7 to 
–14·7)*
–3·8
(–6·4 to 
–1·1)*
Diet high in trans fatty acids 7·8
(3·5 to 
14·2)
8·0
(3·7 to 
14·5)
8·1
(3·8 to 
14·6)
2·4
(0·5 to 5·3)*
1·5
(–0·3 to 
3·8)
4·0
(2·5 to 
7·0)*
7·9
(3·6 to 
14·3)
8·1
(3·7 to 
14·6)
8·3
(3·9 to 
14·8)
2·6
(0·9 to 
5·4)*
2·3
(0·6 to 
5·2)*
5·0
(3·2 to 
8·8)*
Intimate partner violence ·· ·· ·· ·· ·· ·· 15·6
(13·2 to 
17·8)
15·4
(13·2 to 
17·4)
16·3
(14·0 to 
18·5)
–1·4
(–3·7 to 
1·1)
5·7
(4·4 to 
7·6)*
4·5
(2·7 to 
6·6)*
Ambient particulate matter 
pollution
46·4
(39·8 to 
53·4)
47·7
(41·1 to 
54·7)
48·9
(42·2 to 
55·8)
2·8
(2·1 to 3·7)*
2·3
(1·8 to 3·1)*
5·3
(4·0 to 
6·6)*
45·5
(39·0 to 
52·5)
46·8
(40·2 to 
53·7)
48·0
(41·4 to 
54·9)
2·7
(2·0 to 
3·6)*
2·6
(2·0 to 
3·3)*
5·4
(4·1 to 
6·8)*
High systolic blood pressure 18·2
(15·7 to 
21·0)
18·9
(16·2 to 
21·8)
20·7
(17·9 to 
23·8)
3·3
(2·3 to 
4·3)*
8·8
(8·7 to 
10·8)*
13·3
(12·1 to 
14·7)*
18·2
(15·8 to 
20·8)
17·4
(15·0 to 
20·1)
18·1
(15·6 to 
20·8)
–4·6
(–5·9 to 
–3·3)*
3·7
(2·8 to 
4·9)*
–0·9
(–2·3 to 
0·5)
Diet high in sodium 12·2
(5·1 to 
23·5)
12·8
(5·6 to 
24·3)
13·1
(6·0 to 
24·9)
4·9
(2·2 to 
10·3)*
2·1
(–1·8 to 
8·4)
7·2
(0·7 to 
19·0)*
9·0
(3·4 to 
19·0)
9·4
(3·7 to 
19·4)
9·4
(3·7 to 
19·4)
4·0
(1·8 to 
8·7)*
–0·0
(–2·6 to 
3·8)
4·0
(–0·3 to 
12·1)
Residential radon 14·7
(12·6 to 
16·8)
15·2
(13·0 to 
17·4)
15·6
(13·5 to 
17·9)
3·4
(2·3 to 
4·4)*
3·0
(2·6 to 
3·8)*
6·6
(5·0 to 
8·2)*
14·8
(12·6 to 
17·0)
15·3
(13·1 to 
17·5)
15·8
(13·6 to 
18·1)
3·4
(2·2 to 
4·6)*
3·2
(2·7 to 
3·9)*
6·8
(5·1 to 
8·5)*
Diet high in sugar-sweetened 
beverages
8·3
(7·5 to 
9·0)
8·8
(7·9 to 
9·7)
8·7
(7·8 to 
9·7)
6·6
(1·6 to 
11·2)*
–1·0
(–2·9 to 1·0)
5·6
(–0·4 to 
10·9)
6·4
(5·7 to 
7·1)
7·0
(6·3 to 
7·6)
7·0
(6·2 to 
7·7)
8·8
(3·1 to 
14·0)*
0·4
(–1·9 to 
2·5)
9·2
(1·5 to 
15·6)*
Occupational exposure to 
chromium
1·3
(1·3 to 
1·3)
1·4
(1·4 to 
1·5)
1·4
(1·4 to 
1·4)
12·5
(11·2 to 
13·8)*
–4·3
(–5·0 to 
–3·2)*
7·9
(6·4 to 
9·4)*
0·6
(0·6 to 
0·6)
0·7
(0·7 to 
0·7)
0·6
(0·6 to 
0·6)
19·7
(17·3 to 
22·3)*
–10·3
(–10·7 to 
–8·0)*
8·5
(5·8 to 
11·2)*
Occupational exposure to 
formaldehyde
1·1
(1·0 to 
1·1)
1·1
(1·0 to 
1·1)
1·1
(1·1 to 
1·2)
5·9
(4·9 to 
6·9)*
1·7
(0·8 to 
2·4)*
7·7
(6·4 to 
9·0)*
0·6
(0·5 to 
0·6)
0·6
(0·6 to 
0·6)
0·6
(0·6 to 
0·6)
12·7
(11·0 to 
14·6)*
–1·8
(–3·0 to 
–0·6)*
10·7
(8·6 to 
12·8)*
Occupational exposure to 
trichloroethylene
0·5
(0·5 to 
0·5)
0·5
(0·5 to 
0·5)
0·5
(0·5 to 
0·5)
13·5
(12·3 to 
14·6)*
–1·2
(–2·0 to 
–0·3)*
12·2
(10·8 to 
13·5)*
0·2
(0·2 to 
0·2)
0·2
(0·2 to 
0·2)
0·2
(0·2 to 
0·2)
20·6
(18·5 to 
22·8)*
–5·8
(–6·6 to 
–4·1)*
14·0
(11·6 to 
16·4)*
Diet low in polyunsaturated fatty 
acids
34·1
(32·1 to 
36·8)
35·7
(32·4 to 
40·0)
39·8
(34·5 to 
46·3)
4·7
(–1·4 to 
11·9)
10·3
(4·1 to 
19·5)*
16·7
(4·8 to 
31·0)*
35·8
(33·6 to 
38·5)
37·6
(33·8 to 
42·1)
41·7
(35·9 to 
48·4)
5·1
(–1·7 to 
12·7)
9·8
(3·7 to 
18·2)*
16·5
(4·4 to 
29·8)*
Occupational exposure to sulphuric 
acid
1·4
(1·2 to 
1·5)
1·6
(1·4 to 
1·8)
1·6
(1·4 to 
1·8)
16·7
(14·9 to 
18·6)*
–0·4
(–2·0 to 
0·9)
16·3
(14·5 to 
18·1)*
0·5
(0·5 to 
0·6)
0·6
(0·6 to 
0·7)
0·6
(0·6 to 
0·7)
22·9
(20·5 to 
25·4)*
–6·8
(–8·1 to 
–4·9)*
15·1
(12·4 to 
17·7)*
Occupational exposure to cadmium 0·3
(0·3 to 
0·3)
0·4
(0·4 to 
0·4)
0·4
(0·4 to 
0·4)
17·1
(15·8 to 
18·5)*
1·3
(0·4 to 
2·3)*
18·7
(17·1 to 
20·3)*
0·1
(0·1 to 
0·1)
0·2
(0·2 to 
0·2)
0·1
(0·1 to 
0·2)
21·3
(18·9 to 
23·8)*
–10·0
(–10·4 to 
–7·7)*
10·3
(7·6 to 
12·9)*
Occupational exposure to 
second-hand smoke
14·3
(14·2 to 
14·3)
16·2
(16·1 to 
16·2)
16·5
(16·4 to 
16·6)
13·3
(12·7 to 
14·0)*
2·0
(1·5 to 2·7)*
15·6
(14·8 to 
16·4)*
5·4
(5·3 to 
5·4)
6·5
(6·5 to 
6·6)
7·0
(7·0 to 
7·1)
21·4
(20·8 to 
22·1)*
7·4
(7·5 to 
8·6)*
31·2
(30·3 to 
32·0)*
High fasting plasma glucose 6·8
(5·7 to 
8·2)
7·6
(6·4 to 
9·1)
8·5
(7·2 to 
10·1)
11·7
(10·8 to 
12·7)*
10·6
(11·0 to 
12·7)*
25·0
(23·3 to 
26·7)*
6·6
(5·4 to 
7·9)
7·2
(6·0 to 
8·6)
8·0
(6·7 to 
9·6)
9·4
(8·6 to 
10·4)*
10·8
(11·2 to 
13·1)*
22·7
(21·1 to 
24·4)*
Ambient ozone pollution 38·5
(13·9 to 
67·9)
42·8
(15·5 to 
73·7)
48·2
(17·6 to 
78·3)
11·2
(8·4 to 
13·8)*
11·2
(6·3 to 
16·8)*
25·2
(15·3 to 
32·8)*
38·2
(13·8 to 
67·4)
42·2
(15·3 to 
72·8)
47·4
(17·2 to 
77·4)
10·3
(7·9 to 
12·7)*
11·0
(6·3 to 
16·4)*
24·0
(14·8 to 
31·0)*
Drug use 0·4
(0·2 to 
0·7)
0·4
(0·2 to 
0·8)
0·5
(0·2 to 
0·9)
17·6
(12·7 to 
24·4)*
9·5
(7·7 to 
13·7)*
29·9
(22·4 to 
40·3)*
0·2
(0·1 to 
0·3)
0·2
(0·1 to 
0·4)
0·2
(0·1 to 
0·4)
15·6
(12·5 to 
19·3)*
11·3
(9·9 to 
15·6)*
30·3
(24·3 to 
36·7)*
High body-mass index 3·6
(1·6 to 
6·1)
4·4
(2·2 to 
7·3)
5·0
(2·5 to 
8·0)
23·7
(18·5 to 
33·9)*
10·8
(9·6 to 
16·5)*
38·7
(29·9 to 
55·6)*
4·6
(2·5 to 
7·3)
5·7
(3·2 to 
8·7)
6·2
(3·7 to 
9·4)
21·9
(17·8 to 
28·8)*
9·3
(8·1 to 
13·9)*
34·4
(27·7 to 
45·7)*
(Table 3 continues on next page)
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musculoskeletal disorders and 22·5% [20·1–25·4] for 
mental and substance use disorders). In 2015, 
approximately 40–60% of DALYs due to cancers, 
cirrhosis, and chronic respiratory diseases could be 
attributed to risk factors assessed in this study. Except 
for YLDs, less than 50% of disease burden for Group 1 
causes—communicable, maternal, neonatal, and nutri-
tional diseases—could be attributed to analysed risk 
factors. Risk factors accounted for less than 20% of early 
death and disability from maternal disorders (eg, 10·2% 
[4·1–16·8] of DALYs).
Categories of risk factors—metabolic, environmental 
or occupational, and behavioural risks—often jointly 
contribute to disease burden. In 2015, 41·2% (95% UI 
39·8–42·8) of global DALYs could be attributed to 
analysed risk factors, whereas 58·8% (57·2–60·2) of 
global disease burden could not be explicitly attributed to 
speciﬁ c risk factors. In terms of individual risk categories, 
behavioural risk factors accounted for 30·3% (28·6–32·0) 
of attributable DALYs in 2015, followed by metabolic 
(15·5% [14·7–16·3]) and environmental or occupational 
risk factors (13·0 [11·9–14·0]). Regionally, total risk-
attributable burden ranged from 59·0% (57·0–60·9) in 
southern sub-Saharan Africa to 33·5% (32·1–35·1) in 
north Africa and the Middle East; furthermore, ten 
regions had less than 40% of total DALYs attributable to 
risks being analysed (ﬁ gure 1).
Levels and trends in the burden attributable to risk factors
Table 4 reports all-cause deaths and DALYs attributable to 
all risk factors from 2005 to 2015, including detail on 
attributable deaths and DALYs by risk-outcome pair 
(results appendix pp 3–2488 contains results for 
every geography). Globally, 32·2 million (95% UI 
31·5 million to 33·0 million) deaths were attributable to 
all risk factors in 2015, a 4·9% (3·2–6·7) increase since 
2005; however, age-standardised attributable deaths 
declined from 2005 to 2015 (a 17·9% decrease [16·6–19·2] 
to 497·5 deaths per 100 000 [485·2–510·0]). By contrast, 
total DALYs attributable to all risks decreased since 2005 
by 5·6% (3·8–7·5) to 1·0 billion DALYs (0·96–1·09 billion) 
in 2015 and age-standardised DALYs attributable to all 
risks decreased since 2005 by 20·9% (19·5–22·5) to 
14 412·9 DALYs per 100 000 (13 553·0–15 360·1) in 2015. 
Deaths and burden attributable to environmental and 
occupational risks signiﬁ cantly fell across measures, 
with age-standardised deaths falling by 22·5% 
(20·6–24·4) to 142·6 deaths per 100 000 (130·1–155·6) in 
2015 and age-standardised DALYs decreasing by 24·8% 
(22·1–27·1) to 4500 DALYs per 100 000 (4164·6–4853·9) 
in 2015.
Progress in environmental risks was mainly driven by 
sizeable reductions in mortality and disease burden 
attributable to unsafe water, sanitation, and hygiene, as 
well as to household air pollution. From 2005 to 2015, 
global deaths attributable to unsafe water and no 
handwashing with soap fell by more than 12%, whereas 
DALYs decreased by more than 20%. More rapid declines 
than in the above-mentioned risks in attributable deaths 
(27·5% [95% UI 22·3–32·7]) and burden (31·9% 
[25·7–37·4]) occurred for unsafe sanitation since 2005, to 
807 904·2 deaths (727 439·6–895 462·5) in 2015 and to 
46·3 million DALYs (41·1 million to 51·8 million) in 
2015. Reductions in attributable mortality and DALYs due 
to diarrhoeal diseases (associated with unsafe water, 
sanitation, and hygiene) were particularly prominent. 
Attributable deaths due to household air pollution 
decreased by 13·0% (9·3–17·0) to 2·9 million deaths 
(2·2 million to 3·6 million) in 2015 and disease burden 
decreased by 20·3% (16·6–24·5) to 85·6 million DALYs 
(66·7 million to 106·1 million) in 2015; large declines 
also occurred in age-standardised rates of attributable 
mortality and DALYs. Occupational risk factors generally 
accounted for a smaller proportion of global deaths and 
Men Women
1990 (%) 2005 (%) 2015 (%) Percentage 
change 
1990–2005
Percentage 
change 
2005–15
Percentage 
change 
1990–2015
1990 (%) 2005 (%) 2015 (%) Percentage 
change 
1990–2005
Percentage 
change 
2005–15
Percentage 
change 
1990–2015
(Continued from previous page)
Occupational exposure to polycyclic 
aromatic hydrocarbons
1·6
(1·6 to 
1·6)
2·0
(2·0 to 
2·0)
2·2
(2·2 to 
2·2)
27·7
(26·4 to 
28·9)*
6·4
(5·9 to 
7·8)*
36·4
(34·9 to 
38·0)*
0·6
(0·5 to 
0·6)
0·8
(0·8 to 
0·8)
0·8
(0·8 to 
0·8)
37·6
(35·3 to 
39·8)*
2·9
(1·7 to 
4·2)*
41·7
(39·0 to 
44·4)*
Occupational exposure to benzene 1·3
(1·2 to 
1·4)
1·6
(1·5 to 
1·8)
1·9
(1·7 to 
2·1)
26·3
(24·4 to 
28·2)*
15·0
(16·1 to 
19·2)*
48·5
(46·0 to 
51·2)*
0·6
(0·6 to 
0·7)
0·9
(0·9 to 
1·0)
1·2
(1·1 to 
1·3)
52·6
(50·6 to 
54·5)*
22·7
(28·2 to 
30·8)*
97·5
(94·5 to 
100·5)*
Occupational exposure to silica 6·6
(6·5 to 
6·7)
9·6
(9·5 to 
9·7)
11·3
(11·2 to 
11·5)
46·5
(44·4 to 
48·7)*
15·1
(16·3 to 
19·3)*
72·6
(69·6 to 
75·4)*
1·3
(1·2 to 
1·3)
1·8
(1·7 to 
1·8)
1·8
(1·8 to 
1·8)
40·5
(38·6 to 
42·4)*
3·1
(2·0 to 
4·5)*
44·9
(42·6 to 
47·4)*
Occupational exposure to diesel 
engine exhaust
6·7
(6·6 to 
6·7)
9·9
(9·8 to 
10·0)
11·5
(11·4 to 
11·6)
47·9
(46·5 to 
49·3)*
14·0
(15·3 to 
17·4)*
72·1
(69·9 to 
74·1)*
1·5
(1·5 to 
1·6)
2·7
(2·6 to 
2·7)
3·5
(3·5 to 
3·6)
72·9
(70·7 to 
75·0)*
24·7
(30·9 to 
35·3)*
129·8
(125·0 to 
134·7)*
Data in parentheses are 95% uncertainty intervals. Risks are reported in order of percentage change for both sexes combined, 1990–2015. *Statistically signiﬁ cant increase or decrease. 
Table 3: Global age-standardised summary exposure values for all risk factors for 1990, 2005, and 2015 
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2005 deaths
(in thousands)
2015 deaths
(in thousands)
Percentage 
change of 
2005–15 deaths 
Percentage 
change of 
2005–15 age-
standardised 
PAF
2005 DALYs
(in thousands)
2015 DALYs
(in thousands)
Percentage 
change of 
2005–15 DALYs
Percentage 
change of 
2005–15 age-
standardised 
DALYs PAF 
All risk factors: all causes 30 718
(30 074 to 
31 360)
32 234
(31 456 to 
33 035)
4·9
(3·2 to 6·7)*
–1·1
(–1·7 to –0·4)*
1 076 067
(1 022 161 to 
1 137 872)
1 015 470
(953 300 to 
1 084 249)
–5·6
(–7·5 to –3·8)*
–4·6
(–5·8 to –3·5)*
Environmental or 
occupational risks: 
all causes
9523
(8704 to 
10 321)
9315
(8523 to 
10 145)
–2·2
(–4·8 to 0·6)
–6·7
(–8·3 to –5·1)*
362 041
(335 616 to 387 712)
319 569
(295 706 to 
344 884)
–11·7
(–14·7 to –8·3)*
–9·2
(–11·8 to –6·5)*
Unsafe water, sanitation, 
and handwashing: 
all causes
2179
(1993 to 2386)
1766
(1586 to 1944)
–18·9
(–23·6 to –14·2)*
–16·0
(–20·3 to –11·8)*
129 221
(116 430 to 142 602)
95 305
(85 818 to 105 821)
–26·2
(–31·4 to 
–20·5)*
–18·9
(–24·5 to 
–12·6)*
Unsafe water source: all 
causes
1587
(1284 to 1812)
1251
(1008 to 1428)
–21·2
(–26·3 to –16·0)*
–18·0
(–22·9 to –13·0)*
97 248
(78 516 to 112 113)
71 745
(57 707 to 83 257)
–26·2
(–31·9 to –19·8)*
–18·8
(–25·0 to 
–12·1)*
Diarrhoeal diseases 1411
(1147 to 1592)
1101
(887 to 1244)
–22·0
(–27·4 to –16·5)*
–1·4
(–1·9 to –0·9)*
84 526
(68 642 to 96 429)
61 104
(49 352 to 69 584)
–27·7
(–33·6 to –21·2)*
–0·6
(–1·0 to –0·4)*
Typhoid fever 147
(77 to 245)
126
(67 to 215)
–14·6
(–21·0 to –8·8)*
–0·7
(–1·5 to –0·3)*
10 688
(5712 to 17 653)
8943
(4822 to 15 133)
–16·3
(–23·1 to –10·0)*
–0·7
(–1·5 to –0·3)*
Paratyphoid fever 29
(13 to 57)
25
(11 to 48)
–14·8
(–22·2 to –7·1)*
–0·8
(–1·6 to –0·3)*
2034
(898 to 4009)
1699
(757 to 3318)
–16·5
(–24·8 to –8·1)*
–0·7
(–1·6 to –0·3)*
Unsafe sanitation: all 
causes
1114
(1012 to 1230)
808
(727 to 895)
–27·5
(–32·7 to –22·3)*
–24·7
(–29·7 to –19·9)*
67 949
(61 085 to 75 899)
46 275
(41 065 to 51 818)
–31·9
(–37·4 to –25·7)*
–25·1
(–31·1 to 
–18·1)*
Diarrhoeal diseases 997
(914 to 1087)
720
(657 to 792)
–27·8
(–33·5 to –22·3)*
–8·9
(–10·9 to –7·2)*
59 454
(53 638 to 65 649)
40 005
(36 020 to 44 351)
–32·7
(–38·8 to –26·1)*
–7·6
(–9·4 to –5·9)*
Typhoid fever 98
(53 to 164)
74
(40 to 125)
–24·7
(–30·9 to –18·4)*
–12·4
(–15·2 to –10·0)*
7149
(3893 to 11 816)
5290
(2877 to 8857)
–26·0
(–32·6 to –19·3)*
–12·2
(–15·0 to –9·8)*
Paratyphoid fever 19
(9 to 36)
14
(7 to 27)
–25·8
(–32·7 to –18·8)*
–13·6
(–16·5 to –10·9)*
1346
(627 to 2551)
981
(456 to 1902)
–27·1
(–34·7 to –19·7)*
–13·4
(–16·3 to 
–10·8)*
No handwashing with 
soap: all causes
1116
(927 to 1296)
927
(760 to 1082)
–16·9
(–21·3 to –12·6)*
–14·3
(–18·3 to –10·4)*
64 152
(53 252 to 74 634)
47 271
(39 034 to 55 164)
–26·3
(–31·0 to –21·0)*
–19·0
(–24·0 to 
–13·4)*
Diarrhoeal diseases 643
(514 to 763)
502
(402 to 599)
–21·9
(–27·4 to –16·5)*
–1·4
(–2·0 to –0·9)*
38 311
(30 403 to 45 759)
27 628
(22 106 to 32 796)
–27·9
(–33·9 to –21·3)*
–0·9
(–1·4 to –0·5)*
Typhoid fever 67
(34 to 114)
56
(29 to 97)
–15·2
(–21·6 to –9·2)*
–1·4
(–2·1 to –0·8)*
4831
(2568 to 8256)
4019
(2135 to 6933)
–16·8
(–24·0 to –10·4)*
–1·3
(–2·1 to –0·7)*
Paratyphoid fever 13
(6 to 26)
11
(5 to 22)
–15·2
(–22·7 to –7·5)*
–1·4
(–2·2 to –0·8)*
918
(422 to 1837)
763
(355 to 1543)
–16·9
(–25·0 to –8·5)*
–1·3
(–2·1 to –0·7)*
Air pollution: all causes 6466
(5675 to 7291)
6485
(5708 to 7292)
0·3
(–2·6 to 3·3)
–6·3
(–8·2 to –4·4)*
186 850
(164 716 to 209 142)
167 290
(148 167 to 185 780)
–10·5
(–13·6 to –7·3)*
–10·5
(–13·1 to –7·9)*
Ambient particulate 
matter pollution: all causes
3934
(3437 to 4448)
4241
(3698 to 4777)
7·8
(5·1 to 10·8)*
0·3
(–1·5 to 1·9)
107 582
(94 319 to 121 177)
103 066
(90 830 to 115 073)
–4·2
(–7·5 to –0·7)*
–4·9
(–7·7 to –2·3)*
Lower respiratory 
infections
736
(549 to 957)
675
(492 to 889)
–8·3
(–13·2 to –3·6)*
–3·4
(–5·8 to –1·6)*
38 632
(29 407 to 48 531)
28 360
(21 142 to 35 797)
–26·6
(–31·4 to –21·5)*
–3·1
(–5·4 to –1·4)*
Tracheal, bronchial, and 
lung cancer
225
(140 to 318)
283
(178 to 399)
25·7
(20·8 to 32·0)*
5·0
(3·2 to 7·7)*
5171
(3244 to 7263)
6209
(3935 to 8689)
20·1
(14·9 to 27·1)*
5·0
(3·2 to 7·6)*
Ischaemic heart disease 1284
(1060 to 1530)
1521
(1232 to 1821)
18·5
(14·3 to 22·4)*
3·1
(1·7 to 4·5)*
28 484
(24 254 to 32 699)
32 406
(27 078 to 37 427)
13·8
(10·0 to 17·5)*
3·4
(2·4 to 4·7)*
Ischaemic stroke 347
(260 to 432)
381
(283 to 483)
9·9
(3·9 to 15·2)*
3·2
(0·9 to 5·5)*
6271
(5039 to 7454)
6618
(5328 to 7905)
5·5
(0·7 to 10·1)*
3·5
(1·8 to 5·5)*
Haemorrhagic stroke 505
(417 to 599)
517
(425 to 614)
2·3
(–2·2 to 7·1)
0·4
(–0·9 to 1·6)
12 605
(10 552 to 14 743)
12 625
(10 570 to 14 867)
0·2
(–3·9 to 4·6)
1·3
(0·3 to 2·5)*
Chronic obstructive 
pulmonary disease
837
(522 to 1174)
864
(538 to 1213)
3·2
(–1·1 to 8·4)
0·2
(–0·9 to 1·9)
16 418
(10 295 to 23 033)
16 848
(10 517 to 23 590)
2·6
(–1·6 to 7·7)
1·2
(–0·1 to 3·3)
Household air pollution 
from solid fuels: all causes
3280
(2505 to 4068)
2854
(2179 to 3587)
–13·0
(–17·0 to –9·3)*
–17·8
(–21·1 to –14·8)*
107 509
(83 554 to 132 012)
85 644
(66 659 to 106 136)
–20·3
(–24·5 to –16·6)*
–19·2
(–22·7 to –15·8)*
Lower respiratory 
infections
905
(663 to 1160)
729
(523 to 949)
–19·5
(–24·2 to –14·5)*
–13·8
(–16·7 to –10·9)*
52 898
(38 845 to 67 622)
36 883
(26 631 to 46 916)
–30·3
(–35·1 to –25·0)*
–7·6
(–10·2 to –4·9)*
(Table 4 continues on next page)
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2005 deaths
(in thousands)
2015 deaths
(in thousands)
Percentage 
change of 
2005–15 deaths 
Percentage 
change of 
2005–15 age-
standardised 
PAF
2005 DALYs
(in thousands)
2015 DALYs
(in thousands)
Percentage 
change of 
2005–15 DALYs
Percentage 
change of 
2005–15 age-
standardised 
DALYs PAF 
(Continued from previous page)
Tracheal, bronchial, and 
lung cancer
159
(83 to 249)
149
(76 to 241)
–6·3
(–12·6 to 0·4)
–21·4
(–25·9 to –17·4)*
3806
(1996 to 5932)
3439
(1767 to 5534)
–9·6
(–15·8 to –3·2)*
–20·8
(–25·2 to –16·9)*
Ischaemic heart disease 778
(621 to 964)
765
(598 to 965)
–1·6
(–7·0 to 3·7)
–13·8
(–18·0 to –10·1)*
18 865
(15 180 to 22 902)
18 200
(14 417 to 22 512)
–3·5
(–9·1 to 1·8)
–11·9
(–16·0 to –8·0)*
Ischaemic stroke 245
(177 to 324)
214
(152 to 290)
–12·6
(–18·2 to –7·0)*
–17·5
(–21·5 to –13·6)*
4778
(3479 to 6282)
4104
(2931 to 5426)
–14·1
(–19·6 to –8·6)*
–15·6
(–19·6 to –12·0)*
Haemorrhagic stroke 418
(306 to 542)
340
(252 to 446)
–18·6
(–23·5 to –13·7)*
–20·2
(–24·1 to –16·8)*
10 857
(8159 to 13 941)
8902
(6581 to 11 543)
–18·0
(–23·0 to –13·2)*
–17·2
(–21·2 to –13·7)*
Chronic obstructive 
pulmonary disease
776
(422 to 1183)
657
(360 to 1014)
–15·3
(–21·2 to –9·8)*
–17·5
(–22·0 to –13·4)*
15 600
(8513 to 23 817)
13 373
(7246 to 20 608)
–14·3
(–19·9 to –8·8)*
–15·5
(–20·0 to –11·2)*
Cataract ·· ·· ·· ·· 705
(484 to 972)
742
(512 to 1021)
5·3
(1·7 to 9·1)*
–15·9
(–18·6 to –13·2)*
Ambient ozone pollution: 
all causes
207
(77 to 353)
254
(97 to 422)
22·7
(16·6 to 30·3)*
10·6
(5·5 to 17·0)*
3472
(1281 to 5913)
4116
(1577 to 6789)
18·5
(12·1 to 26·5)*
9·6
(3·7 to 17·3)*
Chronic obstructive 
pulmonary disease
207
(77 to 353)
254
(97 to 422)
22·7
(16·6 to 30·3)*
19·1
(16·0 to 23·6)*
3472
(1281 to 5913)
4116
(1577 to 6789)
18·5
(12·1 to 26·5)*
16·6
(12·9 to 21·7)*
Other environmental 
risks: all causes
514
(273 to 804)
558
(293 to 883)
8·6
(4·9 to 11·8)*
–2·1
(–5·3 to 0·3)
10 400
(5470 to 16 412)
10 673
(5516 to 16 975)
2·6
(–0·8 to 5·4)
–4·0
(–7·1 to –1·5)*
Residential radon: all 
causes
53
(36 to 71)
64
(42 to 86)
19·7
(12·5 to 28·2)*
10·6
(5·8 to 17·6)*
1212
(841 to 1638)
1386
(941 to 1871)
14·3
(8·3 to 20·6)*
6·9
(3·1 to 12·0)*
Tracheal, bronchial, and 
lung cancer
53
(36 to 71)
64
(42 to 86)
19·7
(12·5 to 28·2)*
–0·0
(–4·1 to 6·0)
1212
(841 to 1638)
1386
(941 to 1871)
14·3
(8·3 to 20·6)*
–0·1
(–3·2 to 4·6)
Lead exposure: all causes 461
(227 to 745)
495
(237 to 815)
7·3
(2·6 to 10·7)*
–3·4
(–7·8 to –0·7)*
9188
(4357 to 15 216)
9287
(4200 to 15 594)
1·1
(–3·7 to 4·4)
–5·3
(–9·5 to –2·3)*
Rheumatic heart disease 4
(1 to 7)
3
(1 to 6)
–8·2
(–14·7 to –2·0)*
–6·1
(–10·8 to –3·1)*
97
(31 to 204)
83
(25 to 175)
–14·9
(–21·6 to –9·3)*
–9·9
(–16·4 to –6·2)*
Ischaemic heart disease 220
(107 to 359)
240
(111 to 396)
8·8
(3·3 to 12·7)*
–7·0
(–11·4 to –4·3)*
3984
(1823 to 6675)
4123
(1807 to 7049)
3·5
(–1·8 to 7·1)
–7·6
(–11·9 to –5·0)*
Ischaemic stroke 67
(32 to 115)
68
(31 to 118)
1·1
(–5·3 to 6·9)
–5·7
(–10·5 to –2·6)*
1092
(485 to 1882)
1055
(457 to 1828)
–3·4
(–9·3 to 1·0)
–5·9
(–10·5 to –3·3)*
Haemorrhagic stroke 89
(38 to 155)
87
(37 to 154)
–1·4
(–6·7 to 3·6)
–4·7
(–8·7 to –2·1)*
1901
(750 to 3415)
1807
(695 to 3293)
–4·9
(–9·4 to –1·2)*
–5·2
(–9·7 to –2·7)*
Hypertensive heart 
disease
40
(12 to 92)
47
(13 to 112)
18·1
(7·0 to 26·8)*
–7·9
(–14·2 to –4·0)*
710
(232 to 1561)
772
(240 to 1738)
8·8
(–0·1 to 15·4)
–9·1
(–15·1 to –5·4)*
Cardiomyopathy and 
myocarditis
5
(2 to 8)
5
(2 to 8)
1·3
(–4·7 to 7·8)
–8·5
(–13·8 to –4·8)*
99
(34 to 202)
91
(31 to 183)
–8·5
(–13·2 to –3·1)*
–9·1
(–13·7 to –5·6)*
Atrial ﬁ brillation and 
ﬂ utter
3
(1 to 4)
3
(1 to 5)
22·1
(13·1 to 27·9)*
–9·7
(–15·8 to –6·3)*
65
(30 to 113)
72
(30 to 130)
10·1
(0·7 to 15·5)*
–13·3
(–20·5 to –9·2)*
Aortic aneurysm 2
(1 to 4)
2
(1 to 4)
7·4
(–3·1 to 14·5)
–13·5
(–20·9 to –9·3)*
38
(16 to 67)
39
(15 to 73)
1·8
(–8·9 to 9·0)
–14·8
(–22·9 to –10·1)*
Peripheral vascular 
disease
0
(0 to 1)
1
(0 to 1)
17·3
(3·0 to 28·6)*
–14·4
(–24·2 to –9·1)*
11
(4 to 20)
12
(4 to 23)
11·9
(–0·6 to 19·7)
–14·2
(–23·2 to –9·6)*
Endocarditis 1
(0 to 2)
1
(0 to 2)
11·8
(2·8 to 18·6)*
–11·6
(–18·6 to –7·6)*
21
(8 to 39)
21
(8 to 42)
4·1
(–4·9 to 10·9)
–13·5
(–22·2 to –7·6)*
Other cardiovascular and 
circulatory diseases
8
(4 to 14)
9
(4 to 15)
9·0
(2·6 to 14·3)*
–8·5
(–13·7 to –5·5)*
223
(98 to 388)
235
(98 to 422)
5·4
(–2·3 to 10·4)
–10·3
(–16·9 to –6·5)*
Idiopathic developmental 
intellectual disability
·· ·· ·· ·· 471
(214 to 815)
423
(188 to 739)
–10·3
(–15·7 to –6·1)*
–13·7
(–19·2 to –9·8)*
Chronic kidney disease 
due to diabetes mellitus
7
(3 to 12)
9
(4 to 17)
28·9
(20·2 to 34·6)*
–9·0
(–14·7 to –5·9)*
150
(58 to 293)
179
(65 to 356)
19·4
(10·5 to 24·7)*
–10·5
(–17·1 to –6·9)*
Chronic kidney disease 
due to hypertension
11
(5 to 18)
14
(6 to 23)
28·0
(20·9 to 33·0)*
–7·2
(–11·5 to –4·7)*
196
(84 to 353)
231
(97 to 416)
17·8
(10·8 to 22·8)*
–8·4
(–13·5 to –5·4)*
Chronic kidney disease 
due to 
glomerulonephritis
4
(2 to 7)
5
(2 to 8)
22·1
(16·9 to 27·8)*
0·1
(–2·1 to 2·0)
94
(34 to 180)
102
(37 to 197)
8·7
(4·5 to 12·9)*
–3·6
(–6·7 to –1·4)*
(Table 4 continues on next page)
Articles
www.thelancet.com   Vol 388   October 8, 2016 1679
2005 deaths
(in thousands)
2015 deaths
(in thousands)
Percentage 
change of 
2005–15 deaths 
Percentage 
change of 
2005–15 age-
standardised 
PAF
2005 DALYs
(in thousands)
2015 DALYs
(in thousands)
Percentage 
change of 
2005–15 DALYs
Percentage 
change of 
2005–15 age-
standardised 
DALYs PAF 
(Continued from previous page)
Chronic kidney disease 
due to other causes
0
(0 to 1)
1
(0 to 1)
33·1
(24·5 to 42·3)*
–2·3
(–8·2 to 1·9)
36
(14 to 73)
41
(16 to 86)
13·7
(7·8 to 17·7)*
–9·4
(–15·1 to –5·6)*
Occupational risks: 
all causes
951
(889 to 1016)
1086
(1013 to 1165)
14·2
(10·4 to 18·6)*
7·2
(4·2 to 10·5)*
55 835
(47 024 to 65 679)
63 615
(53 616 to 75 415)
13·9
(11·0 to 17·3)*
13·0
(10·2 to 16·2)*
Occupational carcinogens: 
all causes
391
(370 to 410)
489
(461 to 517)
25·1
(20·4 to 30·2)*
15·9
(12·0 to 20·2)*
8109
(7708 to 8503)
9832
(9318 to 10 385)
21·2
(16·5 to 26·7)*
12·9
(8·6 to 18·0)*
Occupational exposure to 
asbestos: all causes
135
(118 to 154)
180
(158 to 205)
33·4
(27·3 to 40·1)*
21·5
(16·2 to 27·2)*
2210
(1919 to 2529)
2769
(2391 to 3185)
25·3
(19·4 to 31·6)*
16·1
(10·6 to 21·7)*
Laryngeal cancer 1
(1 to 1)
1
(1 to 2)
38·5
(25·8 to 56·8)*
19·4
(9·0 to 35·4)*
17
(11 to 25)
22
(14 to 31)
27·8
(17·9 to 41·3)*
14·5
(6·5 to 25·6)*
Tracheal, bronchial, and 
lung cancer
117
(101 to 135)
155
(132 to 179)
31·6
(25·6 to 38·6)*
8·3
(4·1 to 12·5)*
1875
(1590 to 2179)
2314
(1947 to 2732)
23·4
(17·3 to 29·9)*
6·8
(2·7 to 11·0)*
Ovarian cancer 1
(1 to 2)
1
(1 to 2)
27·3
(18·6 to 37·3)*
3·7
(–2·6 to 10·4)
19
(9 to 31)
23
(11 to 38)
22·1
(12·3 to 33·8)*
0·7
(–6·0 to 8·2)
Mesothelioma 16
(12 to 18)
23
(19 to 26)
47·2
(39·4 to 55·0)*
3·9
(1·9 to 7·1)*
298
(226 to 362)
410
(320 to 488)
37·3
(30·2 to 44·1)*
3·9
(1·8 to 6·8)*
Occupational exposure to 
arsenic: all causes
9
(7 to 11)
9
(7 to 11)
–0·1
(–5·3 to 5·9)
–6·5
(–11·2 to –1·2)*
196
(152 to 242)
194
(150 to 242)
–0·9
(–6·2 to 5·4)
–7·6
(–12·4 to –1·7)*
Tracheal, bronchial, and 
lung cancer
9
(7 to 11)
9
(7 to 11)
–0·1
(–5·3 to 5·9)
–15·5
(–18·6 to –12·2)*
196
(152 to 242)
194
(150 to 242)
–0·9
(–6·2 to 5·4)
–13·7
(–16·8 to –10·7)*
Occupational exposure 
to benzene: all causes
4
(4 to 5)
6
(5 to 7)
31·6
(26·4 to 36·6)*
29·0
(24·9 to 33·2)*
162
(137 to 190)
211
(178 to 247)
30·8
(25·4 to 36·0)*
31·0
(25·9 to 36·5)*
Leukaemia 4
(4 to 5)
6
(5 to 7)
31·6
(26·4 to 36·6)*
13·6
(10·7 to 16·4)*
162
(137 to 190)
211
(178 to 247)
30·8
(25·4 to 36·0)*
17·5
(14·4 to 20·7)*
Occupational exposure to 
beryllium: all causes
1
(0 to 1)
1
(0 to 1)
–1·2
(–6·7 to 5·4)
–7·5
(–12·3 to –1·7)*
13
(10 to 15)
12
(10 to 15)
–2·1
(–7·7 to 4·7)
–8·7
(–14·0 to –2·7)*
Tracheal, bronchial, and 
lung cancer
1
(0 to 1)
1
(0 to 1)
–1·2
(–6·7 to 5·4)
–16·4
(–19·7 to –12·8)*
13
(10 to 15)
12
(10 to 15)
–2·1
(–7·7 to 4·7)
–14·7
(–17·9 to –11·2)*
Occupational exposure 
to cadmium: all causes
2
(2 to 2)
2
(2 to 3)
9·5
(3·6 to 16·2)*
2·4
(–2·6 to 8·2)
43
(36 to 51)
47
(38 to 56)
8·7
(2·8 to 15·5)*
1·2
(–4·2 to 7·5)
Tracheal, bronchial, and 
lung cancer
2
(2 to 2)
2
(2 to 3)
9·5
(3·6 to 16·2)*
–7·4
(–10·8 to –3·7)*
43
(36 to 51)
47
(38 to 56)
8·7
(2·8 to 15·5)*
–5·5
(–8·6 to –2·0)*
Occupational exposure to 
chromium: all causes
7
(6 to 8)
7
(6 to 8)
4·4
(–1·1 to 10·8)
–2·2
(–6·8 to 3·6)
151
(133 to 171)
157
(137 to 178)
3·6
(–2·1 to 10·1)
–3·5
(–8·3 to 2·4)
Tracheal, bronchial, and 
lung cancer
7
(6 to 8)
7
(6 to 8)
4·4
(–1·1 to 10·8)
–11·7
(–14·6 to –8·5)*
151
(133 to 171)
157
(137 to 178)
3·6
(–2·1 to 10·1)
–9·8
(–12·6 to –6·8)*
Occupational exposure to 
diesel engine exhaust: all 
causes
91
(81 to 103)
120
(106 to 136)
30·8
(24·6 to 37·8)*
22·2
(17·0 to 28·3)*
2048
(1815 to 2304)
2657
(2341 to 2994)
29·8
(23·6 to 37·1)*
20·8
(15·3 to 27·6)*
Tracheal, bronchial, and 
lung cancer
91
(81 to 103)
120
(106 to 136)
30·8
(24·6 to 37·8)*
10·4
(7·4 to 13·7)*
2048
(1815 to 2304)
2657
(2341 to 2994)
29·8
(23·6 to 37·1)*
12·8
(10·0 to 15·7)*
Occupational exposure to 
second-hand smoke: all 
causes
84
(79 to 89)
96
(90 to 103)
14·7
(9·9 to 20·1)*
7·3
(3·4 to 11·8)*
1860
(1742 to 1972)
2113
(1966 to 2262)
13·6
(8·9 to 18·9)*
5·7
(1·6 to 10·9)*
Tracheal, bronchial, and 
lung cancer
84
(79 to 89)
96
(90 to 103)
14·7
(9·9 to 20·1)*
–3·0
(–5·1 to –0·7)*
1860
(1742 to 1972)
2113
(1966 to 2262)
13·6
(8·9 to 18·9)*
–1·2
(–3·1 to 0·8)
Occupational exposure to 
formaldehyde: all causes
2
(2 to 2)
2
(2 to 2)
1·7
(–4·6 to 7·9)
–1·1
(–6·8 to 4·7)
71
(57 to 87)
71
(57 to 87)
–0·1
(–6·4 to 6·2)
–1·0
(–7·1 to 5·0)
Nasopharyngeal cancer 1
(1 to 1)
1
(1 to 1)
–6·0
(–16·3 to 4·0)
–15·3
(–20·2 to –9·5)*
36
(23 to 51)
33
(21 to 47)
–8·8
(–19·4 to 1·8)
–13·4
(–18·5 to –7·1)*
Occupational exposure to 
nickel: all causes
32
(24 to 42)
33
(24 to 43)
2·2
(–3·7 to 9·0)
–4·3
(–10·0 to 2·0)
720
(535 to 927)
729
(535 to 956)
1·3
(–4·9 to 8·5)
–5·6
(–11·3 to 1·2)
Tracheal, bronchial, and 
lung cancer
32
(24 to 42)
33
(24 to 43)
2·2
(–3·7 to 9·0)
–13·6
(–17·5 to –9·5)*
720
(535 to 927)
729
(535 to 956)
1·3
(–4·9 to 8·5)
–11·8
(–15·7 to –7·9)*
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2005 deaths
(in thousands)
2015 deaths
(in thousands)
Percentage 
change of 
2005–15 deaths 
Percentage 
change of 
2005–15 age-
standardised 
PAF
2005 DALYs
(in thousands)
2015 DALYs
(in thousands)
Percentage 
change of 
2005–15 DALYs
Percentage 
change of 
2005–15 age-
standardised 
DALYs PAF 
(Continued from previous page)
Occupational exposure to 
polycyclic aromatic 
hydrocarbons: all causes
15
(13 to 18)
18
(15 to 21)
16·9
(11·1 to 23·7)*
9·3
(4·2 to 15·5)*
342
(283 to 402)
397
(327 to 470)
16·1
(10·1 to 23·1)*
8·1
(2·6 to 14·4)*
Tracheal, bronchial, and 
lung cancer
15
(13 to 18)
18
(15 to 21)
16·9
(11·1 to 23·7)*
–1·2
(–4·5 to 2·3)
342
(283 to 402)
397
(327 to 470)
16·1
(10·1 to 23·1)*
1·0
(–2·1 to 4·1)
Occupational exposure to 
silica: all causes
65
(59 to 71)
86
(79 to 95)
32·9
(25·8 to 40·8)*
24·6
(18·6 to 31·3)*
1444
(1308 to 1578)
1894
(1724 to 2073)
31·1
(24·2 to 39·3)*
22·4
(16·2 to 29·8)*
Tracheal, bronchial, and 
lung cancer
65
(59 to 71)
86
(79 to 95)
32·9
(25·8 to 40·8)*
12·6
(8·7 to 17·0)*
1444
(1308 to 1578)
1894
(1724 to 2073)
31·1
(24·2 to 39·3)*
14·4
(10·6 to 18·4)*
Occupational exposure to 
sulphuric acid: all causes
7
(5 to 9)
8
(6 to 10)
13·9
(9·1 to 18·9)*
5·7
(1·5 to 10·2)*
175
(134 to 219)
199
(151 to 253)
13·8
(9·2 to 18·7)*
5·3
(1·0 to 10·0)*
Laryngeal cancer 7
(5 to 9)
8
(6 to 10)
13·9
(9·1 to 18·9)*
0·7
(–2·4 to 3·7)
175
(134 to 219)
199
(151 to 253)
13·8
(9·2 to 18·7)*
2·0
(–0·8 to 5·0)
Occupational exposure to 
trichloroethylene: all 
causes
0
(0 to 0)
0
(0 to 0)
25·3
(19·4 to 30·3)*
16·6
(11·3 to 20·5)*
3
(1 to 6)
4
(1 to 8)
26·3
(20·4 to 31·2)*
17·2
(11·6 to 21·8)*
Kidney cancer 0
(0 to 0)
0
(0 to 0)
25·3
(19·4 to 30·3)*
–3·5
(–6·4 to –0·6)*
3
(1 to 6)
4
(1 to 8)
26·3
(20·4 to 31·2)*
–2·7
(–5·5 to 0·7)
Occupational asthmagens: 
all causes
50
(39 to 61)
42
(35 to 48)
–16·9
(–26·0 to –2·4)*
–21·0
(–29·8 to –7·0)*
2754
(2190 to 3373)
2621
(2081 to 3223)
–4·8
(–12·0 to 3·6)
–5·3
(–12·2 to 3·8)
Asthma 50
(39 to 61)
42
(35 to 48)
–16·9
(–26·0 to –2·4)*
–4·6
(–11·0 to 3·0)
2754
(2190 to 3373)
2621
(2081 to 3223)
–4·8
(–12·0 to 3·6)
–5·4
(–9·1 to –1·7)*
Occupational particulate 
matter, gases, and fumes: 
all causes
337
(280 to 392)
357
(293 to 419)
5·9
(0·9 to 11·6)*
–3·7
(–7·4 to 0·6)
8405
(7325 to 9570)
8787
(7598 to 9987)
4·5
(0·5 to 9·2)*
–1·8
(–5·2 to 2·4)
Chronic obstructive 
pulmonary disease
334
(278 to 389)
354
(290 to 417)
6·0
(1·0 to 11·8)*
3·8
(1·2 to 6·9)*
8346
(7264 to 9509)
8729
(7541 to 9926)
4·6
(0·6 to 9·3)*
4·5
(2·5 to 6·8)*
Occupational noise: 
all causes
·· ·· ·· ·· 8659
(5925 to 11 948)
10 875
(7410 to 15 038)
25·6
(23·5 to 27·7)*
26·6
(24·1 to 29·2)*
Age-related and other 
hearing loss
·· ·· ·· ·· 8659
(5925 to 11 948)
10 875
(7410 to 15 038)
25·6
(23·5 to 27·7)*
3·8
(2·8 to 4·8)*
Occupational injuries: 
all causes
189
(168 to 207)
204
(191 to 232)
8·0
(–3·4 to 24·3)
12·4
(0·1 to 29·3)*
12 212
(10 736 to 13 682)
13 492
(12 006 to 15 545)
10·5
(–0·2 to 25·9)
16·9
(5·7 to 33·3)*
Pedestrian road injuries 26
(22 to 30)
30
(27 to 37)
16·9
(–0·9 to 42·4)
23·3
(3·0 to 54·6)*
1320
(1110 to 1528)
1510
(1362 to 1842)
14·4
(–2·9 to 39·0)
26·8
(6·3 to 58·0)*
Cyclist road injuries 3
(3 to 3)
3
(3 to 4)
21·9
(8·3 to 35·5)*
33·3
(18·7 to 50·2)*
190
(166 to 215)
243
(211 to 280)
27·8
(16·1 to 40·6)*
39·9
(26·6 to 55·3)*
Motorcyclist road 
injuries
19
(17 to 21)
22
(20 to 26)
17·7
(3·2 to 36·2)*
13·3
(1·5 to 28·3)*
1101
(975 to 1222)
1287
(1158 to 1469)
16·9
(3·6 to 33·4)*
16·5
(4·8 to 31·0)*
Motor vehicle road 
injuries
42
(38 to 47)
46
(43 to 51)
9·4
(–0·1 to 21·1)
15·2
(5·8 to 27·7)*
2419
(2206 to 2692)
2668
(2457 to 2977)
10·3
(1·2 to 21·5)*
18·2
(8·5 to 30·1)*
Other road injuries 2
(1 to 3)
2
(1 to 3)
–6·0
(–32·1 to 41·6)
–14·8
(–39·3 to 28·1)
127
(86 to 169)
127
(95 to 182)
–0·1
(–26·0 to 42·7)
–9·4
(–32·9 to 29·2)
Other transport injuries 5
(4 to 6)
6
(5 to 8)
23·5
(0·3 to 55·7)*
21·5
(1·2 to 52·9)*
275
(229 to 325)
332
(286 to 408)
20·8
(–0·6 to 51·1)
23·6
(3·7 to 53·3)*
Falls 19
(17 to 22)
23
(21 to 26)
21·2
(7·1 to 39·4)*
6·2
(–7·0 to 21·7)
1847
(1520 to 2255)
2329
(1892 to 2877)
26·1
(13·2 to 41·2)*
17·9
(6·0 to 32·0)*
Drowning 26
(20 to 31)
22
(19 to 31)
–15·0
(–33·5 to 15·9)
3·8
(–19·8 to 42·5)
1358
(1052 to 1625)
1137
(967 to 1591)
–16·3
(–33·9 to 14·8)
10·7
(–13·5 to 50·2)
Fire, heat, and hot 
substances
12
(10 to 14)
12
(11 to 15)
7·7
(–6·0 to 25·5)
21·9
(7·2 to 42·1)*
815
(704 to 964)
909
(771 to 1084)
11·5
(–2·2 to 28·7)
26·6
(10·7 to 46·4)*
Poisonings 4
(3 to 4)
3
(3 to 4)
–19·5
(–26·2 to –11·5)*
–4·9
(–18·9 to 9·0)
233
(193 to 262)
199
(168 to 225)
–14·6
(–22·0 to –6·1)*
0·2
(–20·3 to 20·8)
Unintentional ﬁ rearm 
injuries
2
(1 to 2)
2
(1 to 2)
–1·4
(–11·2 to 8·9)
3·8
(–6·2 to 14·3)
100
(71 to 113)
99
(73 to 112)
–1·5
(–10·9 to 8·4)
5·0
(–5·8 to 17·0)
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2005–15 deaths 
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change of 
2005–15 age-
standardised 
DALYs PAF 
(Continued from previous page)
Unintentional 
suﬀ ocation
0
(0 to 0)
0
(0 to 0)
46·8
(7·5 to 75·3)*
39·4
(12·7 to 68·3)*
9
(8 to 11)
13
(10 to 15)
33·1
(11·7 to 54·0)*
34·6
(13·0 to 61·0)*
Other exposure to 
mechanical forces
9
(8 to 10)
10
(8 to 12)
15·0
(–1·1 to 28·9)
18·1
(7·8 to 31·2)*
737
(625 to 859)
875
(704 to 1055)
18·7
(6·7 to 31·0)*
23·2
(11·9 to 35·9)*
Venomous animal 
contact
3
(2 to 4)
3
(2 to 4)
–8·1
(–23·4 to 15·9)
2·2
(–12·2 to 18·8)
210
(152 to 247)
202
(143 to 247)
–3·8
(–17·2 to 15·6)
8·9
(–7·1 to 26·2)
Non-venomous animal 
contact
0
(0 to 1)
0
(0 to 0)
–10·1
(–24·7 to 10·9)
0·6
(–14·0 to 17·7)
36
(29 to 45)
36
(29 to 46)
–0·1
(–14·3 to 16·5)
11·1
(–6·1 to 30·1)
Pulmonary aspiration 
and foreign body in 
airway
3
(3 to 4)
4
(3 to 4)
28·0
(15·5 to 40·1)*
20·7
(10·3 to 32·0)*
192
(163 to 225)
239
(205 to 274)
24·4
(14·1 to 34·8)*
25·3
(11·8 to 40·9)*
Foreign body in eyes ·· ·· ·· ·· 3
(1 to 6)
4
(2 to 8)
38·6
(28·8 to 49·0)*
20·1
(11·8 to 29·2)*
Foreign body in other 
body part
2
(1 to 3)
2
(1 to 2)
6·1
(–12·7 to 24·0)
13·5
(–0·2 to 28·2)
138
(105 to 179)
157
(124 to 191)
13·8
(–2·8 to 29·5)
20·1
(4·4 to 36·1)*
Other unintentional 
injuries
11
(10 to 13)
11
(9 to 14)
–5·8
(–22·6 to 23·4)
6·3
(–12·0 to 38·6)
1101
(882 to 1349)
1128
(895 to 1490)
2·4
(–12·1 to 24·5)
12·5
(–3·4 to 37·4)
Occupational ergonomic 
factors: all causes
·· ·· ·· ·· 16 792
(11 730 to 23 448)
18 573
(12 979 to 25 759)
10·6
(9·2 to 12·0)*
11·7
(9·5 to 14·2)*
Low back pain ·· ·· ·· ·· 16 792
(11 730 to 23 448)
18 573
(12 979 to 25 759)
10·6
(9·2 to 12·0)*
–4·9
(–5·6 to –4·1)*
Behavioural risks: all causes 22 355
(21 183 to 
23 567)
22 744
(21 408 to 
24 126)
1·7
(–0·3 to 3·8)
–3·1
(–4·2 to –2·0)*
825 546
(781 724 to 872 847)
745 463
(698273 to 797 964)
–9·7
(–11·8 to –7·7)*
–7·9
(–9·3 to –6·5)*
Child and maternal 
malnutrition: all causes
2280
(2113 to 2453)
1414
(1308 to 1533)
–38·0
(–41·9 to –33·7)*
–30·4
(–34·9 to –25·6)*
248 339
(226 327 to 275 262)
172 120
(151 792 to 196 176)
–30·7
(–34·6 to –26·9)*
–22·2
(–26·4 to –18·3)*
Suboptimal breastfeeding: 
all causes
592
(390 to 843)
391
(258 to 550)
–33·9
(–39·7 to –27·5)*
–25·3
(–31·8 to –18·1)*
51 338
(33 863 to 73 062)
34 030
(22 497 to 47 771)
–33·7
(–39·5 to –27·2)*
–24·9
(–31·2 to –17·6)*
Non-exclusive 
breastfeeding: all causes
551
(347 to 789)
364
(227 to 520)
–34·0
(–39·5 to –27·6)*
–25·3
(–31·7 to –18·3)*
47 654
(30 141 to 68 060)
31 507
(19 669 to 44 929)
–33·9
(–39·4 to –27·5)*
–25·0
(–31·2 to –18·0)*
Diarrhoeal diseases 228
(141 to 309)
156
(98 to 216)
–31·5
(–40·4 to –21·0)*
–5·0
(–15·2 to 7·9)
19 768
(12 250 to 26 755)
13 579
(8489 to 18 758)
–31·3
(–40·1 to –20·8)*
–2·2
(–10·7 to 7·6)
Lower respiratory 
infections
323
(137 to 555)
208
(86 to 355)
–35·7
(–41·6 to –30·2)*
–24·9
(–31·0 to –19·0)*
27 886
(11 846 to 47 863)
17 928
(7453 to 30 580)
–35·7
(–41·5 to –30·2)*
–12·4
(–18·2 to –6·2)*
Discontinued 
breastfeeding: all causes
55
(19 to 103)
37
(13 to 69)
–33·2
(–42·7 to –21·6)*
–25·2
(–35·9 to –12·3)*
4909
(1745 to 9248)
3356
(1147 to 6281)
–31·6
(–40·8 to –20·5)*
–23·2
(–33·3 to –10·8)*
Diarrhoeal diseases 55
(19 to 103)
37
(13 to 69)
–33·2
(–42·7 to –21·6)*
–8·3
(–19·9 to 3·9)
4909
(1745 to 9248)
3356
(1147 to 6281)
–31·6
(–40·8 to –20·5)*
–3·6
(–12·1 to 5·5)
Childhood undernutrition: 
all causes
2093
(1931 to 2261)
1265
(1160 to 1383)
–39·6
(–43·6 to –35·1)*
–32·1
(–36·9 to –27·0)*
184 339
(170 596 to 199 097)
113 280
(103 941 to 123 401)
–38·5
(–42·5 to –34·2)*
–30·8
(–35·2 to –26·0)*
Childhood underweight: all 
causes
666
(531 to 857)
373
(304 to 468)
–44·0
(–52·0 to –34·8)*
–37·2
(–46·1 to –27·1)*
60 146
(48 823 to 76 465)
34 911
(28 903 to 43 357)
–42·0
(–49·6 to –33·2)*
–34·7
(–43·0 to –25·0)*
Diarrhoeal diseases 124
(101 to 157)
69
(55 to 87)
–44·7
(–51·5 to –36·1)*
–23·8
(–31·6 to –15·2)*
10 975
(8985 to 13 785)
6162
(4984 to 7724)
–43·9
(–50·7 to –35·6)*
–20·6
(–26·2 to –14·9)*
Lower respiratory 
infections
209
(139 to 359)
110
(70 to 197)
–47·5
(–52·7 to –42·3)*
–38·9
(–44·2 to –34·0)*
17 904
(11 962 to 30 872)
9416
(5994 to 16 919)
–47·4
(–52·6 to –42·2)*
–28·7
(–33·4 to –24·5)*
Measles 100
(21 to 252)
20
(4 to 56)
–79·9
(–88·1 to –68·7)*
–20·2
(–37·5 to –9·6)*
8476
(1751 to 21 476)
1701
(311 to 4763)
–79·9
(–88·1 to –68·7)*
–20·2
(–37·3 to –9·9)*
Protein-energy 
malnutrition
233
(180 to 301)
174
(131 to 227)
–25·3
(–42·5 to –3·6)*
–5·9
(–16·9 to 6·5)
22 791
(18 010 to 28 484)
17 633
(13 635 to 22 230)
–22·6
(–38·0 to –3·6)*
–0·8
(–4·3 to 2·8)
Childhood wasting: all 
causes
1882
(1608 to 2125)
1169
(982 to 1306)
–37·9
(–42·9 to –32·8)*
–30·2
(–35·7 to –24·3)*
166 166
(142 764 to 186 926)
104 945
(88 636 to 117 151)
–36·8
(–41·7 to –32·0)*
–28·8
(–34·2 to –23·4)*
Diarrhoeal diseases 663
(543 to 749)
431
(353 to 490)
–34·9
(–42·9 to –25·2)*
–10·4
(–19·4 to –1·0)*
58 779
(48 152 to 66 140)
38 905
(31 778 to 44 310)
–33·8
(–41·7 to –24·5)*
–6·5
(–11·4 to –1·3)*
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(Continued from previous page)
Lower respiratory 
infections
861
(623 to 1010)
535
(377 to 639)
–37·9
(–43·3 to –32·4)*
–27·8
(–32·6 to –22·6)*
73 987
(53 576 to 86 771)
45 989
(32 457 to 54 877)
–37·8
(–43·2 to –32·4)*
–15·7
(–19·7 to –12·0)*
Measles 125
(30 to 374)
28
(6 to 92)
–77·2
(–86·2 to –63·8)*
–9·3
(–27·5 to –0·8)*
10 608
(2529 to 31 860)
2419
(483 to 7851)
–77·2
(–86·2 to –63·8)*
–9·3
(–27·4 to –0·9)*
Protein-energy 
malnutrition
233
(180 to 301)
174
(131 to 227)
–25·3
(–42·5 to –3·6)*
–5·9
(–16·9 to 6·5)
22 791
(18 010 to 28 484)
17 633
(13 635 to 22 230)
–22·6
(–38·0 to –3·6)*
–0·8
(–4·3 to 2·8)
Childhood stunting: all 
causes
508
(248 to 853)
257
(114 to 454)
–49·4
(–58·0 to –43·2)*
–43·1
(–53·0 to –36·2)*
43 961
(21 558 to 73 511)
22 420
(9964 to 39 448)
–49·0
(–57·4 to –42·9)*
–42·5
(–52·3 to –35·6)*
Diarrhoeal diseases 154
(59 to 268)
87
(31 to 156)
–43·6
(–51·1 to –33·4)*
–22·3
(–30·5 to –13·0)*
13 638
(5210 to 23 658)
7824
(2807 to 13 947)
–42·6
(–50·1 to –32·8)*
–18·9
(–24·7 to –13·1)*
Lower respiratory 
infections
282
(25 to 615)
155
(12 to 348)
–45·1
(–50·9 to –36·6)*
–36·1
(–42·0 to –26·4)*
24 248
(2170 to 52 767)
13 335
(1014 to 29 932)
–45·0
(–50·8 to –36·5)*
–25·4
(–31·1 to –16·1)*
Measles 71
(7 to 202)
15
(1 to 45)
–79·2
(–87·9 to –61·9)*
–16·9
(–30·7 to –5·4)*
6074
(612 to 17 171)
1262
(108 to 3787)
–79·2
(–87·9 to –61·9)*
–16·9
(–30·6 to –5·3)*
Iron deﬁ ciency: all causes 87
(59 to 116)
84
(58 to 114)
–3·5
(–14·8 to 10·0)
1·7
(–9·3 to 14·7)
55 120
(37 924 to 76 937)
52 870
(36 518 to 74 437)
–4·1
(–5·8 to –2·4)*
6·1
(3·9 to 8·5)*
Maternal haemorrhage 30
(12 to 48)
24
(9 to 40)
–20·3
(–32·7 to –7·6)*
–4·4
(–11·2 to 2·2)
1694
(672 to 2705)
1338
(509 to 2236)
–21·0
(–32·8 to –8·8)*
–4·5
(–11·1 to 2·1)
Maternal sepsis and 
other pregnancy-related 
infections
8
(3 to 13)
5
(2 to 9)
–34·1
(–47·7 to –17·6)*
–8·8
(–14·7 to –3·0)*
475
(187 to 776)
315
(118 to 543)
–33·7
(–46·9 to –17·2)*
–8·7
(–14·6 to –2·9)*
Iron-deﬁ ciency anaemia 48
(32 to 63)
54
(35 to 73)
12·1
(–2·1 to 28·0)
·· 52 951
(36 342 to 74 874)
51 217
(35 014 to 72 661)
–3·3
(–4·8 to –1·8)*
··
Vitamin A deﬁ ciency: all 
causes
191
(116 to 291)
83
(50 to 119)
–56·7
(–66·6 to –47·3)*
–51·6
(–62·5 to –41·0)*
16 864
(10 421 to 25 457)
7611
(4693 to 10 841)
–54·9
(–64·7 to –45·6)*
–49·4
(–60·2 to –39·1)*
Diarrhoeal diseases 107
(60 to 158)
64
(36 to 93)
–40·2
(–48·1 to –30·7)*
–17·9
(–26·8 to –8·5)*
9531
(5402 to 14 012)
5805
(3234 to 8402)
–39·1
(–46·7 to –29·8)*
–14·2
(–20·1 to –8·0)*
Measles 84
(31 to 176)
19
(7 to 41)
–77·9
(–86·0 to –66·3)*
–12·1
(–23·1 to –2·7)*
7124
(2655 to 14 910)
1574
(556 to 3469)
–77·9
(–86·0 to 
–66·3)*
–12·0
(–22·8 to –2·8)*
Vitamin A deﬁ ciency ·· ·· ·· ·· 209
(131 to 309)
232
(143 to 346)
10·9
(7·5 to 14·6)*
··
Zinc deﬁ ciency: all causes 93
(5 to 208)
55
(3 to 125)
–40·5
(–49·1 to –28·8)*
–33·8
(–43·3 to –21·0)*
8162
(819 to 17 948)
4967
(600 to 10 853)
–39·1
(–47·3 to –25·0)*
–32·2
(–40·9 to –16·2)*
Diarrhoeal diseases 51
(0 to 119)
31
(0 to 73)
–39·7
(–50·0 to 0·0)
–17·9
(–30·1 to 0·0)
4663
(301 to 10 330)
2911
(275 to 6369)
–37·6
(–47·4 to –8·3)*
–12·8
(–22·8 to 29·3)
Lower respiratory 
infections
41
(0 to 143)
24
(0 to 83)
–41·4
(–49·4 to 0·0)
–32·8
(–40·8 to 0·0)
3498
(13 to 12 111)
2056
(11 to 7031)
–41·2
(–48·8 to –11·0)*
–21·4
(–29·4 to 21·5)
Tobacco smoke: all causes 6879
(6207 to 7522)
7165
(6544 to 7775)
4·2
(0·9 to 7·6)*
–4·0
(–6·4 to –1·5)*
174 309
(158 980 to 190 805)
170 889
(156 216 to 185 988)
–2·0
(–5·1 to 1·3)
–6·4
(–9·0 to –3·6)*
Smoking: all causes 6113
(5402 to 6780)
6402
(5749 to 7037)
4·7
(1·2 to 8·5)*
–3·9
(–6·7 to –0·8)*
147 153
(131 914 to 161 831)
148 623
(134 236 to 163 140)
1·0
(–2·4 to 4·6)
–5·0
(–8·1 to –1·9)*
Tuberculosis 114
(57 to 180)
87
(41 to 140)
–23·9
(–32·0 to –16·9)*
–9·4
(–15·3 to –4·8)*
3717
(1859 to 5830)
2836
(1357 to 4514)
–23·7
(–31·0 to –17·4)*
–9·0
(–15·5 to –3·9)*
Lower respiratory 
infections
332
(265 to 405)
350
(276 to 433)
5·4
(1·0 to 9·4)*
–1·3
(–4·6 to 2·0)
7119
(5724 to 8603)
7044
(5589 to 8640)
–1·1
(–5·4 to 3·3)
13·3
(7·0 to 19·9)*
Lip and oral cavity cancer 48
(41 to 55)
60
(50 to 71)
25·8
(18·6 to 32·7)*
–4·9
(–8·8 to –1·6)*
1288
(1099 to 1487)
1548
(1284 to 1831)
20·2
(12·5 to 27·8)*
–6·8
(–10·9 to –3·1)*
Nasopharyngeal cancer 21
(15 to 28)
23
(16 to 30)
8·3
(–2·0 to 20·0)
–4·5
(–9·9 to 2·3)
640
(431 to 887)
643
(451 to 867)
0·5
(–11·1 to 14·2)
–6·4
(–13·5 to 2·9)
Oesophageal cancer 163
(101 to 236)
157
(104 to 216)
–4·0
(–13·8 to 8·6)
0·3
(–7·2 to 13·0)
3736
(2336 to 5384)
3418
(2286 to 4696)
–8·5
(–18·1 to 4·4)
–1·1
(–8·9 to 11·6)
Stomach cancer 88
(51 to 138)
81
(47 to 126)
–8·0
(–14·7 to –1·5)*
–7·0
(–11·9 to –2·3)*
2030
(1162 to 3180)
1706
(958 to 2630)
–16·0
(–23·2 to –8·8)*
–10·0
(–15·9 to –4·6)*
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(Continued from previous page)
Colon and rectal cancer 45
(32 to 60)
50
(35 to 66)
10·2
(4·8 to 15·3)*
–10·3
(–13·7 to –7·4)*
978
(682 to 1293)
996
(696 to 1314)
1·9
(–3·4 to 6·8)
–14·0
(–17·5 to –11·1)*
Liver cancer due to 
hepatitis B
37
(17 to 72)
35
(16 to 64)
–5·0
(–20·0 to 13·1)
–5·1
(–15·4 to 10·9)
1176
(512 to 2280)
1022
(467 to 1899)
–13·1
(–29·5 to 7·7)
–8·6
(–21·7 to 11·0)
Liver cancer due to 
hepatitis C
20
(12 to 29)
24
(14 to 35)
20·3
(12·8 to 28·6)*
–0·4
(–6·0 to 5·0)
426
(248 to 634)
474
(275 to 712)
11·4
(2·1 to 21·4)*
–2·7
(–8·7 to 4·1)
Liver cancer due to 
alcohol use
34
(17 to 58)
40
(20 to 69)
18·2
(6·8 to 31·0)*
–5·9
(–12·1 to –0·1)*
849
(426 to 1476)
958
(467 to 1652)
12·8
(–0·3 to 26·9)
–7·8
(–14·9 to –0·7)*
Liver cancer due to other 
causes
16
(8 to 29)
16
(9 to 28)
0·5
(–12·5 to 18·5)
–0·1
(–10·4 to 15·6)
440
(204 to 817)
396
(202 to 684)
–9·8
(–24·7 to 11·0)
–4·0
(–16·4 to 15·6)
Pancreatic cancer 62
(50 to 75)
73
(59 to 89)
18·0
(14·0 to 22·2)*
–9·3
(–11·8 to –6·9)*
1330
(1068 to 1630)
1467
(1159 to 1820)
10·3
(6·2 to 14·7)*
–12·4
(–15·3 to –9·6)*
Tracheal, bronchial, and 
lung cancer
1014
(880 to 1127)
1175
(1012 to 1324)
15·8
(11·1 to 21·1)*
–3·6
(–5·3 to –2·1)*
22 060
(18 918 to 24 709)
24 140
(20 463 to 27 427)
9·4
(4·3 to 15·5)*
–4·7
(–6·7 to –2·8)*
Cervical cancer 12
(4 to 21)
12
(4 to 21)
0·7
(–11·2 to 15·6)
–3·6
(–11·9 to 6·2)
355
(117 to 647)
330
(109 to 588)
–7·1
(–21·0 to 9·4)
–8·0
(–17·8 to 3·9)
Kidney cancer 20
(13 to 26)
23
(15 to 31)
16·6
(10·1 to 22·4)*
–11·1
(–14·6 to –8·1)*
481
(326 to 625)
531
(349 to 709)
10·4
(3·9 to 16·1)*
–14·4
(–18·9 to –10·9)*
Bladder cancer 44
(33 to 54)
51
(38 to 64)
16·8
(11·2 to 21·9)*
–6·2
(–9·0 to –3·6)*
835
(629 to 1034)
907
(674 to 1146)
8·6
(3·3 to 13·7)*
–8·8
(–11·8 to –6·1)*
Ischaemic heart disease 1236
(1020 to 1455)
1280
(1049 to 1515)
3·5
(0·1 to 6·9)*
–8·9
(–11·1 to –6·6)*
32 669
(26 987 to 38 407)
33 161
(26 987 to 39 130)
1·5
(–2·1 to 4·9)
–7·4
(–9·4 to –5·4)*
Ischaemic stroke 362
(301 to 420)
352
(293 to 416)
–2·7
(–6·8 to 1·3)
–7·6
(–10·6 to –4·5)*
7810
(6500 to 9146)
7520
(6258 to 8897)
–3·7
(–7·8 to 0·2)
–5·4
(–8·2 to –2·6)*
Haemorrhagic stroke 609
(510 to 706)
573
(475 to 673)
–5·9
(–10·3 to –1·1)*
–7·1
(–10·1 to –3·9)*
16 619
(14 010 to 19 207)
15 512
(12 884 to 18 266)
–6·7
(–10·9 to –2·2)*
–5·5
(–8·2 to –2·6)*
Hypertensive heart 
disease
99
(77 to 122)
114
(89 to 138)
14·9
(8·1 to 21·6)*
–6·8
(–11·2 to –1·4)*
2527
(1976 to 3091)
2771
(2168 to 3364)
9·7
(3·3 to 16·4)*
–5·9
(–9·9 to –1·3)*
Atrial ﬁ brillation and 
ﬂ utter
12
(8 to 15)
14
(10 to 18)
18·0
(13·9 to 22·2)*
–11·0
(–13·9 to –8·1)*
537
(379 to 732)
617
(433 to 846)
14·9
(12·7 to 16·9)*
–8·1
(–9·5 to –6·7)*
Aortic aneurysm 22
(17 to 26)
23
(18 to 28)
6·3
(0·1 to 10·8)*
–12·9
(–15·0 to –10·6)*
542
(426 to 651)
572
(448 to 693)
5·6
(–1·1 to 10·4)
–10·3
(–12·4 to –8·1)*
Peripheral vascular 
disease
4
(3 to 5)
5
(4 to 6)
15·3
(8·8 to 22·0)*
–13·4
(–17·4 to –9·5)*
144
(99 to 199)
167
(114 to 237)
16·3
(12·0 to 20·6)*
–10·6
(–12·9 to –8·4)*
Other cardiovascular and 
circulatory diseases
58
(45 to 71)
61
(47 to 75)
5·9
(1·2 to 10·8)*
–8·8
(–11·7 to –5·5)*
2187
(1699 to 2688)
2348
(1816 to 2910)
7·4
(3·5 to 11·2)*
–6·7
(–9·2 to –4·2)*
Chronic obstructive 
pulmonary disease
1355
(1010 to 1686)
1427
(1149 to 1699)
5·3
(–2·5 to 17·1)
1·8
(–4·5 to 13·4)
25 834
(20 021 to 31 596)
26 443
(21 842 to 31 310)
2·4
(–4·6 to 12·6)
0·6
(–5·4 to 10·8)
Silicosis 2
(1 to 2)
1
(1 to 2)
–7·1
(–21·0 to 8·8)
–8·7
(–17·1 to –0·8)*
39
(22 to 66)
33
(18 to 56)
–15·2
(–29·6 to 1·8)
–14·6
(–24·6 to –4·8)*
Asbestosis 1
(0 to 1)
1
(0 to 1)
18·5
(6·9 to 30·1)*
–8·5
(–13·2 to –3·3)*
12
(9 to 15)
13
(9 to 17)
7·8
(0·0 to 15·9)*
–12·6
(–16·9 to –7·8)*
Coal workers 
pneumoconiosis
1
(0 to 1)
0
(0 to 1)
–18·5
(–30·4 to –5·7)*
–12·8
(–21·5 to –5·3)*
11
(8 to 15)
9
(6 to 13)
–17·0
(–29·5 to –2·5)*
–14·7
(–22·6 to –6·4)*
Other pneumoconiosis 2
(1 to 2)
2
(2 to 3)
15·1
(4·9 to 27·8)*
–5·3
(–14·8 to 5·8)
49
(35 to 67)
52
(37 to 71)
6·3
(–2·8 to 15·5)
–13·5
(–20·2 to –6·6)*
Asthma 55
(41 to 69)
45
(35 to 56)
–17·6
(–27·0 to –4·2)*
–8·2
(–17·3 to 2·6)
2226
(1692 to 2804)
2024
(1514 to 2579)
–9·0
(–15·9 to –0·7)*
–13·3
(–18·5 to –7·8)*
Interstitial lung disease 
and pulmonary 
sarcoidosis
12
(9 to 16)
17
(12 to 21)
37·2
(26·4 to 45·4)*
–9·7
(–13·2 to –5·2)*
244
(179 to 302)
302
(224 to 377)
24·1
(15·2 to 31·7)*
–13·0
(–16·5 to –8·1)*
Other chronic respiratory 
diseases
3
(2 to 4)
4
(3 to 6)
30·6
(16·5 to 49·4)*
6·3
(–4·5 to 20·5)
191
(140 to 248)
211
(150 to 278)
10·0
(0·6 to 20·1)*
3·2
(–6·7 to 13·2)
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2005 deaths
(in thousands)
2015 deaths
(in thousands)
Percentage 
change of 
2005–15 deaths 
Percentage 
change of 
2005–15 age-
standardised 
PAF
2005 DALYs
(in thousands)
2015 DALYs
(in thousands)
Percentage 
change of 
2005–15 DALYs
Percentage 
change of 
2005–15 age-
standardised 
DALYs PAF 
(Continued from previous page)
Diabetes mellitus 56
(17 to 98)
68
(19 to 120)
21·2
(13·4 to 27·9)*
–7·6
(–13·1 to –3·5)*
2873
(831 to 5122)
3402
(949 to 6090)
18·4
(13·6 to 22·4)*
–8·5
(–11·7 to –6·1)*
Second-hand smoke: all 
causes
884
(685 to 1093)
886
(695 to 1091)
0·2
(–3·5 to 3·9)
–4·8
(–7·4 to –2·4)*
29 996
(22 370 to 38 043)
25 212
(19 297 to 31 653)
–15·9
(–20·0 to –11·2)*
–13·3
(–16·5 to –9·7)*
Lower respiratory 
infections
238
(151 to 330)
183
(114 to 259)
–23·0
(–27·4 to –19·0)*
–15·0
(–17·5 to –12·5)*
15 685
(9917 to 21 832)
10 103
(6305 to 14 390)
–35·6
(–39·9 to –31·4)*
–13·5
(–15·9 to 
–11·1)*
Otitis media 0
(0 to 0)
0
(0 to 0)
–32·6
(–40·5 to –23·5)*
–11·7
(–25·4 to 2·6)
266
(149 to 426)
250
(138 to 406)
–5·8
(–9·4 to –3·0)*
–3·8
(–5·9 to –1·6)*
Tracheal, bronchial, and 
lung cancer
22
(11 to 37)
29
(15 to 49)
32·6
(26·5 to 37·2)*
10·7
(6·1 to 14·9)*
536
(282 to 928)
691
(371 to 1189)
29·0
(21·4 to 35·0)*
13·5
(7·4 to 19·0)*
Ischaemic heart disease 331
(252 to 422)
386
(291 to 494)
16·5
(12·1 to 20·5)*
0·9
(–0·8 to 2·6)
7187
(5734 to 8847)
8066
(6409 to 9894)
12·2
(7·9 to 16·2)*
1·9
(–0·0 to 3·9)
Ischaemic stroke 69
(51 to 90)
72
(52 to 95)
5·4
(–0·7 to 10·9)
–1·5
(–4·2 to 0·9)
1229
(948 to 1561)
1248
(947 to 1589)
1·5
(–3·8 to 6·3)
–0·6
(–3·2 to 1·7)
Haemorrhagic stroke 104
(81 to 132)
103
(80 to 132)
–0·6
(–5·2 to 4·7)
–2·5
(–5·1 to 0·1)
2637
(2076 to 3305)
2548
(1991 to 3201)
–3·4
(–8·2 to 2·2)
–2·1
(–4·9 to 0·9)
Alcohol and drug use: 
all causes
2595
(2314 to 2866)
2750
(2424 to 3051)
6·0
(3·0 to 8·8)*
3·2
(1·0 to 5·4)*
108 717
(100 094 to 117 134)
111 365
(102 247 to 120 352)
2·4
(0·0 to 4·8)*
3·4
(1·2 to 5·5)*
Alcohol use: all causes 2228
(1943 to 2500)
2306
(1986 to 2608)
3·5
(0·0 to 6·8)*
0·5
(–2·1 to 3·0)
86 048
(78 266 to 93 716)
84 990
(77 180 to 93 010)
–1·2
(–3·9 to 1·5)
–0·9
(–3·4 to 1·9)
Tuberculosis 147
(117 to 187)
126
(94 to 169)
–13·9
(–23·0 to –5·2)*
4·7
(–3·7 to 11·1)
5498
(4497 to 6911)
4725
(3591 to 6198)
–14·1
(–22·4 to –6·2)*
4·7
(–3·3 to 11·0)
Lower respiratory 
infections
93
(83 to 104)
106
(89 to 121)
13·6
(6·7 to 20·2)*
8·7
(2·9 to 14·5)*
2279
(2036 to 2495)
2355
(1995 to 2628)
3·3
(–4·2 to 10·9)
20·9
(11·7 to 30·3)*
Lip and oral cavity cancer 29
(26 to 31)
38
(33 to 41)
31·9
(24·7 to 38·9)*
0·5
(–4·4 to 4·5)
820
(759 to 874)
1046
(929 to 1134)
27·5
(20·5 to 34·4)*
–0·3
(–4·8 to 3·6)
Nasopharyngeal cancer 15
(11 to 16)
18
(13 to 20)
18·8
(7·8 to 28·3)*
5·2
(–0·6 to 9·6)
494
(367 to 538)
556
(407 to 623)
12·6
(1·9 to 22·3)*
5·6
(0·3 to 9·9)*
Other pharyngeal cancer 16
(14 to 17)
20
(17 to 22)
26·3
(18·9 to 32·8)*
2·2
(–2·7 to 6·1)
454
(418 to 486)
560
(499 to 611)
23·4
(16·3 to 29·7)*
2·0
(–2·6 to 5·4)
Oesophageal cancer 73
(66 to 80)
75
(64 to 84)
2·3
(–6·2 to 10·9)
7·6
(0·8 to 12·9)*
1847
(1673 to 2002)
1826
(1579 to 2027)
–1·1
(–9·3 to 7·3)
7·1
(0·9 to 11·9)*
Colon and rectal cancer 27
(24 to 29)
32
(28 to 36)
20·8
(15·8 to 25·4)*
–1·4
(–5·2 to 1·6)
599
(548 to 650)
702
(626 to 771)
17·2
(12·3 to 21·5)*
–1·0
(–4·7 to 2·0)
Liver cancer due to 
hepatitis B
1
(1 to 2)
1
(1 to 1)
–26·6
(–41·4 to –8·1)*
–17·6
(–33·3 to –2·5)*
75
(53 to 97)
56
(38 to 76)
–24·9
(–39·5 to –7·1)*
–12·8
(–28·3 to 1·5)
Liver cancer due to 
hepatitis C
0
(0 to 0)
0
(0 to 0)
–10·0
(–26·7 to 8·8)
–14·5
(–30·3 to 2·0)
4
(3 to 6)
4
(2 to 5)
–12·0
(–27·8 to 5·2)
–12·2
(–27·1 to 3·5)
Liver cancer due to 
alcohol use
195
(169 to 208)
245
(225 to 267)
26·1
(18·5 to 37·1)*
·· 4787
(4075 to 5169)
5889
(5368 to 6441)
23·0
(14·8 to 36·1)*
··
Liver cancer due to other 
causes
0
(0 to 0)
0
(0 to 0)
–30·2
(–43·3 to –13·8)*
–20·6
(–35·7 to –5·6)*
19
(13 to 25)
14
(9 to 19)
–28·7
(–41·6 to –12·5)*
–15·0
(–29·8 to –0·7)*
Laryngeal cancer 18
(16 to 19)
20
(17 to 22)
9·9
(3·9 to 15·2)*
–3·0
(–7·9 to 0·7)
486
(443 to 523)
520
(456 to 572)
6·9
(1·6 to 11·9)*
–3·2
(–7·8 to 0·2)
Breast cancer 27
(24 to 29)
30
(26 to 34)
13·8
(7·2 to 20·0)*
–6·1
(–10·7 to –1·7)*
801
(712 to 889)
899
(768 to 1023)
12·3
(5·4 to 18·7)*
–6·0
(–10·8 to –1·3)*
Ischaemic heart disease 35
(–110 to 176)
10
(–130 to 150)
–71·4
(–400·6 to 
326·2)
–85·9
(–325·6 to 241·9)
1760
(–648 to 4072)
1004
(–1092 to 2983)
–42·9
(–285·7 to 181·1)
–46·7
(–187·7 to 
215·6)
Ischaemic stroke 13
(–8 to 34)
8
(–11 to 27)
–38·1
(–206·5 to 
204·3)
–31·8
(–162·0 to 138·1)
517
(210 to 814)
455
(213 to 691)
–12·0
(–21·3 to 10·0)
–11·9
(–21·3 to 16·5)
Haemorrhagic stroke 237
(213 to 261)
248
(214 to 280)
4·7
(–2·1 to 11·3)
2·8
(–3·8 to 8·0)
5659
(5148 to 6143)
5754
(5004 to 6385)
1·7
(–4·8 to 7·3)
2·7
(–3·2 to 7·1)
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(in thousands)
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2005–15 DALYs
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change of 
2005–15 age-
standardised 
DALYs PAF 
(Continued from previous page)
Hypertensive heart 
disease
40
(29 to 51)
51
(34 to 68)
30·0
(9·7 to 45·7)*
7·5
(–9·6 to 22·1)
1023
(840 to 1211)
1271
(970 to 1538)
24·3
(12·0 to 33·8)*
7·2
(–2·9 to 15·6)
Atrial ﬁ brillation and 
ﬂ utter
8
(6 to 9)
10
(8 to 13)
35·4
(26·8 to 43·1)*
0·5
(–5·9 to 5·8)
237
(184 to 303)
301
(233 to 391)
26·9
(20·6 to 32·3)*
0·5
(–4·6 to 4·5)
Cirrhosis and other 
chronic liver diseases due 
to hepatitis B
82
(69 to 95)
87
(69 to 105)
6·9
(–3·0 to 14·9)
–1·5
(–10·2 to 4·4)
2456
(2076 to 2832)
2526
(1989 to 3019)
2·8
(–6·8 to 10·5)
–1·8
(–10·4 to 3·9)
Cirrhosis and other 
chronic liver diseases due 
to hepatitis C
66
(54 to 77)
73
(57 to 88)
10·1
(–0·0 to 17·3)
–2·9
(–12·0 to 3·1)
1895
(1538 to 2203)
2017
(1542 to 2419)
6·4
(–3·5 to 13·4)
–2·6
(–11·8 to 3·3)
Cirrhosis and other 
chronic liver diseases due 
to alcohol use
310
(289 to 333)
348
(323 to 375)
12·2
(8·4 to 16·7)*
·· 10 093
(9424 to 10 841)
10 997
(10 197 to 11 875)
9·0
(5·0 to 13·7)*
··
Cirrhosis and other 
chronic liver diseases due 
to other causes
48
(41 to 55)
52
(42 to 61)
7·9
(–0·5 to 14·8)
–0·7
(–8·5 to 4·5)
1399
(1197 to 1587)
1430
(1157 to 1681)
2·2
(–6·1 to 8·9)
1·1
(–7·0 to 6·7)
Pancreatitis 16
(15 to 18)
19
(16 to 21)
13·3
(4·3 to 22·0)*
–4·4
(–11·1 to 1·5)
633
(567 to 691)
695
(600 to 778)
9·7
(1·4 to 18·1)*
–5·1
(–11·5 to 0·5)
Epilepsy 12
(11 to 13)
14
(12 to 15)
10·9
(2·9 to 19·7)*
2·0
(–4·1 to 7·9)
1038
(866 to 1219)
1039
(859 to 1239)
0·1
(–6·5 to 6·5)
–0·7
(–6·4 to 4·1)
Alcohol use disorders 157
(147 to 163)
138
(131 to 144)
–12·6
(–16·7 to –7·0)*
·· 11 567
(9618 to 13 835)
11 194
(9136 to 13 871)
–3·2
(–7·0 to 0·6)
··
Diabetes mellitus –58
(–63 to –53)
–64
(–70 to –58)
10·5
(0·8 to 19·7)*
–18·4
(–25·9 to –10·3)*
–2324
(–2840 to –1866)
–2685
(–3321 to –2142)
15·5
(10·4 to 20·0)*
–11·7
(–15·4 to –8·2)*
Pedestrian road injuries 107
(89 to 127)
100
(84 to 119)
–6·1
(–13·2 to –0·0)*
–0·4
(–3·1 to 2·1)
5360
(4475 to 6380)
4806
(4012 to 5678)
–10·3
(–16·8 to –4·6)*
0·3
(–2·5 to 2·9)
Cyclist road injuries 13
(10 to 15)
11
(9 to 13)
–11·4
(–19·4 to –3·5)*
–2·4
(–5·7 to 0·7)
701
(578 to 838)
607
(511 to 720)
–13·4
(–19·8 to –6·7)*
–3·6
(–6·9 to –0·5)*
Motorcyclist road 
injuries
77
(64 to 88)
81
(69 to 93)
4·3
(–5·1 to 16·4)
–0·0
(–3·3 to 3·5)
4299
(3632 to 4895)
4324
(3713 to 5003)
0·6
(–7·4 to 11·6)
–0·0
(–3·2 to 3·3)
Motor vehicle road 
injuries
148
(130 to 167)
135
(120 to 152)
–8·8
(–14·7 to –2·9)*
–4·6
(–6·6 to –2·4)*
7917
(7015 to 8956)
7067
(6301 to 7927)
–10·7
(–15·9 to –5·6)*
–4·5
(–6·6 to –2·3)*
Falls 42
(36 to 50)
50
(41 to 60)
17·8
(8·7 to 24·6)*
–1·2
(–5·0 to 2·2)
2416
(1951 to 2968)
2602
(2097 to 3230)
7·7
(2·2 to 12·2)*
–3·2
(–5·9 to –0·0)*
Drowning 27
(24 to 32)
24
(21 to 28)
–13·2
(–17·0 to –9·1)*
3·0
(–2·9 to 8·4)
1225
(1057 to 1435)
1001
(871 to 1168)
–18·3
(–22·1 to –14·4)*
4·9
(–2·9 to 11·9)
Fire, heat, and hot 
substances
14
(12 to 16)
12
(10 to 15)
–10·1
(–16·6 to –1·9)*
–3·6
(–10·3 to 1·7)
694
(586 to 832)
619
(511 to 755)
–10·8
(–16·2 to –4·5)*
–3·1
(–10·2 to 2·2)
Poisonings 9
(7 to 11)
7
(5 to 9)
–15·8
(–21·5 to –8·5)*
–4·9
(–16·2 to 7·1)
386
(303 to 478)
319
(246 to 388)
–17·4
(–22·1 to –11·0)*
–7·0
(–23·3 to 11·0)
Unintentional ﬁ rearm 
injuries
3
(2 to 4)
3
(2 to 3)
–8·0
(–13·1 to –2·2)*
–6·7
(–9·8 to –3·0)*
145
(112 to 174)
129
(99 to 154)
–10·7
(–15·7 to –5·1)*
–6·9
(–10·6 to –2·5)*
Unintentional 
suﬀ ocation
1
(1 to 1)
2
(1 to 2)
42·5
(16·3 to 57·0)*
27·3
(9·8 to 43·3)*
68
(55 to 84)
88
(68 to 108)
28·9
(13·2 to 38·9)*
25·8
(9·5 to 43·3)*
Other exposure to 
mechanical forces
14
(11 to 17)
15
(10 to 18)
0·5
(–15·2 to 12·4)
–0·1
(–5·4 to 4·4)
913
(724 to 1127)
905
(684 to 1140)
–0·9
(–10·2 to 6·8)
–0·4
(–3·7 to 3·1)
Self-harm 110
(95 to 129)
111
(96 to 130)
1·4
(–4·3 to 6·2)
0·6
(–3·6 to 3·8)
4649
(4032 to 5436)
4552
(3953 to 5303)
–2·1
(–7·5 to 2·7)
0·6
(–3·8 to 3·9)
Assault by ﬁ rearm 23
(21 to 26)
23
(20 to 26)
–0·6
(–4·2 to 4·2)
–5·3
(–6·9 to –3·6)*
1313
(1158 to 1481)
1285
(1128 to 1459)
–2·2
(–5·7 to 2·5)
–5·1
(–6·7 to –3·3)*
Assault by sharp object 16
(14 to 18)
12
(11 to 14)
–19·7
(–24·0 to –14·5)*
–5·3
(–8·0 to –2·8)*
840
(744 to 968)
668
(590 to 769)
–20·5
(–24·7 to –15·2)*
–4·7
(–7·5 to –2·2)*
Assault by other means 18
(16 to 22)
16
(14 to 19)
–13·9
(–18·4 to –7·3)*
–6·2
(–9·0 to –3·1)*
1007
(880 to 1181)
868
(745 to 1022)
–13·7
(–18·2 to –7·0)*
–5·0
(–7·9 to –1·8)*
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(Continued from previous page)
Drug use: all causes 407
(364 to 448)
489
(439 to 537)
20·2
(15·9 to 25·0)*
19·2
(15·2 to 24·2)*
24 036
(21 317 to 26 732)
27 831
(24 437 to 31 171)
15·8
(12·6 to 18·8)*
19·5
(16·1 to 23·0)*
HIV/AIDS—tuberculosis 11
(9 to 14)
8
(7 to 10)
–25·7
(–33·4 to –15·9)*
22·1
(10·1 to 36·9)*
567
(465 to 698)
413
(333 to 513)
–27·1
(–33·9 to –18·2)*
19·4
(8·2 to 33·6)*
HIV/AIDS resulting in 
other diseases
53
(46 to 65)
52
(44 to 63)
–3·6
(–12·0 to 7·2)
39·5
(28·9 to 51·1)*
2746
(2380 to 3317)
2594
(2216 to 3176)
–5·6
(–13·6 to 4·0)
34·4
(25·3 to 44·9)*
Hepatitis B 1
(0 to 1)
0
(0 to 1)
–27·7
(–35·2 to –18·4)*
–21·3
(–29·3 to –10·3)*
18
(8 to 30)
13
(6 to 21)
–28·0
(–35·8 to –18·8)*
–22·3
(–30·6 to 
–12·2)*
Hepatitis C 1
(0 to 2)
1
(0 to 2)
–12·0
(–30·1 to 11·0)
–1·4
(–13·0 to 11·5)
37
(9 to 83)
33
(8 to 72)
–12·3
(–30·1 to 10·0)
–3·8
(–14·3 to 7·5)
Liver cancer due to 
hepatitis B
3
(1 to 5)
4
(2 to 6)
15·2
(1·3 to 38·4)*
15·3
(4·8 to 30·9)*
104
(43 to 171)
110
(49 to 179)
6·2
(–7·1 to 29·1)
11·7
(1·8 to 26·0)*
Liver cancer due to 
hepatitis C
53
(38 to 68)
74
(57 to 91)
39·0
(28·8 to 54·2)*
16·6
(8·5 to 29·2)*
1316
(998 to 1627)
1678
(1329 to 2012)
27·5
(18·2 to 41·4)*
12·7
(5·5 to 24·1)*
Cirrhosis and other 
chronic liver diseases due 
to hepatitis B
3
(1 to 5)
3
(1 to 5)
20·9
(10·3 to 35·7)*
12·6
(3·0 to 26·4)*
90
(38 to 149)
101
(43 to 162)
12·1
(2·3 to 24·9)*
8·1
(–1·3 to 20·6)
Cirrhosis and other 
chronic liver diseases due 
to hepatitis C
124
(98 to 147)
147
(118 to 175)
19·0
(12·9 to 27·0)*
7·0
(2·2 to 14·1)*
4064
(3321 to 4750)
4556
(3727 to 5374)
12·1
(6·4 to 19·0)*
4·3
(0·2 to 10·2)*
Opioid use disorders 94
(91 to 100)
122
(110 to 130)
29·6
(18·2 to 37·2)*
·· 9864
(8127 to 11 517)
12 068
(9878 to 14 145)
22·3
(17·5 to 26·1)*
··
Cocaine use disorders 7
(5 to 8)
11
(9 to 12)
49·7
(33·6 to 75·4)*
·· 729
(558 to 902)
999
(773 to 1234)
37·0
(29·2 to 47·0)*
··
Amphetamine use 
disorders
7
(4 to 8)
12
(8 to 14)
67·5
(25·6 to 118·9)*
·· 1001
(706 to 1348)
1403
(1025 to 1847)
40·1
(26·1 to 55·2)*
··
Cannabis use disorders ·· ·· ·· ·· 548
(352 to 781)
577
(372 to 818)
5·3
(3·7 to 7·1)*
··
Other drug use disorders 20
(19 to 23)
25
(23 to 27)
23·0
(12·7 to 32·1)*
·· 1529
(1245 to 1861)
1862
(1502 to 2274)
21·8
(15·7 to 27·5)*
··
Self-harm 28
(19 to 41)
29
(20 to 41)
2·6
(–3·0 to 8·9)
5·6
(1·3 to 10·0)*
1423
(951 to 2030)
1425
(955 to 2037)
0·1
(–5·4 to 6·3)
5·8
(1·4 to 10·3)*
Dietary risks: all causes 10 738
(9473 to 
12 010)
12 058
(10 615 to 
13 538)
12·3
(10·0 to 14·5)*
2·4
(1·1 to 3·6)*
242 781
(217 378 to 269 659)
264411
(236 098 to 
294 989)
8·9
(6·3 to 11·3)*
2·1
(0·0 to 4·1)*
Diet low in fruits: all causes 2713
(1806 to 3703)
2924
(1905 to 4018)
7·8
(4·3 to 10·9)*
–0·6
(–3·1 to 1·5)
68 838
(46 616 to 92 835)
72 590
(48 514 to 98 667)
5·5
(1·7 to 8·6)*
–0·3
(–3·4 to 2·5)
Lip and oral cavity cancer 8
(0 to 17)
10
(0 to 22)
32·7
(0·0 to 37·5)*
0·1
(–0·6 to 0·7)
208
(0 to 451)
266
(0 to 583)
28·1
(0·0 to 33·1)*
–0·1
(–0·8 to 0·5)
Nasopharyngeal cancer 4
(0 to 9)
5
(0 to 10)
11·3
(0·0 to 18·2)*
–1·7
(–2·7 to 0·0)
132
(0 to 281)
138
(0 to 293)
4·5
(–3·7 to 11·1)
–2·1
(–3·3 to 0·0)
Other pharyngeal cancer 4
(0 to 8)
4
(0 to 10)
23·4
(0·0 to 29·4)*
–0·6
(–1·4 to 0·1)
99
(0 to 221)
119
(0 to 266)
20·2
(0·0 to 26·2)*
–0·6
(–1·4 to 0·1)
Oesophageal cancer 106
(26 to 187)
99
(24 to 174)
–6·4
(–11·3 to –0·8)*
–2·0
(–3·2 to –1·2)*
2466
(618 to 4362)
2221
(542 to 3911)
–9·9
(–15·1 to –4·0)*
–2·5
(–3·9 to –1·6)*
Laryngeal cancer 7
(0 to 15)
7
(0 to 17)
13·4
(0·0 to 17·4)*
–0·3
(–1·0 to 0·2)
168
(0 to 374)
184
(0 to 413)
9·8
(0·0 to 13·8)*
–0·5
(–1·3 to 0·1)
Tracheal, bronchial, and 
lung cancer
172
(70 to 291)
207
(84 to 351)
20·1
(16·5 to 24·4)*
0·1
(–0·5 to 0·7)
3858
(1577 to 6495)
4391
(1780 to 7445)
13·8
(9·9 to 18·7)*
–0·5
(–1·3 to 0·1)
Ischaemic heart disease 947
(340 to 1585)
1086
(388 to 1818)
14·7
(12·1 to 17·0)*
–0·3
(–0·9 to 0·3)
21 685
(7921 to 35 741)
23 777
(8598 to 39 451)
9·6
(6·3 to 12·4)*
–0·0
(–0·8 to 0·6)
Ischaemic stroke 509
(271 to 776)
521
(274 to 805)
2·3
(–1·1 to 5·2)
–2·4
(–3·6 to –1·5)*
10 961
(5937 to 16 258)
11 001
(5940 to 16 513)
0·4
(–3·1 to 3·5)
–0·7
(–1·8 to 0·1)
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2005 deaths
(in thousands)
2015 deaths
(in thousands)
Percentage 
change of 
2005–15 deaths 
Percentage 
change of 
2005–15 age-
standardised 
PAF
2005 DALYs
(in thousands)
2015 DALYs
(in thousands)
Percentage 
change of 
2005–15 DALYs
Percentage 
change of 
2005–15 age-
standardised 
DALYs PAF 
(Continued from previous page)
Haemorrhagic stroke 838
(465 to 1239)
831
(458 to 1241)
–0·9
(–4·5 to 2·9)
–1·7
(–2·8 to –0·8)*
22 973
(13 194 to 33 252)
22 476
(12 752 to 32 682)
–2·2
(–5·8 to 1·5)
–0·4
(–1·4 to 0·3)
Diet low in vegetables: all 
causes
1842
(943 to 2869)
1994
(1024 to 3121)
8·2
(4·5 to 11·2)*
–1·1
(–3·7 to 0·7)
42 617
(22 635 to 65 749)
44 632
(23 572 to 68 817)
4·7
(1·5 to 7·9)*
–1·3
(–4·2 to 1·3)
Ischaemic heart disease 1261
(489 to 2099)
1418
(548 to 2363)
12·5
(10·3 to 14·7)*
–2·8
(–3·7 to –2·1)*
27 791
(11 029 to 45 849)
30 048
(11 828 to 49 331)
8·1
(5·2 to 10·9)*
–1·9
(–2·8 to –1·1)*
Ischaemic stroke 226
(51 to 412)
224
(51 to 412)
–0·8
(–3·8 to 2·0)
–5·7
(–7·1 to –4·4)*
4869
(1120 to 8768)
4762
(1097 to 8586)
–2·2
(–5·8 to 0·9)
–3·4
(–4·8 to –2·1)*
Haemorrhagic stroke 355
(99 to 666)
352
(99 to 653)
–1·0
(–4·1 to 2·5)
–1·9
(–3·4 to –0·4)*
9957
(2799 to 18 328)
9823
(2800 to 18 053)
–1·3
(–4·6 to 2·3)
0·6
(–0·8 to 2·2)
Diet low in whole grains: 
all causes
2879
(2056 to 3818)
3142
(2215 to 4189)
9·1
(6·3 to 11·8)*
0·4
(–1·5 to 2·0)
74 523
(54 213 to 96 519)
79 813
(57 571 to 104 238)
7·1
(3·7 to 9·8)*
1·3
(–1·3 to 3·5)
Ischaemic heart disease 1497
(888 to 2168)
1713
(1013 to 2481)
14·4
(12·0 to 16·6)*
–0·6
(–1·2 to –0·2)*
33 870
(20 349 to 48 312)
36 933
(21 938 to 53 267)
9·0
(5·7 to 11·6)*
–0·7
(–1·4 to –0·2)*
Ischaemic stroke 459
(311 to 620)
463
(311 to 631)
0·9
(–2·5 to 3·8)
–3·6
(–4·9 to –2·6)*
10 195
(6993 to 13 536)
10 143
(6849 to 13 505)
–0·5
(–4·0 to 2·7)
–1·5
(–2·6 to –0·6)*
Haemorrhagic stroke 729
(515 to 982)
716
(497 to 962)
–1·8
(–5·4 to 2·2)
–2·6
(–3·7 to –1·6)*
20 024
(14 326 to 26 601)
19 443
(13 708 to 25 849)
–2·9
(–6·5 to 0·9)
–1·1
(–2·1 to –0·4)*
Diabetes mellitus 195
(105 to 301)
250
(135 to 387)
28·5
(23·6 to 33·3)*
–1·5
(–2·4 to –0·7)*
10 434
(5659 to 16 438)
13 295
(7183 to 21 043)
27·4
(24·4 to 30·3)*
–0·8
(–1·4 to –0·3)*
Diet low in nuts and seeds: 
all causes
1830
(1160 to 2583)
2131
(1354 to 3011)
16·4
(14·2 to 18·6)*
6·0
(4·5 to 7·5)*
43 725
(29 136 to 60 125)
49 411
(32 716 to 68 196)
13·0
(9·8 to 15·9)*
6·5
(3·9 to 9·0)*
Ischaemic heart disease 1706
(1062 to 2438)
1970
(1226 to 2810)
15·5
(13·2 to 17·6)*
–0·0
(–0·4 to 0·3)
37 340
(23 613 to 52 283)
41 199
(26 175 to 57 706)
10·3
(7·3 to 12·9)*
0·3
(–0·2 to 0·8)
Diabetes mellitus 123
(64 to 193)
160
(83 to 253)
29·9
(25·2 to 34·6)*
–0·5
(–1·1 to 0·1)
6384
(3038 to 10 211)
8212
(3923 to 13 200)
28·6
(25·6 to 31·5)*
0·1
(–0·2 to 0·5)
Diet low in milk: all causes 101
(35 to 171)
126
(44 to 212)
24·7
(22·0 to 27·7)*
13·8
(11·6 to 15·9)*
2177
(750 to 3688)
2603
(897 to 4382)
19·6
(16·8 to 22·6)*
11·9
(9·3 to 14·7)*
Colon and rectal cancer 101
(35 to 171)
126
(44 to 212)
24·7
(22·0 to 27·7)*
1·3
(0·9 to 1·8)*
2177
(750 to 3688)
2603
(897 to 4382)
19·6
(16·8 to 22·6)*
1·1
(0·7 to 1·6)*
Diet high in red meat: all 
causes
37
(16 to 60)
43
(19 to 69)
14·8
(11·8 to 18·0)*
5·8
(3·4 to 8·3)*
1476
(549 to 2473)
1752
(638 to 2957)
18·7
(14·8 to 21·7)*
12·2
(8·2 to 15·1)*
Colon and rectal cancer 20
(4 to 36)
24
(5 to 42)
17·1
(13·8 to 20·2)*
–4·5
(–6·2 to –2·7)*
442
(93 to 778)
504
(108 to 904)
14·2
(10·8 to 17·5)*
–3·8
(–5·5 to –1·9)*
Diabetes mellitus 17
(2 to 31)
19
(2 to 35)
12·2
(9·0 to 15·2)*
–14·1
(–16·5 to –11·7)*
1034
(120 to 1958)
1247
(146 to 2359)
20·6
(17·2 to 23·5)*
–6·4
(–8·4 to –4·5)*
Diet high in processed 
meat: all causes
476
(132 to 809)
541
(156 to 914)
13·8
(11·1 to 21·8)*
3·7
(1·4 to 11·6)*
13 088
(5240 to 20 672)
14 907
(6450 to 23 452)
13·9
(9·3 to 24·4)*
7·2
(3·2 to 18·2)*
Colon and rectal cancer 31
(17 to 46)
37
(20 to 56)
20·7
(17·6 to 23·6)*
–2·5
(–3·8 to –1·3)*
644
(350 to 964)
745
(399 to 1123)
15·8
(12·8 to 18·7)*
–2·7
(–4·0 to –1·4)*
Ischaemic heart disease 363
(16 to 680)
402
(17 to 759)
10·7
(7·5 to 12·8)*
–4·0
(–5·3 to –2·7)*
7931
(340 to 14 939)
8401
(357 to 15 858)
5·9
(1·8 to 8·5)*
–3·9
(–5·5 to –2·1)*
Diabetes mellitus 82
(40 to 122)
102
(50 to 153)
24·8
(20·5 to 29·1)*
–4·9
(–6·5 to –3·5)*
4513
(2121 to 7031)
5761
(2708 to 8961)
27·6
(24·3 to 30·7)*
–0·9
(–2·1 to 0·3)
Diet high in sugar-
sweetened beverages: all 
causes
34
(23 to 47)
39
(27 to 55)
15·3
(12·5 to 18·0)*
7·3
(5·1 to 9·2)*
1234
(852 to 1748)
1449
(1004 to 2059)
17·4
(14·3 to 20·3)*
12·3
(9·9 to 14·7)*
Oesophageal cancer 1
(0 to 1)
1
(0 to 1)
16·0
(9·5 to 21·3)*
21·7
(13·7 to 28·3)*
13
(4 to 24)
15
(4 to 27)
13·0
(6·3 to 18·6)*
22·7
(14·8 to 29·5)*
Colon and rectum cancer 1
(0 to 1)
1
(0 to 1)
19·9
(16·4 to 23·5)*
–1·8
(–4·4 to 0·7)
14
(9 to 21)
17
(11 to 24)
17·8
(14·1 to 21·3)*
–0·1
(–3·0 to 2·8)
Liver cancer due to 
hepatitis B
0
(0 to 0)
0
(0 to 0)
21·7
(13·0 to 30·4)*
21·8
(12·2 to 30·7)*
5
(2 to 9)
6
(3 to 10)
17·7
(8·5 to 27·3)*
24·4
(13·5 to 33·8)*
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2015 deaths
(in thousands)
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change of 
2005–15 deaths 
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2005–15 age-
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2015 DALYs
(in thousands)
Percentage 
change of 
2005–15 DALYs
Percentage 
change of 
2005–15 age-
standardised 
DALYs PAF 
(Continued from previous page)
Liver cancer due to 
hepatitis C
0
(0 to 0)
0
(0 to 0)
28·9
(23·8 to 33·9)*
6·7
(3·1 to 10·5)*
4
(2 to 6)
5
(2 to 8)
25·3
(19·8 to 31·0)*
9·2
(4·9 to 13·7)*
Liver cancer due to 
alcohol use
0
(0 to 0)
0
(0 to 0)
30·5
(24·2 to 36·6)*
3·5
(–4·2 to 9·1)
5
(2 to 9)
7
(3 to 12)
28·1
(21·0 to 35·2)*
4·2
(–4·7 to 10·6)
Liver cancer due to other 
causes
0
(0 to 0)
0
(0 to 0)
26·6
(19·3 to 33·4)*
25·0
(16·3 to 33·2)*
3
(1 to 5)
3
(2 to 5)
21·3
(13·4 to 28·3)*
28·3
(18·4 to 37·2)*
Gallbladder and biliary 
tract cancer
0
(0 to 0)
0
(0 to 0)
8·2
(–0·3 to 14·6)
–3·4
(–7·5 to –0·3)*
4
(2 to 6)
4
(2 to 6)
4·9
(–2·7 to 11·0)
–1·5
(–6·1 to 2·0)
Pancreatic cancer 0
(0 to 0)
0
(0 to 0)
25·2
(22·0 to 28·8)*
–3·7
(–6·1 to –1·5)*
4
(2 to 8)
5
(2 to 10)
22·0
(18·7 to 25·9)*
–3·0
(–5·4 to –0·4)*
Breast cancer 0
(0 to 0)
0
(0 to 0)
25·6
(18·1 to 33·7)*
2·1
(–2·2 to 7·3)
8
(5 to 11)
10
(6 to 14)
26·6
(17·5 to 36·1)*
3·5
(–1·6 to 9·1)
Uterine cancer 0
(0 to 0)
0
(0 to 0)
18·5
(11·9 to 25·7)*
7·7
(3·6 to 11·9)*
6
(4 to 9)
8
(5 to 11)
19·1
(11·7 to 26·8)*
10·5
(5·7 to 15·3)*
Ovarian cancer 0
(0 to 0)
0
(0 to 0)
18·5
(0·0 to 22·9)*
–1·3
(–4·0 to 1·4)
1
(0 to 2)
1
(0 to 3)
17·9
(0·0 to 22·7)*
–0·4
(–3·4 to 2·5)
Kidney cancer 0
(0 to 0)
0
(0 to 0)
25·6
(21·4 to 29·9)*
–4·1
(–6·6 to –1·7)*
6
(4 to 9)
7
(5 to 11)
23·2
(18·9 to 27·5)*
–3·9
(–7·4 to –0·5)*
Thyroid cancer 0
(0 to 0)
0
(0 to 0)
25·9
(20·9 to 30·9)*
1·7
(–2·4 to 7·3)
1
(0 to 1)
1
(1 to 2)
46·0
(35·5 to 55·2)*
12·7
(5·5 to 20·1)*
Ischaemic heart disease 12
(8 to 17)
13
(9 to 18)
8·4
(5·6 to 11·0)*
–4·4
(–6·4 to –2·5)*
326
(224 to 462)
348
(236 to 494)
6·7
(3·8 to 9·3)*
–1·9
(–4·1 to 0·2)
Ischaemic stroke 2
(1 to 3)
2
(1 to 3)
2·7
(–1·5 to 6·7)
–1·1
(–4·0 to 1·9)
53
(37 to 75)
55
(39 to 78)
3·8
(0·3 to 7·2)*
3·5
(0·8 to 6·5)*
Haemorrhagic stroke 5
(4 to 8)
6
(4 to 8)
7·5
(3·2 to 11·7)*
9·0
(5·1 to 12·2)*
186
(130 to 263)
198
(137 to 280)
6·6
(2·3 to 10·8)*
10·9
(7·3 to 14·2)*
Hypertensive heart 
disease
2
(1 to 3)
3
(2 to 4)
20·9
(14·5 to 26·9)*
–2·4
(–6·8 to 3·2)
59
(39 to 86)
68
(45 to 100)
16·0
(10·8 to 21·0)*
0·2
(–3·6 to 4·5)
Cardiomyopathy and 
myocarditis
·· ·· ·· ·· ·· ·· ·· ··
Atrial ﬁ brillation and 
ﬂ utter
·· ·· ·· ·· ·· ·· ·· ··
Peripheral vascular 
disease
·· ·· ·· ·· ·· ·· ·· ··
Endocarditis ·· ·· ·· ·· ·· ·· ·· ··
Other cardiovascular and 
circulatory diseases
·· ·· ·· ·· ·· ·· ·· ··
Diabetes mellitus 6
(4 to 8)
7
(5 to 11)
23·2
(19·3 to 27·0)*
–5·1
(–7·7 to –2·3)*
378
(248 to 559)
488
(315 to 731)
28·9
(25·3 to 32·3)*
0·9
(–1·4 to 3·1)
Chronic kidney disease 
due to diabetes mellitus
1
(1 to 2)
2
(1 to 4)
51·5
(44·8 to 58·8)*
8·7
(5·0 to 12·2)*
43
(19 to 75)
62
(28 to 107)
43·8
(37·8 to 51·5)*
8·5
(5·3 to 11·7)*
Chronic kidney disease 
due to hypertension
1
(1 to 2)
2
(1 to 3)
28·4
(19·6 to 38·6)*
–4·5
(–8·4 to –0·5)*
33
(15 to 58)
42
(19 to 73)
24·7
(19·9 to 30·8)*
–1·4
(–4·9 to 1·8)
Chronic kidney disease 
due to 
glomerulonephritis
0
(0 to 0)
0
(0 to 1)
27·5
(18·3 to 38·1)*
7·3
(2·5 to 12·1)*
12
(4 to 24)
15
(5 to 29)
24·6
(19·7 to 33·5)*
12·8
(8·9 to 16·9)*
Chronic kidney disease 
due to other causes
0
(0 to 0)
0
(0 to 0)
36·1
(21·8 to 49·1)*
5·6
(–0·1 to 11·3)
8
(3 to 15)
10
(4 to 18)
28·3
(22·9 to 36·4)*
5·0
(2·0 to 8·0)*
Diet low in ﬁ bre: all causes 334
(158 to 578)
387
(183 to 670)
15·8
(12·4 to 19·6)*
4·3
(1·6 to 7·1)*
7666
(3534 to 13 299)
8393
(3908 to 14 657)
9·5
(5·6 to 13·8)*
3·6
(0·1 to 7·1)*
Colon and rectal cancer 38
(17 to 66)
47
(21 to 83)
24·4
(20·6 to 28·9)*
–0·5
(–2·8 to 2·1)
741
(327 to 1318)
870
(385 to 1545)
17·4
(13·5 to 21·5)*
–1·4
(–4·1 to 1·4)
Ischaemic heart disease 297
(136 to 531)
340
(156 to 610)
14·7
(11·5 to 18·5)*
–1·6
(–4·0 to 0·7)
6925
(3137 to 12 333)
7523
(3410 to 13 333)
8·6
(4·7 to 12·9)*
–0·5
(–3·3 to 2·2)
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2005–15 age-
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DALYs PAF 
(Continued from previous page)
Diet low in calcium: all 
causes
127
(74 to 185)
160
(95 to 232)
26·1
(23·3 to 29·7)*
14·9
(12·4 to 17·6)*
2721
(1608 to 3966)
3284
(1966 to 4755)
20·7
(17·6 to 24·3)*
13·0
(10·1 to 16·2)*
Colon and rectal cancer 127
(74 to 185)
160
(95 to 232)
26·1
(23·3 to 29·7)*
2·3
(1·3 to 3·9)*
2721
(1608 to 3966)
3284
(1966 to 4755)
20·7
(17·6 to 24·3)*
2·0
(1·0 to 3·5)*
Diet low in seafood 
omega-3 fatty acids: all 
causes
1279
(537 to 2079)
1472
(616 to 2378)
15·0
(12·5 to 17·5)*
5·3
(3·7 to 6·8)*
28 350
(11 995 to 45 414)
31 310
(13 272 to 49 823)
10·4
(7·2 to 13·3)*
4·1
(1·2 to 6·8)*
Ischaemic heart disease 1279
(537 to 2079)
1472
(616 to 2378)
15·0
(12·5 to 17·5)*
0·3
(–0·3 to 0·9)
28 350
(11 995 to 45 414)
31 310
(13 272 to 49 823)
10·4
(7·2 to 13·3)*
0·6
(–0·1 to 1·4)
Diet low in 
polyunsaturated fatty 
acids: all causes
348
(145 to 548)
388
(158 to 610)
11·5
(3·6 to 20·8)*
1·2
(–6·1 to 10·3)
7535
(3243 to 11 727)
8270
(3534 to 12 996)
9·7
(2·0 to 18·7)*
2·9
(–4·4 to 11·3)
Ischaemic heart disease 348
(145 to 548)
388
(158 to 610)
11·5
(3·6 to 20·8)*
–3·6
(–10·5 to 4·7)
7535
(3243 to 11 727)
8270
(3534 to 12 996)
9·7
(2·0 to 18·7)*
–0·6
(–7·3 to 6·7)
Diet high in trans fatty 
acids: all causes
384
(158 to 713)
448
(190 to 827)
16·7
(13·1 to 22·8)*
7·8
(4·8 to 13·4)*
10 121
(4348 to 18 081)
11 578
(5138 to 20 322)
14·4
(9·9 to 21·4)*
8·9
(4·6 to 15·6)*
Ischaemic heart disease 384
(158 to 713)
448
(190 to 827)
16·7
(13·1 to 22·8)*
2·7
(0·4 to 7·6)*
10 121
(4348 to 18 081)
11 578
(5138 to 20 322)
14·4
(9·9 to 21·4)*
5·2
(2·4 to 11·0)*
Diet high in sodium: all 
causes
3668
(2145 to 5680)
4130
(2446 to 6419)
12·6
(8·3 to 16·9)*
2·8
(–0·1 to 6·3)
77 456
(45 739 to 118 672)
83 008
(49 326 to 127 452)
7·2
(2·7 to 11·3)*
0·2
(–3·4 to 3·8)
Stomach cancer 413
(271 to 567)
397
(246 to 553)
–3·9
(–11·9 to 3·0)
–2·9
(–7·7 to 0·6)
9470
(6286 to 12 765)
8540
(5502 to 11 691)
–9·8
(–17·2 to –3·7)*
–3·4
(–7·8 to –0·4)*
Rheumatic heart disease 30
(14 to 53)
28
(13 to 51)
–7·6
(–15·4 to –1·3)*
–4·9
(–11·3 to –0·1)*
873
(420 to 1603)
772
(359 to 1428)
–11·6
(–19·0 to –6·1)*
–6·6
(–13·1 to –2·1)*
Ischaemic heart disease 1348
(682 to 2306)
1632
(852 to 2754)
21·1
(16·7 to 27·8)*
4·7
(2·0 to 9·7)*
26 945
(13 814 to 45 258)
31 088
(16 524 to 51 139)
15·4
(11·2 to 21·3)*
3·8
(1·6 to 8·1)*
Ischaemic stroke 513
(278 to 848)
562
(308 to 916)
9·5
(3·7 to 17·1)*
3·4
(0·1 to 9·1)*
9239
(5141 to 14731)
9756
(5537 to 15 527)
5·6
(0·6 to 11·8)*
3·6
(0·6 to 8·6)*
Haemorrhagic stroke 876
(516 to 1340)
875
(514 to 1347)
–0·0
(–6·1 to 6·0)
–2·7
(–7·0 to 1·4)
19 630
(11 721 to 29 698)
19 052
(11 138 to 28 916)
–2·9
(–9·2 to 2·6)
–3·1
(–7·5 to 0·8)
Hypertensive heart 
disease
246
(88 to 484)
325
(116 to 634)
32·2
(18·7 to 45·3)*
4·3
(–0·6 to 11·9)
4756
(2134 to 8876)
5810
(2603 to 10 709)
22·2
(13·2 to 30·9)*
2·8
(–0·5 to 8·4)
Cardiomyopathy and 
myocarditis
28
(12 to 51)
31
(14 to 57)
12·0
(5·8 to 20·4)*
3·5
(0·3 to 9·3)*
737
(312 to 1377)
764
(342 to 1396)
3·6
(–2·0 to 11·1)
4·3
(0·9 to 10·6)*
Atrial ﬁ brillation and 
ﬂ utter
14
(6 to 25)
19
(9 to 35)
39·1
(34·0 to 46·2)*
4·0
(1·6 to 9·2)*
449
(221 to 790)
592
(297 to 1033)
31·9
(28·8 to 37·4)*
4·8
(2·6 to 9·3)*
Aortic aneurysm 13
(6 to 24)
16
(8 to 30)
25·9
(19·0 to 32·8)*
2·5
(0·3 to 6·2)*
262
(124 to 460)
319
(153 to 559)
21·8
(14·4 to 28·2)*
2·5
(0·4 to 5·9)*
Peripheral vascular 
disease
2
(1 to 4)
3
(1 to 6)
38·4
(30·2 to 49·6)*
2·9
(–0·4 to 10·0)
70
(28 to 140)
97
(40 to 192)
37·7
(32·4 to 45·6)*
6·4
(3·3 to 12·7)*
Endocarditis 6
(2 to 10)
7
(3 to 13)
28·6
(22·6 to 35·9)*
3·4
(0·3 to 8·1)*
133
(59 to 248)
163
(73 to 299)
22·6
(15·9 to 29·9)*
3·2
(–0·8 to 7·7)
Other cardiovascular and 
circulatory diseases
50
(25 to 85)
59
(29 to 100)
18·1
(11·9 to 24·4)*
0·4
(–3·1 to 5·0)
1584
(804 to 2703)
1920
(993 to 3246)
21·3
(16·3 to 27·4)*
3·7
(1·0 to 8·2)*
Chronic kidney disease 
due to diabetes mellitus
41
(18 to 74)
57
(25 to 103)
39·3
(33·0 to 44·8)*
–0·6
(–3·6 to 2·0)
1048
(467 to 1909)
1391
(635 to 2500)
32·7
(27·2 to 37·9)*
0·2
(–2·6 to 3·1)
Chronic kidney disease 
due to hypertension
52
(22 to 99)
75
(32 to 139)
42·1
(36·0 to 49·9)*
4·4
(1·8 to 9·1)*
1107
(479 to 2079)
1467
(639 to 2717)
32·5
(27·3 to 38·8)*
4·1
(1·5 to 8·6)*
Chronic kidney 
disease due to 
glomerulonephritis
35
(18 to 57)
40
(21 to 67)
15·1
(6·5 to 22·8)*
–2·9
(–8·9 to 2·1)
918
(471 to 1516)
971
(496 to 1648)
5·8
(–2·3 to 13·0)
–4·6
(–11·2 to 0·3)
Chronic kidney disease 
due to other causes
2
(1 to 4)
3
(1 to 6)
43·8
(34·1 to 54·4)*
7·5
(3·0 to 12·7)*
236
(98 to 449)
306
(131 to 576)
29·9
(26·2 to 34·6)*
4·8
(2·6 to 8·4)*
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2005 deaths
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(in thousands)
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change of 
2005–15 deaths 
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2005–15 age-
standardised 
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2005 DALYs
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2015 DALYs
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Percentage 
change of 
2005–15 DALYs
Percentage 
change of 
2005–15 age-
standardised 
DALYs PAF 
(Continued from previous page)
Sexual abuse and 
violence: all causes
338
(244 to 444)
281
(199 to 378)
–16·9
(–23·6 to –9·4)*
–15·2
(–21·9 to –8·3)*
22 527
(17 002 to 28 715)
20 801
(15 633 to 26 810)
–7·7
(–14·0 to –1·5)*
–4·0
(–9·8 to 2·2)
Childhood sexual abuse: all 
causes
118
(34 to 229)
113
(31 to 221)
–4·9
(–11·8 to 1·1)
–3·1
(–10·2 to 2·6)
8200
(3468 to 14 180)
8107
(3472 to 14 062)
–1·1
(–8·5 to 5·8)
3·7
(–3·3 to 10·6)
Alcohol use disorders 7
(0 to 16)
6
(0 to 13)
–22·0
(–26·6 to 0·0)
–10·1
(–12·5 to 0·0)
568
(0 to 1299)
512
(0 to 1183)
–9·9
(–14·6 to 0·0)
–6·3
(–8·3 to 0·0)
Major depressive 
disorder
·· ·· ·· ·· 2062
(231 to 4518)
2321
(257 to 5097)
12·5
(10·7 to 14·0)*
–3·7
(–5·0 to –2·6)*
Dysthymia ·· ·· ·· ·· 426
(46 to 943)
484
(53 to 1074)
13·8
(11·3 to 15·9)*
–4·1
(–5·4 to –2·8)*
Self-harm 111
(27 to 222)
107
(27 to 213)
–3·8
(–10·5 to 2·1)
–2·5
(–4·5 to –0·7)*
5145
(1265 to 10 175)
4791
(1194 to 9542)
–6·9
(–13·6 to –0·9)*
–1·8
(–3·8 to 0·0)
Intimate partner violence: 
all causes
237
(180 to 293)
186
(148 to 224)
–21·8
(–28·1 to –12·9)*
–20·1
(–26·5 to –11·9)*
15 431
(12 234 to 19 068)
13 803
(11 078 to 16 954)
–10·5
(–17·8 to –2·8)*
–7·4
(–14·0 to 0·1)
HIV/AIDS—tuberculosis 20
(11 to 31)
10
(5 to 16)
–49·0
(–52·8 to –44·1)*
–18·0
(–23·3 to –13·0)*
937
(490 to 1432)
496
(251 to 775)
–47·1
(–50·6 to –42·5)*
–15·3
(–20·0 to 
–10·5)*
HIV/AIDS resulting in 
other diseases
86
(45 to 128)
49
(25 to 72)
–43·5
(–47·8 to –38·9)*
–18·7
(–23·9 to –13·3)*
4301
(2252 to 6424)
2520
(1287 to 3716)
–41·4
(–45·9 to 
–36·8)*
–17·4
(–22·4 to 
–12·0)*
Maternal abortion, 
miscarriage, and ectopic 
pregnancy
0
(0 to 0)
0
(0 to 0)
–22·8
(–36·5 to –5·4)*
0·2
(–11·4 to 12·9)
0
(0 to 0)
0
(0 to 0)
–23·2
(–36·6 to –6·0)*
0·1
(–10·5 to 13·3)
Major depressive 
disorder
·· ·· ·· ·· 3562
(2279 to 5110)
4405
(2825 to 6361)
23·7
(21·3 to 26·0)*
2·8
(1·1 to 4·6)*
Dysthymia ·· ·· ·· ·· 775
(496 to 1148)
980
(623 to 1438)
26·4
(23·3 to 29·8)*
4·0
(2·3 to 6·0)*
Self-harm 104
(72 to 126)
103
(74 to 126)
–1·1
(–11·1 to 13·2)
–2·2
(–9·6 to 6·6)
4367
(2950 to 5417)
4107
(2944 to 5117)
–5·9
(–16·3 to 9·1)
–3·1
(–10·7 to 6·9)
Assault by ﬁ rearm 6
(5 to 7)
6
(5 to 7)
2·2
(–5·9 to 13·8)
–4·8
(–12·2 to 4·9)
315
(252 to 356)
312
(256 to 366)
–1·0
(–9·4 to 11·1)
–4·7
(–12·7 to 5·8)
Assault by sharp object 7
(6 to 7)
5
(5 to 6)
–18·4
(–25·1 to –10·6)*
–4·8
(–12·0 to 2·4)
340
(305 to 379)
269
(238 to 302)
–21·0
(–28·1 to –12·6)*
–5·5
(–13·2 to 2·3)
Assault by other means 14
(13 to 15)
12
(11 to 14)
–12·3
(–19·6 to –4·2)*
–3·8
(–10·7 to 3·3)
835
(760 to 913)
715
(624 to 805)
–14·3
(–21·5 to –6·0)*
–4·6
(–11·4 to 2·7)
Unsafe sex: all causes 2051
(1957 to 2156)
1452
(1381 to 1541)
–29·2
(–31·6 to –26·1)*
–26·2
(–28·9 to –23·1)*
112 703
(106 333 to 120 086)
79 451
(74 248 to 85 532)
–29·5
(–32·0 to –26·8)*
–24·7
(–27·4 to –21·8)*
HIV/AIDS—tuberculosis 334
(267 to 379)
199
(152 to 231)
–40·3
(–44·9 to –34·8)*
–0·8
(–1·4 to –0·4)*
18 403
(14 762 to 20 870)
10 990
(8439 to 12 703)
–40·3
(–44·7 to –34·7)*
–0·7
(–1·1 to –0·3)*
HIV/AIDS resulting in 
other diseases
1356
(1271 to 1455)
906
(844 to 981)
–33·2
(–36·6 to –29·1)*
–1·8
(–2·5 to –1·4)*
75 102
(70 586 to 80 394)
51 167
(47 789 to 55 057)
–31·9
(–35·1 to –28·3)*
–1·5
(–2·1 to –1·1)*
Syphilis 134
(80 to 206)
107
(63 to 165)
–20·3
(–28·5 to –12·4)*
·· 11 190
(6607 to 17 281)
8957
(5273 to 13 970)
–20·0
(–28·4 to –11·8)*
··
Chlamydial infection 0
(0 to 0)
0
(0 to 0)
–5·3
(–17·0 to 10·6)
·· 337
(194 to 538)
370
(214 to 595)
9·7
(6·5 to 13·0)*
··
Gonococcal infection 1
(1 to 1)
1
(1 to 1)
–15·7
(–26·7 to –4·7)*
·· 383
(239 to 573)
470
(283 to 717)
22·7
(15·9 to 28·1)*
··
Trichomoniasis ·· ·· ·· ·· 167
(67 to 355)
194
(78 to 412)
16·1
(15·0 to 17·2)*
··
Genital herpes ·· ·· ·· ·· 198
(61 to 468)
236
(74 to 556)
19·5
(17·4 to 23·0)*
··
Other sexually 
transmitted diseases
0
(0 to 0)
0
(0 to 0)
–16·8
(–27·6 to –6·1)*
·· 103
(75 to 139)
104
(74 to 141)
0·3
(–3·1 to 3·2)
··
Cervical cancer 225
(214 to 238)
239
(225 to 252)
5·8
(–0·5 to 13·8)
·· 6819
(6393 to 7236)
6963
(6526 to 7408)
2·1
(–4·5 to 10·5)
··
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Low physical activity: 
all causes
1351
(1047 to 1661)
1605
(1265 to 1956)
18·9
(16·5 to 21·6)*
7·0
(5·3 to 9·1)*
29 467
(22 694 to 36 268)
34 603
(26 905 to 42 282)
17·4
(14·4 to 20·5)*
9·1
(6·8 to 11·8)*
Colon and rectal cancer 95
(66 to 124)
119
(84 to 156)
25·2
(22·5 to 28·1)*
0·8
(0·2 to 1·6)*
1838
(1263 to 2441)
2209
(1529 to 2916)
20·2
(17·7 to 22·9)*
0·8
(0·1 to 1·8)*
Breast cancer 39
(28 to 50)
48
(35 to 61)
22·1
(16·9 to 27·0)*
–0·3
(–1·5 to 1·3)
1064
(765 to 1369)
1276
(926 to 1644)
20·0
(14·2 to 25·5)*
–0·1
(–1·6 to 1·7)
Ischaemic heart disease 727
(476 to 992)
859
(572 to 1161)
18·1
(15·8 to 20·8)*
1·3
(0·5 to 2·5)*
14 621
(9264 to 20 247)
16 673
(10 684 to 22 821)
14·0
(11·2 to 17·2)*
2·5
(1·6 to 4·1)*
Ischaemic stroke 305
(169 to 449)
333
(188 to 485)
9·2
(6·1 to 12·8)*
1·3
(0·4 to 3·0)*
5049
(2688 to 7537)
5291
(2875 to 7911)
4·8
(1·4 to 8·4)*
2·1
(1·1 to 3·8)*
Diabetes mellitus 184
(142 to 229)
247
(192 to 306)
34·2
(30·1 to 38·2)*
0·6
(–0·3 to 1·5)
6896
(4991 to 9242)
9154
(6647 to 12 251)
32·7
(29·8 to 35·5)*
1·4
(0·8 to 2·1)*
Metabolic risks: all causes 14 403
(13 691 to 
15 063)
16 860
(16 021 to 
17 697)
17·1
(15·1 to 19·2)*
6·0
(5·1 to 7·0)*
335 227
(315 739 to 357 389)
381 845
(357 846 to 
409 436)
13·9
(11·5 to 16·0)*
6·9
(5·2 to 8·4)*
High fasting plasma 
glucose: all causes
4212
(3647 to 5047)
5240
(4547 to 6217)
24·4
(21·5 to 27·4)*
13·3
(11·5 to 15·3)*
117 101
(102 561 to 133 960)
143 076
(125 125 to 163 477)
22·2
(19·5 to 24·8)*
15·3
(13·1 to 17·5)*
Tuberculosis 133
(83 to 189)
118
(73 to 169)
–11·1
(–19·7 to –3·5)*
5·4
(2·1 to 8·3)*
4313
(2737 to 5960)
3802
(2430 to 5304)
–11·9
(–19·5 to –5·2)*
4·2
(–0·6 to 8·1)
Ischaemic heart disease 1415
(946 to 2016)
1761
(1175 to 2528)
24·4
(19·9 to 29·1)*
6·8
(5·3 to 8·4)*
27 891
(19 565 to 37 687)
33 535
(23 674 to 45 228)
20·2
(17·1 to 23·4)*
8·1
(6·9 to 9·5)*
Ischaemic stroke 454
(257 to 803)
514
(291 to 913)
13·2
(7·9 to 20·3)*
6·0
(4·0 to 8·6)*
7750
(4771 to 12 343)
8524
(5350 to 13 291)
10·0
(6·0 to 14·3)*
7·6
(6·1 to 9·6)*
Haemorrhagic stroke 529
(366 to 728)
585
(408 to 802)
10·5
(6·4 to 15·6)*
8·3
(6·8 to 10·2)*
12 434
(8510 to 17 327)
13 556
(9361 to 18 929)
9·0
(5·3 to 13·1)*
9·7
(8·3 to 11·5)*
Diabetes mellitus 1150
(1121 to 1177)
1519
(1470 to 1576)
32·1
(27·7 to 36·3)*
·· 49 725
(41 868 to 58 982)
64 135
(53 490 to 76 113)
29·0
(26·2 to 31·7)*
··
Chronic kidney disease 
due to diabetes mellitus
299
(279 to 314)
418
(389 to 441)
39·5
(35·4 to 43·5)*
·· 8713
(7991 to 9466)
11 258
(10 303 to 12 225)
29·2
(25·9 to 32·5)*
··
Chronic kidney disease 
due to hypertension
149
(105 to 192)
216
(153 to 278)
44·9
(39·7 to 50·1)*
6·2
(5·1 to 7·4)*
3260
(2284 to 4222)
4467
(3172 to 5743)
37·0
(32·0 to 42·4)*
8·0
(6·6 to 9·4)*
Chronic kidney 
disease due to 
glomerulonephritis
68
(48 to 89)
89
(63 to 114)
30·0
(24·2 to 36·0)*
9·2
(7·6 to 11·0)*
2106
(1466 to 2770)
2570
(1805 to 3358)
22·1
(17·1 to 27·1)*
10·5
(8·5 to 12·6)*
Chronic kidney disease 
due to other causes
6
(4 to 8)
9
(6 to 12)
47·2
(39·6 to 55·6)*
10·3
(7·8 to 13·1)*
695
(453 to 983)
936
(615 to 1313)
34·6
(31·8 to 37·5)*
9·3
(7·6 to 11·2)*
High total cholesterol: 
all causes
3816
(2973 to 4849)
4313
(3324 to 5512)
13·0
(9·5 to 16·2)*
1·4
(–0·6 to 3·2)
81 691
(68 219 to 96 877)
88 687
(74 558 to 105 681)
8·6
(5·8 to 11·0)*
0·9
(–1·5 to 3·1)
Ischaemic heart disease 3279
(2594 to 4016)
3743
(2906 to 4650)
14·1
(10·2 to 17·7)*
–2·2
(–3·5 to –1·0)*
71 723
(60 172 to 84 381)
78 590
(65 999 to 92 772)
9·6
(6·6 to 12·1)*
–1·3
(–2·0 to –0·6)*
Ischaemic stroke 537
(220 to 1058)
569
(221 to 1127)
6·0
(–1·8 to 11·5)
–2·7
(–6·2 to –0·5)*
9968
(5939 to 16 618)
10 098
(5961 to 16 912)
1·3
(–2·7 to 4·9)
–2·0
(–3·5 to –0·5)*
High systolic blood 
pressure: all causes
9212
(8326 to 10 101)
10 704
(9601 to 11 787)
16·2
(13·9 to 18·6)*
5·2
(4·0 to 6·4)*
18 9579
(172 703 to 206 696)
211 816
(192 712 to 231 114)
11·7
(9·2 to 14·1)*
4·4
(2·2 to 6·4)*
Rheumatic heart disease 79
(54 to 117)
80
(56 to 121)
1·7
(–3·2 to 7·0)
4·4
(2·9 to 6·3)*
2377
(1588 to 3481)
2363
(1615 to 3402)
–0·6
(–4·9 to 3·9)
5·4
(3·6 to 7·3)*
Ischaemic heart disease 4135
(3408 to 4840)
4862
(3955 to 5740)
17·6
(14·7 to 20·2)*
0·9
(–0·0 to 1·7)
79 828
(68 710 to 90 328)
90 298
(77 837 to 102 138)
13·1
(10·4 to 15·6)*
1·4
(0·8 to 2·0)*
Ischaemic stroke 1367
(1083 to 1656)
1489
(1167 to 1821)
8·9
(4·7 to 13·5)*
1·8
(0·4 to 3·4)*
22 995
(18 429 to 26 872)
24 198
(19 500 to 28 264)
5·2
(1·8 to 8·7)*
2·6
(1·8 to 3·7)*
Haemorrhagic stroke 1819
(1486 to 2144)
1953
(1588 to 2313)
7·4
(3·6 to 12·1)*
4·4
(3·2 to 5·8)*
41 530
(34 162 to 47 708)
43 412
(36 092 to 49 999)
4·5
(1·0 to 8·7)*
4·7
(3·7 to 6·0)*
Hypertensive heart 
disease
761
(712 to 824)
962
(874 to 1025)
26·5
(17·5 to 32·3)*
·· 14 852
(13 919 to 16 053)
17 485
(16 287 to 18 594)
17·7
(11·6 to 22·9)*
··
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Cardiomyopathy and 
myocarditis
121
(98 to 145)
129
(104 to 157)
7·3
(1·6 to 13·0)*
–1·1
(–3·3 to 1·2)
3233
(2594 to 3859)
3188
(2570 to 3795)
–1·4
(–6·3 to 4·0)
–0·4
(–2·9 to 2·3)
Atrial ﬁ brillation and 
ﬂ utter
50
(38 to 65)
68
(50 to 90)
35·2
(31·4 to 39·1)*
0·0
(–1·2 to 1·3)
1409
(1087 to 1820)
1810
(1398 to 2347)
28·5
(26·8 to 30·2)*
1·2
(0·6 to 1·9)*
Aortic aneurysm 49
(39 to 58)
60
(47 to 71)
22·7
(17·3 to 27·2)*
–1·1
(–2·0 to –0·2)*
928
(771 to 1080)
1110
(925 to 1291)
19·7
(13·6 to 23·7)*
0·3
(–0·4 to 1·1)
Peripheral vascular 
disease
11
(8 to 14)
14
(10 to 19)
33·0
(25·1 to 42·0)*
–2·4
(–4·3 to –0·5)*
265
(184 to 386)
346
(235 to 505)
30·4
(26·2 to 34·9)*
0·0
(–1·2 to 1·1)
Endocarditis 22
(17 to 28)
28
(22 to 36)
26·7
(21·8 to 31·6)*
0·8
(–0·5 to 2·0)
518
(403 to 644)
640
(496 to 792)
23·5
(18·0 to 29·1)*
3·7
(1·0 to 6·3)*
Other cardiovascular and 
circulatory diseases
176
(154 to 199)
211
(182 to 240)
19·8
(15·0 to 24·4)*
0·8
(–0·2 to 1·7)
5165
(4411 to 6058)
6267
(5304 to 7424)
21·3
(17·6 to 25·1)*
3·5
(2·4 to 4·7)*
Chronic kidney disease 
due to diabetes mellitus
132
(95 to 167)
190
(135 to 240)
43·5
(39·5 to 47·5)*
1·6
(0·9 to 2·4)*
3186
(2231 to 4120)
4365
(3085 to 5671)
37·0
(33·5 to 40·5)*
3·0
(2·3 to 3·8)*
Chronic kidney disease 
due to hypertension
409
(377 to 428)
550
(502 to 576)
34·5
(30·0 to 38·7)*
·· 10 366
(9401 to 10 985)
12 737
(11 489 to 13 554)
22·9
(18·6 to 27·4)*
··
Chronic kidney 
disease due to 
glomerulonephritis
76
(54 to 97)
98
(71 to 125)
28·8
(23·9 to 34·0)*
7·1
(5·5 to 8·8)*
2151
(1481 to 2852)
2584
(1808 to 3384)
20·1
(15·9 to 24·5)*
7·5
(5·5 to 9·6)*
Chronic kidney disease 
due to other causes
8
(6 to 11)
12
(8 to 15)
42·2
(34·0 to 50·6)*
5·3
(2·7 to 8·1)*
777
(513 to 1063)
1013
(668 to 1386)
30·4
(28·1 to 33·1)*
4·6
(3·2 to 6·2)*
High body-mass index: all 
causes
3314
(2241 to 4504)
3960
(2728 to 5332)
19·5
(15·8 to 23·6)*
10·0
(7·2 to 13·5)*
98 478
(67 219 to 131 972)
120 132
(83 829 to 158 409)
22·0
(18·1 to 26·8)*
14·8
(11·7 to 19·0)*
Oesophageal cancer 67
(20 to 123)
71
(22 to 130)
6·2
(–3·4 to 16·8)
10·7
(1·3 to 20·5)*
1573
(459 to 2901)
1644
(516 to 3015)
4·5
(–5·3 to 15·8)
12·3
(2·8 to 22·9)*
Colon and rectal cancer 48
(29 to 70)
62
(38 to 91)
28·9
(25·5 to 32·9)*
4·7
(2·5 to 7·3)*
1050
(632 to 1527)
1329
(809 to 1924)
26·6
(23·3 to 30·6)*
6·2
(4·0 to 8·8)*
Liver cancer due to 
hepatitis B
24
(9 to 48)
28
(11 to 54)
17·9
(8·3 to 35·0)*
16·0
(9·9 to 25·7)*
762
(268 to 1511)
870
(326 to 1678)
14·2
(3·9 to 33·3)*
18·5
(11·5 to 29·7)*
Liver cancer due to 
hepatitis C
15
(6 to 26)
20
(9 to 35)
32·8
(25·8 to 40·8)*
9·2
(4·0 to 14·4)*
325
(141 to 574)
421
(186 to 733)
29·5
(21·7 to 38·8)*
12·0
(6·2 to 18·4)*
Liver cancer due to 
alcohol use
21
(8 to 41)
30
(11 to 56)
38·0
(28·8 to 50·1)*
8·9
(3·6 to 13·9)*
529
(202 to 1034)
729
(282 to 1393)
37·7
(27·3 to 52·3)*
11·2
(5·8 to 17·3)*
Liver cancer due to other 
causes
12
(5 to 22)
14
(6 to 25)
18·4
(9·2 to 31·4)*
16·3
(8·8 to 26·6)*
317
(127 to 583)
360
(150 to 646)
13·3
(3·6 to 28·1)*
18·7
(10·2 to 30·1)*
Gallbladder and biliary 
tract cancer
18
(10 to 27)
21
(12 to 31)
14·5
(6·3 to 22·5)*
1·2
(–3·1 to 5·2)
362
(209 to 547)
402
(233 to 596)
11·0
(3·6 to 18·6)*
3·1
(–1·0 to 7·3)
Pancreatic cancer 17
(6 to 29)
23
(8 to 40)
35·4
(31·6 to 39·5)*
3·3
(0·6 to 5·7)*
350
(122 to 614)
463
(163 to 812)
32·5
(28·8 to 36·7)*
4·4
(2·0 to 6·8)*
Breast cancer 25
(14 to 39)
34
(20 to 52)
36·5
(25·1 to 48·0)*
7·9
(3·1 to 13·9)*
551
(299 to 887)
774
(439 to 1214)
40·4
(24·5 to 57·5)*
8·9
(1·7 to 17·3)*
Uterine cancer 26
(17 to 35)
31
(21 to 41)
19·6
(11·4 to 28·9)*
8·3
(5·1 to 13·1)*
654
(441 to 891)
780
(538 to 1041)
19·2
(10·1 to 29·8)*
10·0
(6·2 to 15·5)*
Ovarian cancer 4
(0 to 9)
5
(0 to 11)
26·3
(22·1 to 31·7)*
4·3
(2·3 to 7·5)*
98
(–3 to 221)
124
(–4 to 275)
26·0
(21·5 to 31·7)*
5·0
(2·8 to 8·6)*
Kidney cancer 18
(12 to 24)
24
(16 to 33)
34·2
(29·8 to 38·8)*
1·5
(–0·6 to 3·7)
410
(272 to 565)
541
(364 to 741)
31·9
(27·7 to 36·3)*
1·8
(–0·8 to 4·9)
Thyroid cancer 2
(1 to 4)
3
(2 to 5)
32·5
(22·6 to 41·1)*
5·9
(0·4 to 11·3)*
62
(35 to 96)
90
(50 to 141)
45·6
(32·8 to 57·8)*
10·6
(3·8 to 16·8)*
Ischaemic heart disease 1228
(824 to 1687)
1436
(960 to 1965)
16·9
(13·2 to 20·9)*
1·9
(–0·5 to 4·5)
28 614
(19 490 to 38 838)
33 038
(22 659 to 44 539)
15·5
(12·1 to 19·1)*
4·4
(2·3 to 6·9)*
Ischaemic stroke 313
(203 to 449)
320
(204 to 470)
2·3
(–4·1 to 8·1)
–1·9
(–6·4 to 2·5)
7020
(4693 to 9683)
7318
(4859 to 10 062)
4·2
(–0·1 to 8·9)
2·7
(–0·6 to 6·4)
(Table 4 continues on next page)
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2005 deaths
(in thousands)
2015 deaths
(in thousands)
Percentage 
change of 
2005–15 deaths 
Percentage 
change of 
2005–15 age-
standardised 
PAF
2005 DALYs
(in thousands)
2015 DALYs
(in thousands)
Percentage 
change of 
2005–15 DALYs
Percentage 
change of 
2005–15 age-
standardised 
DALYs PAF 
(Continued from previous page)
Haemorrhagic stroke 606
(390 to 850)
651
(431 to 894)
7·3
(1·9 to 13·9)*
6·9
(2·9 to 11·7)*
18 122
(11 921 to 24 775)
19 636
(13 414 to 26 434)
8·4
(3·3 to 15·0)*
10·3
(6·6 to 15·6)*
Hypertensive heart 
disease
234
(144 to 341)
308
(182 to 455)
32·0
(20·8 to 42·0)*
4·9
(–0·5 to 10·3)
5010
(3364 to 6854)
6313
(4255 to 8539)
26·0
(19·4 to 33·6)*
6·8
(3·3 to 11·2)*
Diabetes mellitus 408
(293 to 532)
555
(404 to 718)
36·0
(30·5 to 42·2)*
3·6
(0·9 to 6·8)*
21 809
(15 245 to 29 011)
30 396
(21 544 to 39 884)
39·4
(34·7 to 44·8)*
7·7
(5·3 to 11·4)*
Chronic kidney disease 
due to diabetes mellitus
78
(40 to 124)
119
(62 to 187)
51·5
(41·5 to 62·0)*
8·0
(4·0 to 12·4)*
2205
(1075 to 3430)
3231
(1645 to 4932)
46·5
(40·2 to 55·0)*
10·0
(7·0 to 14·1)*
Chronic kidney disease 
due to hypertension
94
(45 to 151)
134
(61 to 217)
42·5
(25·6 to 53·4)*
5·3
(–1·1 to 9·3)
2315
(1159 to 3656)
3193
(1634 to 4945)
37·9
(31·6 to 45·0)*
8·1
(5·1 to 11·7)*
Chronic kidney 
disease due to 
glomerulonephritis
36
(15 to 61)
46
(19 to 78)
27·4
(11·2 to 42·7)*
7·0
(–2·9 to 14·7)
1275
(473 to 2206)
1583
(612 to 2662)
24·1
(16·8 to 35·7)*
10·9
(6·6 to 17·1)*
Chronic kidney disease 
due to other causes
3
(1 to 6)
5
(1 to 9)
53·8
(10·0 to 69·1)*
16·2
(4·2 to 24·5)*
510
(223 to 850)
696
(308 to 1140)
36·3
(31·0 to 43·2)*
9·7
(6·8 to 13·5)*
Osteoarthritis ·· ·· ·· ·· 1648
(949 to 2565)
2393
(1391 to 3716)
45·2
(42·1 to 49·6)*
7·4
(5·4 to 10·4)*
Low back pain ·· ·· ·· ·· 2501
(1415 to 4001)
3299
(1896 to 5222)
31·9
(29·4 to 35·6)*
8·6
(6·8 to 11·4)*
Low bone mineral density: 
all causes
283
(261 to 295)
361
(325 to 381)
27·7
(22·8 to 32·9)*
12·6
(8·4 to 17·2)*
7499
(6494 to 8674)
8810
(7565 to 10 270)
17·5
(13·9 to 21·1)*
7·8
(4·6 to 11·0)*
Pedestrian road injuries 44
(41 to 48)
50
(46 to 56)
14·4
(6·5 to 21·6)*
5·5
(2·7 to 8·4)*
974
(882 to 1071)
1072
(948 to 1199)
10·0
(2·2 to 17·2)*
7·0
(3·7 to 10·7)*
Cyclist road injuries 4
(4 to 5)
5
(4 to 5)
10·5
(1·0 to 20·0)*
8·0
(3·9 to 12·4)*
240
(193 to 298)
273
(215 to 343)
13·5
(7·3 to 19·1)*
10·9
(6·1 to 15·4)*
Motorcyclist road 
injuries
11
(9 to 12)
14
(12 to 16)
31·4
(16·4 to 48·5)*
10·9
(4·3 to 17·5)*
439
(366 to 517)
559
(461 to 655)
27·2
(18·2 to 37·3)*
11·4
(5·2 to 16·5)*
Motor vehicle road 
injuries
29
(26 to 32)
33
(29 to 37)
13·6
(6·1 to 21·7)*
4·8
(1·5 to 7·5)*
1029
(882 to 1196)
1163
(982 to 1357)
13·0
(7·1 to 18·6)*
6·4
(3·2 to 9·3)*
Other road injuries 1
(1 to 2)
2
(1 to 2)
28·3
(12·6 to 47·9)*
0·6
(–10·6 to 11·8)
51
(40 to 64)
70
(54 to 88)
35·6
(26·3 to 45·0)*
7·2
(–5·5 to 19·7)
Other transport injuries 8
(7 to 10)
10
(8 to 12)
19·6
(8·1 to 32·9)*
4·1
(0·4 to 7·4)*
219
(192 to 252)
247
(208 to 306)
13·0
(2·9 to 25·1)*
2·4
(–1·6 to 5·9)
Falls 170
(151 to 179)
230
(199 to 245)
35·3
(29·0 to 42·3)*
2·3
(–1·2 to 6·1)
3987
(3362 to 4758)
4816
(4020 to 5788)
20·8
(17·2 to 24·7)*
–0·9
(–4·3 to 3·1)
Other exposure to 
mechanical forces
8
(7 to 9)
10
(7 to 11)
21·1
(5·5 to 29·8)*
7·7
(0·0 to 13·4)*
316
(255 to 390)
361
(280 to 454)
14·2
(5·7 to 19·1)*
4·4
(–0·5 to 8·2)
Non-venomous animal 
contact
1
(1 to 1)
1
(1 to 1)
6·4
(–2·5 to 24·9)
3·7
(–4·8 to 10·7)
20
(17 to 24)
20
(17 to 25)
1·1
(–5·9 to 15·2)
–1·1
(–9·2 to 5·5)
Assault by other means 5
(5 to 6)
6
(5 to 6)
7·5
(1·4 to 14·1)*
2·4
(–2·8 to 7·3)
183
(154 to 215)
187
(156 to 222)
2·1
(–2·8 to 7·7)
–1·2
(–6·2 to 3·8)
Exposure to forces of 
nature
·· ·· ·· ·· 40
(24 to 58)
42
(26 to 62)
6·3
(–21·5 to 40·4)
274·6
(178·4 to 
423·0)*
Low glomerular ﬁ ltration 
rate: all causes
1991
(1881 to 2107)
2426
(2290 to 2559)
21·9
(19·2 to 24·5)*
10·7
(8·7 to 12·6)*
47 131
(44 090 to 50 123)
54 433
(50 890 to 57 912)
15·5
(12·7 to 18·2)*
10·4
(8·0 to 12·9)*
Ischaemic heart disease 589
(526 to 656)
691
(618 to 770)
17·3
(14·7 to 20·1)*
0·0
(–1·8 to 2·0)
9659
(8602 to 10 739)
10 901
(9711 to 12 188)
12·9
(10·0 to 15·8)*
0·7
(–1·1 to 2·7)
Ischaemic stroke 230
(197 to 267)
250
(215 to 288)
8·6
(5·0 to 12·6)*
0·4
(–1·9 to 3·0)
3323
(2845 to 3822)
3427
(2934 to 3932)
3·1
(–0·5 to 6·9)
0·2
(–2·3 to 3·0)
Haemorrhagic stroke 228
(192 to 271)
242
(206 to 282)
6·1
(1·8 to 11·0)*
2·5
(–0·3 to 5·8)
4391
(3699 to 5126)
4492
(3791 to 5191)
2·3
(–2·0 to 7·1)
1·9
(–1·1 to 5·3)
Peripheral vascular 
disease
6
(5 to 7)
8
(6 to 9)
36·1
(27·3 to 46·4)*
–0·4
(–3·8 to 3·2)
131
(96 to 187)
172
(125 to 244)
30·6
(26·4 to 35·7)*
0·2
(–1·7 to 2·4)
(Table 4 continues on next page)
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disease burden than did environmental risk factors; 
nonetheless, attributable mortality and DALYS due to 
various occupational risk factors substantially increased 
from 2005 to 2015.
Behavioural risks can be grouped into four main 
categories: generally large reductions for risk-attributable 
mortality and disease burden for risk factors associated 
with child and maternal malnutrition, mixed results for 
risk factors pertaining to alcohol and drug use, rising 
attributable deaths and DALYs due to dietary risk factors, 
and considerably varied trends for other behavioural risks, 
which span from sexual abuse and intimate partner 
violence to low physical activity. Attributable deaths and 
disease burden due to metabolic risks have increased since 
2005, particularly for high fasting plasma glucose, for 
which all measures of attributable mortality and DALYs 
increased by more than 15% from 2005 to 2015. These 
increases in attributable burden from high fasting plasma 
glucose were led by increased deaths and DALYs from 
ischaemic heart disease, haemorrhagic stroke, chronic 
kidney disease, and diabetes. Attributable deaths and 
DALYs for high BMI also increased substantially, with 
645 244 (95% UI 457 647–862 412) more attributable deaths 
in 2015 than in 2005. Attributable mortality and DALYs due 
to low glomerular ﬁ ltration rates also signiﬁ cantly 
increased from 2005 to 2015, with these increases primarily 
associated with rises in attributable deaths and burden due 
to cardiovascular and circulatory diseases and chronic 
kidney disease.
Global risk patterns by sex
In 2015, the relative ranks and attributable burden due to 
Level 2 risk factors varied between men and women 
(ﬁ gure 2). As the leading risk factor for both sexes, dietary 
risks accounted for 12·2% (95% UI 10·8–13·6) of total 
DALYs for men and 9·0% (7·8–10·3%) of total DALYs for 
women. These risks, which include diet high in sodium 
and diet low in fruit, contributed most to DALYs associated 
with three cause groups: cardiovascular and circulatory 
diseases, cancers, and diabetes and urogenital, blood, and 
endocrine diseases. In 2015, high systolic blood pressure 
also ranked among the leading risks for both sexes, 
contributing to 9·2% (8·3–10·2) of DALYs for men and 
7·8% (6·9–8·7) of DALYs for women. Air pollution was 
the ﬁ fth-leading risk for both sexes, largely contributing 
to DALYs associated with cardiovascular and circulatory 
diseases, as well as lower respiratory infections, diarrhoeal 
diseases, and other common infectious diseases. Child 
and maternal malnutrition, the leading global risk factor 
in 1990, was the second-leading risk for women and the 
sixth-leading risk for men in 2015.
Smoking was the second-leading risk factor for men 
in 2015, contributing to 9·6% (95% UI 8·5–10·7) of 
DALYs and a large proportion of male disease burden 
from cardiovascular and circulatory diseases, cancers, 
and chronic respiratory conditions. As the ﬁ fth-leading 
risk for men, alcohol and drug use was associated with 
6·6% (6·1–7·1) of disease burden in 2015, primarily due 
to mental and substance use disorders, as well as 
cirrhosis and other chronic liver diseases; the burden 
attributable to these risk factors was far less for women 
(2·0% [1·8–2·2]) than for men. In 2015, high fasting 
plasma glucose was associated with 6·0% (5·4–6·6) of 
DALYs for men and 5·6% (5·1–6·2) for women. For 
women, 3·8% (3·4–4·3) of burden was attributable to 
unsafe sex, largely from HIV/AIDS and cervical cancer, 
whereas for men, 2·8% (2·5–3·0) was attributable to 
unsafe sex.
Changes in leading risk factors in 1990, 2005, and 2015
Rising total attributable DALYs amid declines from 1990 
to 2015 for age-standardised DALY rates were evident for 
various metabolic and behavioural risks, emphasising 
the need to parse out the eﬀ ects of demographic and 
2005 deaths
(in thousands)
2015 deaths
(in thousands)
Percentage 
change of 
2005–15 deaths 
Percentage 
change of 
2005–15 age-
standardised 
PAF
2005 DALYs
(in thousands)
2015 DALYs
(in thousands)
Percentage 
change of 
2005–15 DALYs
Percentage 
change of 
2005–15 age-
standardised 
DALYs PAF 
(Continued from previous page)
Chronic kidney disease 
due to diabetes mellitus
299
(279 to 314)
418
(389 to 441)
39·5
(35·4 to 43·5)*
·· 8713
(7991 to 9466)
11 258
(10 303 to 12 225)
29·2
(25·9 to 32·5)*
··
Chronic kidney disease 
due to hypertension
409
(377 to 428)
550
(502 to 576)
34·5
(30·0 to 38·7)*
·· 10 366
(9401 to 10 985)
12 737
(11 489 to 13 554)
22·9
(18·6 to 27·4)*
··
Chronic kidney 
disease due to 
glomerulonephritis
206
(185 to 218)
238
(213 to 256)
15·6
(10·9 to 20·2)*
·· 7720
(6930 to 8332)
8136
(7294 to 8861)
5·4
(1·3 to 9·3)*
··
Chronic kidney disease 
due to other causes
24
(20 to 29)
30
(25 to 35)
23·9
(17·8 to 30·2)*
·· 2689
(2209 to 3238)
3128
(2518 to 3803)
16·3
(13·1 to 19·2)*
··
Gout ·· ·· ·· ·· 138
(91 to 191)
181
(120 to 250)
31·2
(29·3 to 33·1)*
0·9
(–0·0 to 1·8)
Data in parentheses are 95% uncertainty intervals. DALYs=disability-adjusted life-years. PAF=population attributable fraction. *Statistically signiﬁ cant increase or decrease. 
Table 4: Global all-age deaths and DALYs attributable to each risk factor at each level of the risk factor hierarchy and outcome for both sexes combined in 2005 and 2015  
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epidemiological factors on global risk proﬁ les (ﬁ gure 3). 
In 1990, childhood undernutrition, unsafe water, and 
high systolic blood pressure were the leading three risk 
factors for attributable DALYs. Of these risks, only high 
systolic blood pressure ranked among the leading three 
risks in 2015. Large reductions in both total attributable 
DALYs and age-standardised DALY rates from 1990 
resulted in childhood undernutrition being ranked as the 
ﬁ fth-leading risk factor in 2015 and unsafe water being 
ranked as the 14th-leading risk factor.
Environmental risk factors, including household air 
pollution and unsafe sanitation, decreased in terms of 
total attributable DALYs, age-standardised DALY rates, 
and relative ranks from 1990 to 2015. Over the period 
1990–2005, attributable total DALYs for occupational risk 
factors, such as ergonomic factors, rose by more than 20% 
from 1990 to 2005, although age-standardised rates 
decreased by 9·5% (95% UI 7·3–11·7) over the same time 
period. Similar patterns occurred for most behavioural 
risk factors from 1990 to 2005, with signiﬁ cant increases 
in total attributable DALYs occurring for many of these 
risks; at the same time, age-standardised DALY rates 
signiﬁ cantly fell (eg, smoking, low physical activity, and 
most dietary risks, including diet high in sodium). Unsafe 
sex and drug use were exceptions, with each measure of 
attributable burden signiﬁ cantly increasing since from 
1990 to 2005. For unsafe sex and drug use in particular, 
this rapid rise corresponded with the global HIV/AIDS 
epidemic. For most risk factors, the time period of 2005–15 
resulted in an extension of earlier trends, with continued 
gains in reductions of attributable DALYs due to various 
environmental risk factors and more varied patterns 
for many metabolic and behavioural risks than for 
environmental risks. Yet, some important changes 
occurred between 2005 and 2015, including large 
reductions in attributable total DALYs (29·5% [26·8–32·0]) 
and age-standardised DALY rates (37·6% [35·2–39·8]) for 
unsafe sex and in attributable total DALYs (10·5% 
[2·8–17·8]) and age-standardised DALY rates (23·2% 
[16·8–29·1]) for intimate partner violence.
Contrasting global changes in risk exposure and 
attributable burden
A comparison of percentage change in risk exposure 
from 1990 to 2015 with the level of attributable DALYs in 
2015 helps to identify large risks for which a long-term 
increase in global exposure has occurred (ﬁ gure 4). 
Although disease burden attributable to unsafe 
sanitation, household air pollution, stunting, and 
underweight caused more than 10 million DALYs 
Figure 1: Global proportion of all-cause DALYs attributable to behavioural, environmental and occupational, and metabolic risk factors and their overlaps by region for both sexes combined in 2015
Locations are reported in order of total all-cause DALYs population attributable fraction. DALYs=disability-adjusted life-years. ∩=interaction. 
So
uth
ern
 su
b- 
     
Sa
ha
ran
 Af
ric
a
Ea
ste
rn 
sub
-   
   
Sa
ha
ran
 Af
ric
a
We
ste
rn 
sub
-   
   
Sa
ha
ran
 Af
ric
a
Ce
ntr
al s
ub
-   
   
Sa
ha
ran
 Af
ric
a
Oc
ea
nia
Ea
ste
rn 
Eu
rop
e
Ce
ntr
al A
sia
Ce
ntr
al E
uro
pe
Ea
st A
sia
So
uth
ea
st A
sia
So
uth
 As
ia
Ca
rib
be
an
Glo
ba
l
Ce
ntr
al L
ati
n A
me
ric
a
Tro
pic
al L
ati
n A
me
ric
a
Hig
h-i
nc
om
e N
ort
h A
me
ric
a
No
rth
 Af
ric
a a
nd
 th
e M
idd
le E
ast
So
uth
ern
 La
tin
 Am
eri
ca
An
de
an
 La
tin
 Am
eri
ca
We
ste
rn 
Eu
rop
e
Au
str
ala
sia
Hig
h-i
nc
om
e A
sia
 Pa
cifi
c
0
25
50
75
100
DA
LY
s (
%
)
Region
Metabolic Environmental and occupational Behavioural Environmental and occupational ∩ Behavioural ∩ Metabolic Environmental and occupational ∩ Metabolic
Environmental and occupational ∩ Behavioural Behavioural ∩ Metabolic Unattributed
Burden type
 
Articles
1696 www.thelancet.com   Vol 388   October 8, 2016
in 2015, exposure to these risks decreased for both sexes 
from 1990 to 2015 by more than 30%. Conversely, two 
risks caused more than 100 million DALYs and increased 
by more than 20%: high fasting plasma glucose and 
high BMI. Other risks with large increases in exposure 
but which caused less than 10 million DALYs include 
various occupational exposures, drug use, ambient 
ozone pollution, second-hand smoke, and diets low in 
Figure 2: Global DALYs attributable to Level 2 risk factors for (A) men and (B) women in 2015
DALYs=disability-adjusted life-years. 
Dietary risks
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polyunsaturated fatty acids (PUFAs). For a large group 
of risks at the global scale, exposure increased or 
decreased by less than 10% from 1990 to 2015. These 
included many components of diet, high systolic blood 
pressure, ambient particulate matter pollution, and 
alcohol use.
Decomposition of changes in risk-attributable DALYs to 
population growth, ageing, risk exposure, and risk-
deleted DALY rates
Drivers of global changes in overall DALYs attributable to 
risk factors varied (ﬁ gure 5). Across Level 3 risk factors, 
overall changes in all-cause attributable DALYs ranged 
from declines exceeding 50% for seven risk factors, 
including childhood undernutrition, suboptimal breast-
feeding, and unsafe sanitation, to increases near to or 
exceeding 100% (ie, high BMI, occupational carcinogens, 
and drug use). Of these 46 Level 3 risk factors, attributable 
all-cause DALYs decreased signiﬁ cantly for ten from 1990 
to 2015, whereas 34 increased signiﬁ cantly; two did not 
signiﬁ cantly change. Population ageing led to increased 
attributable all-cause DALYs for most risk factors, with a 
relative contribution that spanned from lower than 10% 
(for household air pollution from solid fuels and 
occupational injuries) to greater than 60% (for occu-
pational carcinogens). Population ageing contributed to 
reductions in all-cause DALYs attributable to eight risk 
factors, namely environmental risks (eg, a 13·5% 
[95% UI 6·0–19·9] decrease for no handwashing with 
soap), those associated with nutritional deﬁ ciencies (eg, a 
17·6% [12·6–24·0] decline for childhood undernutrition), 
and behavioural risks (eg, a 22·0% [10·9–31·4] decline 
for suboptimal breastfeeding). Changes in risk-deleted 
DALY rates since 1990 were primary drivers of reductions 
in all-cause, risk-attributable burden, with decreases in 
underlying DALY rates exceeding 50% for 13 risks by 
2015. By contrast, changes in risk exposure varied 
markedly, contributing to declines in all-cause DALYs for 
ten risks (eg, 30·0% [29·0–38·0] due to declines in risk 
exposure for household air pollution and 21·7% 
[17·5–30·4] due to declines in risk exposure for iron 
deﬁ ciency); at the same time, change attributable to risk 
exposure increased for 16 risk factors to more than 25%, 
including high fasting blood glucose (25·1% [19·7–27·9]), 
ambient ozone pollution (37·5% [31·5–42·7]), occu-
pational carcinogens (40·1% [28·5–50·8]), occu pational 
injuries (41·1% [37·0–48·1]), high BMI (60·0% 
[54·9–69·2]), and drug use (70·0% [65·5–73·6]).
Figure 3: Leading 30 Level 3 global risk factors for DALYs for both sexes combined, 1990, 2005, and 2015, with percentage change in number of DALYs, and all-age, and age-standardised rates
Risks are connected by lines between time periods. For the time period of 1990 to 2005 and for 2005 to 2015, three measures of change are shown: percent change in the number of DALYs, percent 
change in the all-age DALY rate, and percent change in the age-standardised DALY rate. Changes that are statistically signiﬁ cant are shown in bold. DALYs=disability-adjusted life-years.
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Decreases in underlying cause-speciﬁ c DALY rates—
as opposed to other factors—were generally the main 
drivers of overarching reductions in cause-speciﬁ c 
burden attributable to all risk factors (methods appendix 
pp 164–65). From 1990 to 2015, 36 causes decreased in 
terms of associated risk exposure, including a number 
of communicable causes, nutritional deﬁ ciencies, and 
chronic obstructive pulmonary disease. Notably, risk 
Figure 4: Global attributable DALYs in 2015 for each Level 3 risk factor versus percentage change in SEV from 1990 to 2015 for both sexes combined
Risks with 100 000 DALYs or more are presented. DALYs are represented on a logarithmic scale. We have excluded occupational exposure to benzene, diesel engine 
exhaust, and occupational exposure to silica, which all had SEV increases of greater than 50%. Ambient PM=ambient particulate matter pollution. Arsenic=occupational 
exposure to arsenic. Asbestos=occupational exposure to asbestos. Asthmagens=occupational asthmagens. Beryllium=occupational exposure to beryllium. BMD=low bone 
mineral density. BMI=high body-mass index. Cadmium=occupational exposure to cadmium. Calcium=diet low in calcium. Cholesterol=high total cholesterol. 
Chromium=occupational exposure to chromium. DALYs=disability-adjusted life-years. Ergonomic=occupational ergonomic factors. Fibre=diet low in ﬁ bre. 
Formaldehyde=occupational exposure to formaldehyde. FPG=high fasting plasma glucose. Fruits=diet low in fruits. GFR=low glomerular ﬁ ltration rate. Handwashing=no 
handwashing with soap. Household air=household air pollution. IPV=intimate partner violence. Lead=lead exposure. Milk=diet low in milk. Nickel=occupational exposure 
to nickel. Noise=occupational noise. Nuts and seeds=diet low in nuts and seeds. Occupational SHS=occupational exposure to second-hand smoke. Omega-3=diet low in 
seafood omega-3 fatty acids. Ozone=ambient ozone pollution. PAH=occupational exposure to polycyclic aromatic hydrocarbons. Physical activity=low physical activity. 
PM, gases, and fumes=occupational particulate matter, gases, and fumes. Processed meat=diet high in processed meat. PUFA=diet low in polyunsaturated fatty acids. 
Radon=residential radon. Red meat=diet high in red meat. Sanitation=unsafe sanitation. SBP=high systolic blood pressure. SEV=summary exposure value. SHS=second-
hand smoke. Sodium=diet high in sodium. Sugar-sweetened beverages=diet high in sugar-sweetened beverages. Sulphuric acid=occupational exposure to sulphuric acid. 
Stunting=childhood stunting. Trans fatty acids=diet high in trans fatty acids. Trichloroethylene=occupational exposure to trichloroethylene. Underweight=childhood 
underweight. Vegetables=diet low in vegetables. Wasting=childhood wasting. Water=unsafe water. Whole grains=diet low in whole grains. 
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exposure was the only factor that improved from 1990 to 
2015 for a subset of causes, with changes in population 
growth, ageing, and underlying cause-speciﬁ c DALY 
rates all contributing to rising cause-speciﬁ c disease 
burden; this ﬁ nding was most evident for tracheal, 
bronchial, and lung cancer, as well as for cirrhosis and 
other chronic liver diseases due to alcohol use.
The risk transition and development
Figure 6 shows the evolution of SEV by region for the ten 
leading global risk factors in terms of attributable DALYs 
as SDI changes and also provides the expected SEV level 
on the basis of SDI alone. Two main trends emerged: 
increasing and then levelling of SEVs for most metabolic 
and dietary risks and reductions in SEVs for environmental 
Figure 5: Global decomposition of changes in all-cause DALYs attributable to Level 3 risk factors from 1990 to 2015
Risks are reported in order of percentage change in the number of attributable DALYs from 1990 to 2015. We excluded DALYs attributable to unsafe sex because this 
risk factor is not estimated on the basis of exposure and relative risk. Changes due to population growth, population ageing, risk exposure, and the risk-deleted DALY 
rate are shown. DALYs=disability-adjusted life-years. 
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risks and those associated with childhood undernutrition 
as SDI approached mid-levels. For metabolic and dietary 
risks, above an SDI of approximately 0·8, expected levels 
of risk exposure either moderately dropped or remained 
fairly constant. An exception was alcohol use, for which 
SEVs increased with each increment of SDI. By contrast, 
SEVs for ambient particulate matter pollution did not 
substantially decline until above an SDI of 0·60, and the 
pace of SEV reductions for household air pollution 
accelerated above an SDI of about 0·40. These patterns 
reﬂ ect the complex shifts in risk exposure that accompany 
changes in development, which are further emphasised 
by regional SEV trends by risk factor.
Two risk factors related to nutrition or diet—childhood 
wasting and diet high in sodium—reﬂ ected the nuances 
of changing risk exposure and levels of development. 
Particularly among regions with an SDI below 0·8, SEVs 
for childhood wasting decreased over time and with 
increasing SDI; nonetheless, a subset of regions, including 
south Asia and western sub-Saharan Africa, had con-
sistently higher than expected SEVs for childhood wasting 
on the basis of SDI. For diet high in sodium, most regions 
saw minimal changes in exposure over time, even amid 
increases in SDI. In east Asia, SEVs for diet high in 
sodium were consistently above expected levels of 
exposure given SDI, whereas the opposite trend was 
found for Oceania and central Latin America. Across the 
development spectrum—including high-income Asia 
Paciﬁ c, southeast Asia, and eastern sub-Saharan Africa—
exposure for diet high in sodium was at least moderately 
higher than expected on the basis of the SDI for a given 
region. Heterogeneous risk patterns occurred for two 
leading environmental risks—household air pollution 
and ambient particulate matter pollution—particularly in 
terms of the relationship between SEVs and increasing 
SDI. For smoking and alcohol use, strikingly diﬀ erent 
trends for SEV and SDI occurred. Although nearly every 
region recorded declines in SEVs for smoking, the rate at 
Figure 6: Coevolution of SEV and SDI for the top ten global risks in terms of attributable disability-adjusted life-years in 2015
Coloured points show SEVs for Global Burden of Disease regions. Each point represents 1 year in 5 year intervals from 1990 to 2015. The solid black line represents the expected SEV on the basis of 
SDI alone. SDI=Socio-demographic Index. SEV=summary exposure values.
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which these reductions took place alongside changes in 
SDI varied.
Regional and national risk proﬁ les
Leading risk factors for early death and disability, as 
measured by attributable DALYs, varied by region, level of 
SDI, and sex in 2015 (ﬁ gure 7). In high-income North 
America and the UK, smoking was the leading risk for 
attributable DALYs among both men and women, but for 
most of western Europe, smoking was the leading risk 
factor only for men, whereas high systolic blood pressure 
was the leading risk factor for women. A similar pattern 
emerged in east and southeast Asia, with smoking ranked 
as the leading risk factors for men in China, Thailand, 
Vietnam, and the Philippines, whereas metabolic risk 
factors—namely high systolic blood pressure—was the 
leading risk factor for attributable DALYs for women in 
these countries. Childhood undernutrition ranked as the 
leading risk factor for early death and disability for both 
sexes throughout western and central sub-Saharan Africa, 
as well as in a few countries outside of sub-Saharan Africa 
(eg, Laos and Tajikistan).
In terms of the leading ten risk factors for both sexes, 
regional and country risk proﬁ les showed both distinct 
patterns and heterogeneity. High systolic blood 
pressure was the leading risk for DALYs for 
13 high-income countries and territories in 2015, high 
fasting plasma glucose was the leading risk for three, 
and smoking was the leading risk for 21. For a subset of 
geographies, including the USA, Canada, Australia, 
and the UK, drug use was a major risk for early death 
and disability in 2015. In 2015, high systolic blood 
pressure, high BMI, and high fasting plasma glucose 
were the leading risk factors for almost all geographies 
in Latin America and the Caribbean; Haiti was the 
primary exception, with unsafe sex as its leading risk 
for attributable DALYs in 2015. Across southeast Asia, 
east Asia, and Oceania, high systolic blood pressure 
was the leading risk factor for disease burden in 
nine countries and territories, ranging from China to 
Vanuatu. High BMI was the leading risk for DALYs in 
nine geographies, and high fasting plasma glucose 
ranked as the leading risk factor for three geographies, 
including Taiwan.
(Figure 7 continues on next page)
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High systolic blood pressure was among the leading 
two risk factors for all geographies in south Asia and, 
except for Pakistan and Bhutan, household air pollution 
remained among the leading four risk factors for 
attributable DALYs across geographies in this region. 
Ambient particulate matter pollution ranked as the third-
leading risk factor in India and Nepal, whereas smoking 
was the second-leading risk factor for attributable burden 
in Bangladesh. In central Europe, eastern Europe, and 
central Asia, 28 of 29 countries had high systolic blood 
pressure as their leading risk factor for attributable DALYs 
in 2015; Tajikistan, where childhood undernutrition was 
the leading risk factor, was the only exception. Across 
central Europe, smoking was the second-leading risk 
factor for early death and disability, whereas alcohol use 
was among the leading four risk factors for attributable 
DALYs in geographies including Belarus, Moldova, 
and Russia.
Throughout north Africa and the Middle East, except for 
Tunisia, high systolic blood pressure was among the three 
leading risk factors for disease burden in 2015, with nine 
geographies, including Egypt and Iran, recording this risk 
as the leading driver of early death and disability in that 
year. High BMI accounted for the highest attributable 
DALYs in eight countries, including Jordan and Saudi 
Arabia, and was also among the leading six risks for all 
countries in the region. For Afghanistan and Sudan, 
childhood undernutrition was the leading risk for DALYs 
in 2015, whereas it was the second-leading risk for DALYs 
in Yemen and the eighth-leading risk in Egypt. Unlike 
most of sub-Saharan Africa, several metabolic risks also 
emerged as leading drivers of attributable DALYs in 
southern sub-Saharan Africa by 2015; high BMI ranked as 
the second-leading risk factor in South Africa, and high 
systolic blood pressure was among the leading three risk 
factors for attributable DALYs in Botswana. In central 
sub-Saharan Africa, childhood undernutrition and unsafe 
sex were ranked ﬁ rst and second for attributable disease 
burden in all geographies except for Gabon. High systolic 
blood pressure ranked among the leading risk factors for 
attributable DALYs in most geographies in the region 
(eg, second in Gabon and third in the Congo).
(Figure 7 continues on next page)
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Discussion
Overview
Drawing from 25 500 data sources, we estimated exposure 
to 79 metabolic, environmental and occupational, and 
behavioural risk factors or clusters of risks from 1990 to 
2015 in 195 countries and territories and attributed deaths 
and overall disease burden to these risks. In 2015, all risks 
combined contributed to 57·8% (95% UI 56·6–58·8) of 
deaths and 41·2% (39·8–42·8) of DALYs worldwide. Since 
1990, global risk exposure for both sexes combined 
increased signiﬁ cantly for 27 risks, did not signiﬁ cantly 
change for seven risks, and declined signiﬁ cantly for 
27 risks. At the same time, that risk exposure increased 
for various leading risks, particularly metabolic risk 
factors associated with NCDs, and age-standardised 
risk-attributable deaths and DALYs declined for most 
risks. Globally, pronounced reductions in risk-deleted or 
underlying cause-speciﬁ c DALY rates oﬀ set minimal 
changes in, or increased, risk exposure. These gains in 
risk-deleted DALY rates might not be large enough in the 
future to compensate for rising levels of risk exposure, 
such as high BMI or high fasting plasma glucose.
Rethinking the risk transition
Societal processes of urbanisation, the so-called 
westernisation of diets and lifestyles, and changes in 
employment activities, have all been viewed as primary 
drivers of changes in human health.21–24 Such shifts have 
been thought to lead to deteriorating diets, rising obesity, 
decreased physical activity, and, ultimately, to worsening 
levels of metabolic risks, with associated higher rates of 
cardiovascular diseases and cancers.25,26 Results from the 
this study point to an ongoing risk transition, but with a 
trajectory complex and nuanced. The relationship 
between SEVs for most risks and SDI identiﬁ ed that poor 
water, poor sanitation, household air pollution, and 
micronutrient deﬁ ciencies and undernutrition decline 
steadily as countries develop. By contrast, some risks 
become worse as development proceeds, at least up to 
levels of SDI of about 0·8; these risks include low 
(Figure 7 continues on next page)
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physical activity, high BMI, high total cholesterol, low 
PUFAs, partial breastfeeding, alcohol use, diet high in 
red meat, smoking, and diet high in sugar-sweetened 
beverages. Some risks that appear to worsen through 
early phases of development improved at the highest 
levels of SDI, such as smoking. As improvements in SDI 
continue and behavioural risks grow in dominance, an 
understanding of how to change behaviours eﬀ ectively at 
both the individual level and for populations becomes 
increasingly relevant. Many other components of diet, 
occupational exposures, and some environmental risks 
do not show a marked relationship with development.
The eﬀ ects of the risk transition, at least globally, are 
often mitigated by trends in risk-deleted death or DALY 
rates. In this study, we identify likely candidates for 
speciﬁ c drivers of improvements. Unmeasured risk 
factors could be driving these trends. Unlike cardio-
vascular diseases and some neoplasms, for other causes 
such as mental disorders or neurological disorders, the 
set of risks included in this study account for 
comparatively little of the observed burden; these causes 
make up an increasing share of the burden for 
geographies at high SDI. To date, we have not identiﬁ ed 
risk factors that meet our criteria of convincing or 
probable evidence, suggesting that research into 
unquantiﬁ ed risks is needed. In accompanying GBD 2015 
analyses,27–29 we documented widespread improvements 
in overall development as measured by SDI. Gains in 
SDI are likely to operate through many pathways, 
including improved access to health care, public health 
programmes, and social and welfare policy. Advances in 
treatment are well documented for various causes, 
including HIV/AIDS,30–32 ischaemic heart disease,33–37 and 
various cancers,38–40 including breast,41–43 testicular,44 and 
Hodgkin’s,45 yet for other causes, such as oesophageal 
cancer and interpersonal violence, the policies, pro-
grammes, and interventions responsible for declining 
risk-deleted death and DALY rates are less clear than for 
the aforementioned causes. Improvement of under-
standing of the risk-deleted rates in cause-speciﬁ c 
mortality and disease burden will strengthen the evi-
dence base for intervention eﬀ ectiveness, the role of 
(Figure 7 continues on next page)
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medical care access in addressing disease burden, and 
the importance of other social and welfare policies.
A global risk typology
We used our decomposition of drivers of attributable 
burden to identify four distinct groups of risks at the 
global level. First, for ten risks, attributable burden is 
declining, as is the exposure to the risk factor. This set of 
risks is dominated by the environmental risks, which are 
particularly common at low levels of SDI, and consist of 
vitamin A deﬁ ciency, undernutrition, zinc deﬁ ciency, 
suboptimal breastfeeding, poor sanitation, no hand-
washing, poor water, second-hand smoke, household air 
pollution, and occupational asthmagens. For these risks 
as a group, not only has exposure been declining, but 
risk-deleted DALY rates also declined, such as for 
diarrhoeal diseases. Furthermore, global shifts in popu-
lation age structure contributed to decreases in both 
cause-speciﬁ c and attributable burdens for risks that 
predominantly aﬀ ect children. A second group of risks 
was characterised by declines in exposure exceeding 10% 
from 1990 to 2015, but increasing attributable burden, 
due in most cases to large increases driven by population 
growth and ageing. This group includes smoking, high 
systolic blood pressure, occupational ergonomic factors, 
childhood sexual abuse, and iron deﬁ ciency; for iron 
deﬁ ciency, the increase in attributable burden was quite 
small over the period 1990–2015. For a third group, 
attributable burden is increasing, and trends in exposure 
account for a less than 10% increase or decrease in 
attributable burden. This larger group of risks than the 
ﬁ rst two groups includes all components of diet except 
for low PUFA intake and diet high in sugar-sweetened 
beverages, some occupational exposures, residential 
radon, low glomerular ﬁ ltration rate, alcohol use, high 
total cholesterol, intimate partner violence, lead exposure, 
low bone mineral density, and low physical activity. For 
these risks, attributable burden is increasing because of 
population growth and ageing. The degree of increase is 
driven by the extent to which declines in risk-deleted 
DALY rates compensate for the increases due to 
population growth and ageing. The ﬁ nal category is the 
(Figure 7 continues on next page)
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risks that are perhaps the most concerning: those with 
increasing attributable burden and exposure contributing 
to an increase of at least 10% since 1990. This list includes 
occupational injuries, ambient ozone pollution, occu-
pational carcinogens, diet low in PUFAs, diet high in 
sugar-sweetened beverages, drug use, high fasting 
plasma glucose, and high BMI. For these risks, declines 
in underlying rates were probably responsible for 
prevention of additional increases in attributable burden. 
Any risk for which attributable deaths and DALYs are 
increasing is a threat to both health systems and societies, 
but the risks that fall within the fourth group—risk 
factors with rising exposure and associated health loss—
require immediate attention from policy makers and 
other stakeholders.
Unsafe water, sanitation, and handwashing
The conventional approach to assessment of the 
contribution of unsafe water to health is to assess access 
to improved water sources as deﬁ ned in the Millennium 
Development Goals.46,47 WHO estimated that, in 2015, 
91% of populations living in low-income and middle-
income countries had access to improved water and 68% 
had access to improved sanitation since 1990.48,49 Implicit 
in the focus on improved is the idea that the most 
important reductions in diarrhoea come from movement 
from an unimproved to an improved source of water or 
sanitation. However, ﬁ ndings from meta-analyses of 
intervention studies and retrospective cohorts show a 
wide variation of relative risks of diarrhoea within the 
category of improved water and improved sanitation. We 
found that the SEV for poor water was only 56·0% 
(95% UI 50·4–62·1) for men and 55·7% (50·2–61·8) for 
women in 2015, a small improvement of just 9·4% 
(5·3–13·0) since 1990. By contrast, for unsafe sanitation, 
the SEV decreased substantially, from 55·0% (53·8–56·5) 
in 1990 for men and 54·2% (52·8–55·7) for women to 
33·7% (32·2–35·1) for both men and women in 2015. 
Our assessment of SEV for water showed that a 
substantial agenda is still needed across the world to 
achieve the overall goal of safe water and sanitation. The 
sixth Sustainable Development Goal includes targets for 
(Figure 7 continues on next page)
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achievement of both universal and equitable access to 
safe drinking water and adequate and equitable sanitation 
for all by 2030.50,51 Given SEVs in many of these areas of 
the world, a large gap remains between current levels of 
safe water and sanitation and universal access. Moreover, 
our analyses show that progress in provision of safe 
water lags behind that of safe sanitation. This shift in 
focus to the lowest risk categories raises the bar 
considerably for what is needed for investment to reduce 
the risk of diarrhoea in all regions of the world.
Tobacco
The SEV for smoking has decreased in many countries 
as well as globally. Global tobacco-attributable deaths and 
DALYs, however, have continued to rise because of 
increases in population numbers and ageing, which 
overwhelm declines in both exposure and risk-deleted 
rates of related disease burden. Given a known highly 
eﬀ ective set of intervention strategies to reduce tobacco 
consumption,52–58 the challenge for tobacco is one of 
political priority for tobacco control. Despite the 
important developments of the Framework Convention 
on Tobacco Control, in many countries, progress has 
been slow or consumption has even increased. Continued 
close monitoring of tobacco consumption and the deaths 
and DALYs attributable to tobacco remains an essential 
aid to promotion of policies to reduce tobacco 
consumption.
In GBD 2015, for long-term eﬀ ects of smoking on lung 
cancer and chronic obstructive pulmonary disease, we 
used the Peto-Lopez method,59 which estimates the 
lifetime cumulative eﬀ ect of cigarette smoking using a 
transformation of the observed lung cancer death rate. 
Although this method provides robust estimates of the 
Figure 7: Leading ten Level 3 risk factors in terms of disability-adjusted life-years for both sexes combined in 2015, by location
The 15 leading risk factors are coloured. Bone mineral density=low bone mineral density. Handwashing=no handwashing with soap. Int partner violence=intimate partner violence. Nuts and 
seeds=diet low in nuts and seeds. Occ=occupational. Particulate matter=ambient particulate matter pollution. Physical activity=low physical activity. Processed meat=diet high in processed meat. 
SDI=Socio-demographic Index. Subopt=suboptimal. Sweetened beverages=diet high in sugar-sweetened beverages. Vegetables=diet low in vegetables.
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burden of cancers related to tobacco, it is not fully 
consistent with the GBD approach of estimation of 
exposure independently of the outcomes aﬀ ected by 
exposure. With a growing body of evidence for the 
association between smoking and other cancers and a 
good estimate of distribution of smoking, direct 
estimation of attributable burden is possible. Modelling 
of the direct relationship between smoking exposure in 
the past and present to cancers will also allow for 
exploration of counterfactual scenarios and other forms 
of CRA, such as estimation of avoidable burden. The set 
of outcomes that have been related to tobacco in pooled 
cohort studies60 includes many outcomes not quantiﬁ ed 
in this study, such as road traﬃ  c accidents, renal failure, 
and infectious diseases; careful assessment of which of 
these new outcomes meet the criteria of convincing or 
probable evidence is needed. Quantiﬁ cation of the full 
eﬀ ects of tobacco will also require inclusion in future 
GBD studies of smokeless tobacco consumption. 
Regardless of the estimation method used or the scope of 
outcomes evaluated, tobacco remains a major global risk 
factor, despite more than 50 years of antitobacco eﬀ orts.
Dietary assessment
Many aspects of dietary assessment remain controversial. 
Evidence for the eﬀ ect of diet on NCDs mostly comes 
from prospective cohort studies using food frequency 
questionnaires (FFQs) with 1 year recall to establish diet 
at baseline. Findings from 24 h recalls or multiple-day 
diary records show a poor correlation with annual 
FFQs.61,62 Proponents of FFQs argue that the rank order 
of levels of intake across individuals in the annual FFQ is 
robust.62 Some authors have argued that measurement 
error for each diet component in the statistical analysis of 
the cohort data will tend to bias the ﬁ ndings towards the 
null and thus underestimate the eﬀ ects of a diet 
component.63 However, the direction of bias in settings 
with measurement error in multiple independent 
variables is unknown in the presence of correlation 
between diﬀ erent variables.64,65 At the population level, 
single 24 h recall has been used in many nutrition 
surveys. 24 h recall probably underestimates, as shown in 
doubly labelled water66 and urinary sodium studies.67
Correlation between diet components is a crucial 
aspect of diet. Intake of beneﬁ cial dietary factors are 
generally, but not always, positively correlated with each 
other and inversely correlated with harmful dietary 
factors. This correlation could overestimate the relative 
risk of each dietary factor in cohorts as well as the total 
eﬀ ect of dietary risks at the population level. Use of 
dietary pattern as the main exposure could potentially 
address this problem; however, several challenges exist 
in adoption of this approach for GBD. Concerns remain 
about the magnitude of the eﬀ ect size of individual 
dietary risk factors on chronic diseases. Although many 
prospective cohorts have collected dietary data,68 
published meta-analyses for most diet-disease pairs have 
included reports from only a fraction of these cohorts, 
indicating the potential for publication bias. Furthermore, 
most cohorts assessing the eﬀ ect of diet on disease 
endpoints have adjusted for total energy intake in their 
statistical models. This practice emerged to address 
measurement error in dietary assessment tools and 
remove the eﬀ ect of energy as a potential confounder. 
The adjustment for total energy intake means that diet 
components are deﬁ ned as risks in terms of the share of 
diet and not as absolute levels of exposure. Because diet 
shares are analysed, increases in any component imply 
reductions in some other component, leading to the 
notion of replacement. Diet components are often 
analysed as pairs in which one component replaces 
another, further complicating analysis of cohort data. 
Given that many cohorts do not include the same dietary 
components in their analyses, the relative risks of dietary 
factors across cohorts might not be strictly comparable. 
This issue has been one of the main reasons for 
inconsistent ﬁ ndings in dietary meta-analyses.69,70 Future 
work to encourage more pooled analyses than at present 
of diet components for all the major cohorts would be 
beneﬁ cial; release of more data than available from the 
present major cohorts would stimulate various alternative 
analyses of diet, which would help strengthen the 
evidence for diet and attributable burden.
Sodium intake
Age-standardised DALYs attributable to diets high in 
sodium and exposure (as measured by SEV) for diets 
high in sodium increased slightly at the global level 
(7·2% [95% UI 0·7–19·0] for men and 4·0% [–0·3 to 
12·1] for women) from 1990 to 2015. Reduction in sodium 
intake at the population level is one of WHO’s nine 
global targets for NCDs.71 Many countries (eg, the UK, 
Finland, Japan, and Brazil) have already implemented or 
are considering implementing (eg, the USA) policies to 
reduce sodium intake.71–75 Reports from countries with 
high levels of sodium intake (eg, Japan) that have 
successfully implemented sodium reduction policies 
have argued for the beneﬁ cial eﬀ ects of a lowering of 
sodium intake in these populations.76 Although multiple 
lines of epidemiological evidence support the harmful 
eﬀ ects of very high levels of sodium intake, no scientiﬁ c 
consensus has been reached on the optimal level of 
sodium intake. In GBD 2013, on the basis of ﬁ ndings of 
the Prospective Urban Rural Epidemiology (PURE) 
collaboration on sodium and cardiovascular mortality13,77 
and to incorporate the absence of scientiﬁ c consensus on 
the optimal intake of sodium, we expanded the 
uncertainty for the TMREL for sodium to 1–5 g per 
day.78–80 PURE collaborators subsequently published a 
further analysis,13 which raised the possibility that, for 
those without hypertension, an inverse relationship 
might exist between sodium intake, all-cause mortality, 
and cardiovascular events. These ﬁ ndings challenge 
longstanding beliefs in the public health community 
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with regard to the importance of modulation of sodium 
intake at the population level. Current policy is grounded 
in the evidence that links sodium intake and systolic 
blood pressure, which shows increases in systolic blood 
pressure with increases in sodium above 1 g per day.81,82 
However, we have identiﬁ ed no prospective cohort 
studies that directly link sodium to disease endpoints 
that support reductions in the risk of outcomes at levels 
of intake below 3 g per day. Proponents of a low TMREL 
for sodium have argued that the cohort studies that 
generally show rising mortality at levels below 3–5 g per 
day might have the issue of reverse causation because ill 
individuals reduce sodium consumption.83,84 Given this 
continued debate, we chose not to change the uncertainty 
range of the TMREL from the current 1–5 g per day. If 
the ﬁ ndings from PURE and the pooled analysis are 
correct, an increased risk might exist for individuals 
without hypertension who consume less than 5 g per day. 
We have not included this potential increased risk in our 
quantiﬁ cation of uncertainty. Many studies have been 
completed or are underway examining the eﬀ ects of 
sodium reduction in population groups or whole 
communities on systolic blood pressure, but none to date 
have been done that report the eﬀ ects of sodium 
reduction on disease endpoints. Such studies, when and 
if they are done, could contribute to a resolution of 
outstanding questions about the TMREL for sodium. 
Regardless of the debate on the TMREL, we found that 
sodium accounted for at least 2·0% of global DALYs in 
2015. The risk proﬁ le of increasing attributable numbers 
of DALYs, and no global progress in a reduction of 
exposure to diets high in sodium, places this risk among 
those of great concern for the management of health 
systems.
Diet and policies
Much of the diet policy debate has focused on the 
importance of reductions of sodium, sugar, and fat.85,86 
Our assessment of the burden from diseases attributable 
to 14 dietary factors showed that, at the global scale, six 
factors each accounted for more than 1% of global DALYs, 
in order of importance: diets high in sodium, low in 
vegetables, low in fruit, low in whole grains, low in nuts 
and seeds, and low in seafood omega-3. Our ﬁ ndings 
suggest that, in addition to a policy focus on sodium, 
sugar, and fat, many other important components of diet 
should be minimised and promoted through education, 
subsidies, and other evidence-based programmes.87 
If our ﬁ ndings are correct, a policy focus on the sugar 
and fat components of diets might have a comparatively 
smaller eﬀ ect than that of promotion of increased uptake 
of vegetables, fruit, whole grains, nuts and seeds, and 
seafood omega-3. The disconnect between the diet policy 
debate and the evidence of which diet factors are most 
important globally can also be seen for red meat, where 
the harm of increased diabetes and colorectal cancer is 
smaller than that for all of the other 13 diet components 
considered under the GBD framework. Consideration of 
diet policy is made more complicated when cost-
eﬀ ectiveness, political feasibility, intensity of implemen-
tation, reactions of various stakeholders (eg, consumers 
and the food industry), and environmental eﬀ ects, 
including climate change, are factored into national diet 
policy discussions. For example, promotion of some 
components of a healthy diet (eg, milk and dairy products) 
might have deleterious eﬀ ects on environmental 
sustainability. These dimensions of diet policy should be 
added to the debates on how to transform national diets 
to be lower risk than at present.
Cholesterol
On the basis of ﬁ ndings from studies12 that showed the 
beneﬁ ts from the reduction of LDL and total cholesterol to 
very low values, for GBD 2015, we revised the TMREL for 
total cholesterol downwards from 3·80–4·00 mmol/L to 
2·78–3·38 mmol/L. This revision increased our estimate of 
the burden of total cholesterol for the year 2010 from 
2·7 million (95% UI 1·9 million to 3·8 million) deaths in 
GBD 2013 to 4·0 million (3·1 million to 5·1 million) deaths 
in GBD 2015 and shifted our placement of cholesterol 
among leading risks from tenth (GBD 2013 ranking for the 
year 2010) to fourth (GBD 2015 ranking for the year 2010). 
Eﬀ ective intervention options to inﬂ uence population total 
cholesterol are available, including eﬀ orts to increase 
physical activity and diet and pharmacological interventions. 
Although consumption of dietary cholesterol is not linked 
to serum cholesterol,88 dietary interventions, such as 
increased consumption of fruits, vegetables, and ﬁ bre, and 
increased physical activity can inﬂ uence LDL and total 
cholesterol89 and should be encouraged.90,91 Statins are 
highly eﬀ ective, with few side-eﬀ ects, justifying their use in 
many individuals, either alone or in combination with 
other medicines. In general, given the existence of proven 
and eﬀ ective intervention strategies, the increase in the 
importance of cholesterol highlights a major opportunity 
for intervention.
Systolic blood pressure
In this assessment, as in GBD 2013, we found that the 
most important Level 3 risk factor globally is elevated 
systolic blood pressure. The TMREL for this estimation, a 
systolic blood pressure of between 110 mm Hg and 
115 mm Hg, is based on evidence from the pooling of 
prospective cohort studies that showed that individuals 
with a baseline blood pressure at this level have the lowest 
risk of future cardiovascular death.92,93 In addition to this 
observational evidence, two randomised clinical trials of 
blood pressure lowering have added substantially to the 
evidence in this area. Findings from the SPRINT trial10 
showed that adults in the USA with elevated vascular risk 
and pre-existing hypertension (mean systolic blood 
pressure at baseline 139·7 mm Hg and on a mean of 
1·8 medications) beneﬁ ted from antihypertensive therapy 
that targeted a systolic blood pressure of 120 mm Hg. 
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Findings from the HOPE-3 trial,77 a multinational study, 
showed that older adults (aged ≥55 years) with elevated 
vascular risk but without susbtantially elevated systolic 
blood pressure (mean systolic blood pressure at baseline 
138·2 mm Hg) did not have any beneﬁ t when they 
received hydrochlorothiazide 12·5 mg plus candesartan 
16 mg daily. However, neither study directly addresses 
selection of the GBD TMREL of 110–115 mm Hg since 
observational studies necessarily reﬂ ect the beneﬁ ts 
accrued through maintenance of a healthy blood pressure 
throughout life rather than through use of blood pressure-
lowering medications. The GBD estimate necessarily 
represents the eﬀ ect of primary prevention and lifestyle 
modiﬁ cation, as well as the possibility of pharmacotherapy 
for achievement of the TMREL. The large potential gain 
in global health that we estimate if an optimal blood 
pressure was to be achieved suggests that further studies 
of blood pressure in people younger than 60 years of age 
remains an important area for investigation. A wide array 
of clinical and population strategies are available to 
reduce systolic blood pressure, including lowering 
population salt intake, increasing physical activity, 
reducing or slowing the rise of high BMI, and providing 
access to eﬀ ective antihypertensives, which merit 
considerable attention in many countries.
Alcohol use
We report that the global SEV for alcohol decreased by 
1·1% (95% UI –6·0 to 2·3) for men and 13·1% (–16·1 to 
–10·7) for women. Of note, however, because of the 
geographical distributions of alcohol consumption and 
background disease rates, alcohol consumption con-
tributed to an increase in alcohol attributable DALYs over 
the same period. Assessment of the burden attributable 
to alcohol is complicated by potentially elevated risks in 
former drinkers compared with abstainers, potential 
protective eﬀ ects of mild-to-moderate use of alcohol, and 
use of a TMREL of zero consumption for this study. 
Findings from meta-analyses have shown considerably 
elevated relative risks in former drinkers, equivalent to 
30 g of pure alcohol per day or more for some outcomes,94,95 
although this ﬁ nding could occur as a result of 
confounding by misclassiﬁ cation of former drinkers as 
lifetime abstainers.96–99 Future GBD studies should 
carefully re-evaluate whether or not the excess risk in 
former drinkers is overestimated. If the relative risks for 
former drinkers have been overestimated, this over-
estimation will also aﬀ ect our assessment of the alcohol 
SEV and the global trend in the SEV. The protective eﬀ ect 
of mild-to-moderate alcohol use reported for ischaemic 
heart disease, diabetes in women, and reduced all-cause 
mortality is controversial;100–105 some authors argue that 
this consistent ﬁ nding is due to confounding.106,107 
However, investigators of studies108 of all-cause mortality 
with certain types of quality exclusions ﬁ nd no overall 
mortality beneﬁ t of mild-to-moderate use. Various 
mendelian randomisation studies have contradicted 
previously claimed beneﬁ ts of moderate alcohol con-
sumption for several outcomes.109–111 Marked diﬀ erences 
in male and female patterns of relative risk, such as for 
diabetes,104,105 raise many questions about the biological 
pathways through which these eﬀ ects might act. Finally, 
our alcohol analysis uses a TMREL of zero consumption; 
use of a higher TMREL than zero for alcohol use would 
increase our estimate of the global burden attributed to 
alcohol. Given the large burden of alcohol and the 
availability of eﬀ ective options to reduce consumption at 
the population level, such as increased alcohol taxes, 
controls on outlet location and density, establishment or 
maintenance of limits on days or hours of sale, and 
screening and advice from health-care givers,112–115 
narrowing of the uncertainty in the alcohol assessment 
is important.
High BMI and fasting plasma glucose
Among the top ﬁ ve Level 3 risk factors, DALYs 
attributable to high BMI increased the most from 
1990 to 2015 while SEV also increased. High BMI is 
mediated through increases in systolic blood pressure, 
cholesterol, and fasting plasma glucose (methods 
appendix pp 28–35). Our decomposition analysis 
suggests that the increase in risk-attributable burden 
due to high BMI is considerably smaller than it could 
have been if underlying rates, particularly for 
cardiovascular diseases, had not declined as much as 
they did over the past decade. The decline in the 
underlying rates is likely due to expanded access to 
preventive treatment and increased quality of care.116–120 
If obesity continues to increase in the future, the 
consequences for health trends might be greater if the 
trend in underlying rates attenuates than if it continues 
to decrease. Although closely linked, we also estimate 
that the rate of increase in high fasting plasma glucose is 
slightly higher than that for obesity. The combined eﬀ ect 
of rising obesity and rising fasting plasma glucose has 
consequences for various health outcomes and health-
care delivery costs. For obesity, various policy options 
have been proposed,121–123 but few, if any, strategies have 
been proven to work at the population level. Analysis of 
obesity options needs to be closely linked to consideration 
of diet and physical activity. Although for most diet 
components we have reported on the eﬀ ect of diet 
composition on health outcomes, a strong argument 
exists to explore the relationship of speciﬁ c diet 
components with overall BMI.
Methods strengths and challenges: uncertainty in 
causality
To move the GBD and CRA ﬁ elds forward, we have 
reported, for the ﬁ rst time, details of the evidence that is 
available to support the causal relationship of each risk-
outcome pair. The strength of the evidence of causality 
varies widely across risk factors. For the risk-outcome 
pairs where evidence from randomised controlled trials 
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or high-quality prospective observational studies was not 
available, we considered the possibility of using other 
types of evidence, including mendelian randomisation, 
to establish causality.124 Although we have not used this 
approach in GBD 2015, this body of evidence seems to 
provide useful information that deserves a more detailed 
evaluation in future iterations of GBD than in this study. 
Likewise, the appropriate use of case-control data to 
support causality needs to be more clearly deﬁ ned than 
in this study.
Being explicit about the supporting evidence also 
shows that some risks have a similar body of evidence 
supporting them, even though, in some debates, the 
strength of evidence is thought to be very diﬀ erent. For 
this study, we focused on evidence mainly from 
prospective studies of exposure and disease endpoints. 
In select cases, we had to use prospective studies of 
intermediate outcomes, including trials of the eﬀ ect of 
sodium on systolic blood pressure, prospective cohort 
studies of the eﬀ ect of lead on systolic blood pressure, 
and trials and cohort studies of sugar-sweetened 
beverages’ eﬀ ect on BMI.125–128 We did not include the 
strength of evidence uncertainty in our estimation of 
attributable burden, which requires more consensus 
than we had available on how diﬀ erent types of evidence 
can be combined to support a causal connection.
Integrated exposure response curve for particulates less 
than 2·5 μg
In this study, as for GBD 2013, we have estimated the 
relative risk of exposure to particulate matter with an 
aerodynamic diameter smaller than 2·5 μm (PM2·5) 
over a broad range of daily doses by integrating relative 
risks from diverse sources of PM2·5, consisting of 
ambient air pollution, household air pollution, second-
hand smoke, and tobacco smoking, using a single 
integrated exposure response (IER) curve.129,130 The 
premise behind this approach is that PM2·5 daily dose is 
a common indicator of risk from diverse sources of 
particulate pollution. Although assessments support an 
assumption of the equitoxicity of particulate matter mass 
from diﬀ erent sources for the purposes of burden 
estimation,131,132 this issue remains an area of active 
research. We expect that the IER will continue to evolve 
in response to the latest evidence in the ﬁ eld of air 
pollution dose response; in keeping with the iterative 
nature of the GBD estimates, inclusion of additional 
cohort studies at lower levels of exposure to PM2·5 than 
those previously identiﬁ ed and included led to a revision 
of the TMREL distribution that is less than half of the 
level used in GBD 2013. Inclusion of new high-quality 
studies and the non-linear nature of the IER curve have 
increased our estimate of global burden. Methodological 
improvements to the curve-ﬁ tting algorithm that better 
capture the heterogeneity of component studies than do 
those in GBD 2013 produce UIs that are considerably 
wider than are those estimated in GBD 2013.
Future directions for GBD CRA
To date, attributable burden has been the primary metric 
that was methodologically and computationally feasible 
for GBD risk assessments. As burden forecasts become 
routinely available, quantiﬁ cation of avoidable burden 
within the GBD analytic framework will become more 
tractable than at present. Development of avoidable 
burden estimates will require resolution of various 
important issues, such as the degree of reversibility for 
some risks and the type of counterfactual distribution 
most relevant to avoidable burden calculation. Arguably, 
feasible or cost-eﬀ ective counterfactual distributions of 
exposure might be more relevant than is minimum risk.
In the next iterations of the GBD CRA, we plan to 
incorporate new risks into two areas: distal socioeconomic 
factors, such as educational attainment, and the absence 
of eﬀ ective health interventions, such as vaccination or 
seat belts. We will assess the evidence supporting new 
risk factors for inclusion and expand the scope of the 
analysis on the basis of both the evidence for causality 
and the availability of evidence for estimation of exposure 
levels. For behavioural, environmental and occupational, 
and metabolic risks, other candidate risks have been 
proposed for inclusion in GBD, including climate 
change, smokeless tobacco, added sugar, and access to 
health care. For existing risks, we will also carefully 
assess inclusion of new risk-outcome pairs. Continued 
close examination of evidence supporting causality 
might lead to modiﬁ cations of the criteria for inclusion. 
For many distal factors, such as educational attainment, 
highly consistent evidence exists from prospective 
cohorts for all-cause mortality, but the relationships for 
cause-speciﬁ c mortality might vary by context; for 
example, where access to treatment might modulate the 
eﬀ ects of education on an outcome. For GBD 2015, we 
have made progress clarifying the evidence base for each 
risk-outcome pair. This type of in-depth examination 
will, we hope, lead to a simpler and more transparent 
approach than has been used before to deﬁ ne which risk-
outcome pairs at any level of the causal web should be 
considered convincing or probable.
Limitations
Since estimation of the attributable burden of disease 
includes estimates of deaths, YLLs, YLDs, or DALYs, the 
limitations described elsewhere for those also apply to 
this analysis.133,134  We have developed our modelling 
strategies to quantify uncertainty given the available data. 
New data—particularly from countries where we 
currently lack data—might reveal levels of exposure that 
are outside the UIs that we have estimated. We assume 
that the joint eﬀ ect for risk factors where we do not 
correct for mediation can be estimated with the multi-
plicative risk model. Although plausible, this model 
might not accurately capture how all risks interact.135 
Analyses of the National Health and Nutrition 
Examination Survey III cohort suggest submultiplicative 
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eﬀ ects for some risks.136 A shift from a multiplicative 
model to a submultiplicative model has profound 
implications for all aspects of risk factor epidemiology, 
beginning at the estimation of relative risks and 
extending to use of relative risks as a generalisable 
construct.
As a consequence of the absence of suﬃ  cient studies 
across all risk-outcome pairs, we did not systematically 
correct relative risks for publication bias. We did not 
correct relative risks for non-masking in studies; however, 
not all risks can be studied in a masked fashion (eg, 
tobacco smoking). Comparability would be compromised 
if we corrected some risks but not others. We generally 
assumed that relative risks were uniform across countries 
for a given age-sex group.137,138 Diﬀ erences in relative risks 
with geography might exist, as has been found for the 
BMI relative risk curve and TMREL, but with the exception 
of breast cancer, we ﬁ nd that insuﬃ  cient evidence exists 
to date to identify statistically signiﬁ cant diﬀ erences.
Development of robust models to estimate variation in 
SD is more diﬃ  cult than for estimations of the mean. 
Because measurement error is necessarily included in 
SD from studies, they are an overestimate of the true SD. 
We did not correct SD for measurement error, with the 
exception of correction of observed systolic blood 
pressure to usual blood pressure. Measurement error 
also aﬀ ects estimation of relative risks through regression 
dilution bias—the attenuation of the association between 
the level of risk and the incidence of disease outcomes. 
Because of the absence of detailed data for key cohorts, 
we have not corrected cholesterol or fasting plasma 
glucose relative risks for regression dilution bias. Our 
approach of estimation of the maximum relative risk on 
the basis of the reported cohorts and trials might 
underestimate burden if risk continues to rise at the 
highest levels of exposure beyond those reported. 
Although a log-linear function for relative risks and levels 
of exposure is adequate for the observed range of 
exposure, available data on the most extreme values are 
few. Given that a very small fraction of the population in 
any country is in these extreme exposure levels, the 
potential bias in our estimates is minimal. Additionally, 
estimation of burden for risks divided into polytomous 
risks might underestimate their burden compared with 
estimation of burden with a continuous risk variable.
Although use of a log-normal distribution is the best 
of the parametric distributions that we have assessed for 
fasting plasma glucose, important deviations from the 
log-normal exist in survey data such as from the 
National Health and Nutrition Examination Survey. We 
have explored diﬀ erent mixtures of distributions, 
including two log-normal or a normal and log-normal, 
some of which provided better overall ﬁ t than the one 
that we used. However, we have so far not been able to 
solve the optimisation problem of estimation of two 
distributions given only a mean and SD reported from 
particular studies.
We did not use the relative risk and exposure PAF 
calculation for unsafe sex, HIV risk from injecting drug 
use, and occupational injuries; we used direct evidence 
of the attributable fraction. Comparability of the results 
derived from these direct or categorical approaches to the 
risks estimated with the relative risk and exposure model 
is not certain.
Too few studies exist to allow estimation of the 
contribution of household air pollution to ambient air 
pollution or vice versa.139 As a consequence, we might 
have underestimated the burden of household air 
pollution as a single risk factor; we might also have 
overestimated the burden of air pollution combined. 
Furthermore, our analysis of ambient air pollution has 
focused on PM2·5; other pollutants, including larger 
particulates than PM2·5 and nitrogen dioxide, might 
also be important to quantify. For cholesterol, we 
established our estimates of burden using total 
cholesterol; however, increasing evidence supporting the 
eﬀ ects of LDL cholesterol—and improvements in data 
availability for serum LDL in diﬀ erent populations—
suggest future estimations of risk from high cholesterol 
should use LDL cholesterol as the unit of estimation.
Proxies for exposure to some risk factors are coarse, 
which is particularly the case for zinc deﬁ ciency, for which 
we estimated the balance between theoretical intake and 
physiological requirements from Food and Agriculture 
Organization food balance sheets for absorbable zinc. 
Although zinc deﬁ ciency can be estimated from the 
proportion of people estimated to have inadequate zinc 
intake, individual-level measurement of exposure truly 
needed to estimate the number of people at risk is not 
available. In a similar fashion, we used the proportion of 
the population in coarse occupational categories as a proxy 
for exposure to speciﬁ c carcinogens and used fuel type as 
a proxy for household air pollution. Our ability to capture 
geographical variation and uncertainty in conversion of 
household solid fuel use to PM2·5 exposure improved the 
validity of our ﬁ ndings and UIs. Use of direct PM2·5 
exposure measurement in households would be preferable 
to calibrate the widely available data for fuel use; however, 
such data have rarely been collected. As with all previous 
studies, we assessed the burden attributable to the 
availability of water and sanitation infrastructure, not the 
use of the infrastructure. Exposure for these risks has 
been deﬁ ned in terms of availability and not use because 
that is what household surveys have collected. Our 
estimates are not biased, however, by this limitation 
because we derived relative risks from similar exposure 
deﬁ nitions. Finally, we have not estimated intimate 
partner violence for men because of a scarcity of evidence 
of the health eﬀ ects among men.
Conclusion
Quantiﬁ cation of the health eﬀ ects of a diverse set of 
largely avoidable risks is an important input into any 
national or global strategy to improve population health 
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and make progress towards the Sustainable Development 
Goals. For the ﬁ rst time, we have been able to separately 
assess and report trends in risk exposure and decompose 
trends in attributable burden into the contribution of 
demographic change, risk exposure, and risk-deleted 
rates. Reductions in some risks strongly associated with 
low levels of development, such as poor water, poor 
sanitation, household air pollution, and undernutrition, 
have been important contributors to global progress. 
Some crucial risks for NCDs, particularly obesity, high 
fasting plasma glucose, and alcohol, are increasing. 
Deleterious trends have had a smaller eﬀ ect than 
expected because of favourable declines in risk-deleted 
DALY rates for many causes, a component of which 
might be due to access to eﬀ ective health care. In an era 
of rapid transition in societies and levels of health, 
tracking of and response to key risks will require constant 
monitoring at the local level. As the set of risk factors 
expands to encompass access to speciﬁ c health-care 
interventions in future iterations of GBD, the GBD CRA 
will provide an even more comprehensive understanding 
than in this study of the drivers of health improvement 
and how they relate to the operation and priorities of 
health systems.
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